ECE2006 - Society for Endocrinology

incorporating the BES 

1-5 April 2006 

Scottish Exhibition and Conference Centre 

GLASGOW, UK 

Programme 

www.ece2006.com

8th European Congress 

of Endocrinology 

incorporating the BES 

1-5 April 2006 

Scottish Exhibition and Conference Centre 

GLASGOW, UK 

ECE 2006 Secretariat 

Society for Endocrinology 

22 Apex Court 

Woodlands 

Bradley Stoke 

Bristol BS32 4JT 

UK 

Contact: Liz Brookes 

Tel: +44 (0)1454 642210 

Fax: +44 (0)1454 642222 

Email: conferences@endocrinology.org 

Web: www.ece2006.com 

The Society for Endocrinology 

Company Limited by Guarantee 

Registered in England No 349408 

Registered office as shown above 

Registered Charity No 26618 

www.ece2006.com

2 

8th European Congress of Endocrinology 

Programme Organising 

Committee: 

Pierre Bouloux, UK (Chair) 

Josef Köhrle, Germany (Chair) 

Maria Alevizaki, Greece 

Paolo Beck-Peccoz, Italy 

Frank Claessens, Belgium 

Kevin Docherty, UK 

Wouter de Herder, The Netherlands 

Ilpo Huhtaniemi, UK 

Chris Kelnar, UK 

Ewa Malecka-Tendera, Poland 

Christoph Meier, Switzerland 

Peter Selby, UK 

Mike Sheppard, UK 

Brian Walker, UK 

Local Organising Committee: 

John Connell, Glasgow (Chair) 

Graham Beastall, Glasgow 

John Bevan, Aberdeen 

Pierre Bouloux, London 

Nick Finer, Cambridge 

Ashley Grossman, London 

Colin Perry, Glasgow 

Martin Savage, London 

Peter Selby, Manchester 

Peter Trainer, Manchester 

European Society of Endocrinology 

(ESE) Executive Committee 

For details please see the ESE web site 

at www.euro-endo.org. 

ECE Abstract Markers 

The Programme Organising Committee 

wishes to thank all the abstract markers, 

who marked all the submissions for ECE 

2006 in their own time. 

Contents 

Congress information 4 

Accreditation, Badges, Business meetings, 

Cloakroom, Commercial exhibition, Disabled 

visitors, Disclaimer, Glasgow, Internet access, 

Language, Meals and refreshments, Media, 

Messages, Posters, Programme changes, 

Registration on-site in Glasgow, Slide preview room, 

Transport links, Venue 

Prize lectures and awards 5 

Social events 6 

Satellite sessions 7 

Overview programme 9 

Programme 15 

Saturday 1 April 15 

Sunday 2 April 15 

Monday 3 April 19 

Tuesday 4 April 22 

Wednesday 5 April 25 

Attended posters 29 

Floor plan 73 

Sponsors and exhibitors 74 

General UK information 80 

Banking, Bureaux de change, Credit cards, Currency, Customs, 

Electricity, Embassies and consulates, Emergency services, Health 

care, Smoking, Telephone, Time, Tipping, Travel insurance, 

Vaccinations, Value-added tax (VAT), 

Visas 

Timetable inside back cover 

www.ece2006.com

Welcome 

Dear Colleagues and Friends 

It is a great pleasure for us to welcome you all to Glasgow and the 8th European 

Congress of Endocrinology, on 1-5 April 2006. This congress incorporates the British 

Endocrine Societies, and we expect delegates from all over Europe to meet and 

exchange experiences with colleagues from all over the world. 

The main scientific programme is very exciting and should attract young doctors and 

scientists in training, as well as established clinicians and basic researchers. The 

meeting will span a broad range of hot topics covering endocrine and metabolic 

subjects, and the plenary lectures are aimed at giving overviews and updates on 

recent research. During the congress, a trade exhibition will take place, in which 

companies working in the field of endocrinology will participate. Company-sponsored 

lunchtime and evening symposia are also arranged. 

Glasgow is one of Europe's most exciting and beautiful destinations, which combines 

the energy and sophistication of a great international city with some of Scotland's 

most spectacular scenery. Glasgow is an architectural dream: Victorian red and honey 

sandstone, Italianate steeples and medieval spires sit harmoniously with neo-gothic 

towers, the sensuous Art Nouveau of Charles Rennie Mackintosh and the titanium, 

glass and steel of the contemporary city. 

We cordially invite you all to join us in Glasgow for a most exciting and 

memorable endocrine meeting! 

Professor Josef Köhrle Professor Pierre Bouloux 

Berlin, Germany London, UK 

CO-CHAIRS OF THE PROGRAMME ORGANISING COMMITTEE FOR ECE 2006 


www.ece2006.com 3

CONGRESS INFORMATION 

4 


Congress Information 

Accreditation 

This event, activity code 28042, has been approved for 

24 external credits for the Continuing Professional 

Development scheme of the Federation of the Royal 

Colleges of Physicians of the UK. 

The 8th European Congress of Endocrinology is 

accredited by the European Accreditation Council for 

Continuing Medical Education (EACCME) to provide the 

following CME activity for medical specialists. The 

EACCME is an institution of the European Union of 

Medical Specialists (UEMS), www.uems.net. 

The EACCME has granted the congress 24 European 

external CME credits for medical specialists. Each 

specialist should claim only those hours of credit that 

they actually spend in educational activity. 

EACCME credits are recognised by the American 

Medical Association (AMA) as contributing towards the 

Physician's Recognition Award (PRA). To convert EACCME 

credits to AMA PRA category 1 credit, contact the AMA. 

Badges 

Each participant will receive a name badge upon 

registration. For security reasons all participants are 

requested to wear their badge during the congress. 

Entrance will not be permitted to those delegates not 

wearing their badge. 

Business meetings 

The European Society of Endocrinology will be holding 

its first AGM on Tuesday 4 April at 12.20-13.50 in the 

Clyde Auditorium. This will be followed by a drinks 

reception for attendees in the Gala Foyer. 

The Society for Endocrinology will hold its EGM on 

Monday 3 April at 13.50-14.00 in the Clyde Auditorium. 

The British Thyroid Association will hold its AGM on 

Monday 3 April at 14.00-14.45 in the Alsh Room. 

Timetables for other meetings arranged during ECE 2006 

will be displayed on the notice board by the registration 

desk in Hall 3. 

Cloakroom 

There is a manned cloakroom available throughout the 

congress. Each item is charged at £1.00. 

Commercial exhibition 

The exhibition will be open all day from Sunday 2 April 

until Wednesday 5 April in Hall 3. It will close at 15.30 

on Wednesday 5 April. Delegates will have the 

opportunity to meet representatives from a number of 

publishers and pharmaceutical and diagnostic equipment 

companies at their stands, to discuss new developments 

and receive up-to-date product information. 

Disabled visitors 

The Scottish Exhibition and Conference Centre (SECC) is 

fully accessible to wheelchair users. For details of access 

to venues around Glasgow and facilities available, please 

contact any Tourist Information Centre or visit 

www.glasgowaccesspanel.org.uk. 

Disclaimer 

The Programme Organising Committee and the Society 

for Endocrinology accept no liability for injuries/losses of 

whatever nature incurred by participants and/or 

accompanying persons, or loss of, or damage to, their 

luggage and/or personal belongings. 

Glasgow 

Glasgow, Scotland's largest city, is one of the liveliest and 

most cosmopolitan destinations in Europe - a true city of 

culture. The city combines an atmosphere of style and 

vitality set against a backdrop of outstanding Victorian 

architecture. Whether you prefer the excitement of the 

city or the tranquillity of the surrounding countryside, 

Glasgow has something for everyone. 

Tourist information can be obtained on Tel: +44 (0)141 

5660800, and further information about Glasgow and the 

surrounding area can be found at www.seeglasgow.com. 

Internet access 

There will be an internet café available in Hall 3 for 

delegates to use during the congress. This has kindly 

been supported by Organon. The SECC also has wifi 

connection, vouchers can be purchased from the 

Information Centre. 

Language 

The official language of the congress is English (no 

translation facilities will be provided). 

Meals and refreshments 

Complimentary tea and coffee will be available in Hall 3 

during scheduled breaks in the programme. A packed 

lunch is included in the cost of registration and will be 

available for delegates from Sunday to Wednesday in Hall 

3. Tea and coffee will be available to purchase outside 

scheduled breaks. 

Media 

PRESS ATTENDANCE: please note that we have had 

requests from journalists to attend scientific sessions and 

view posters. We consider it important that the ECE 

communicates its work to the public. If you do NOT want 

a journalist to attend your talk, please let Liz Brookes know 

as soon as possible. (Email: liz.brookes@endocrinology.org.) 

Messages 

Please use the following number during the congress: 

Tel: +44 (0)141 5763737. 

Posters 

Posters will be on display throughout the meeting at the 

back of Hall 3. The allotted times for the presentation of 

each poster are given before the poster listings on page 

29 of this programme book. 

www.ece2006.com

Programme changes 

The organisers cannot assume liability for any changes in 

the programme due to external or unforeseen 

circumstances. 

Registration on-site in Glasgow 

On-site registration will start on Saturday 1 April at 

12.00 in Hall 3. The registration desk will be open at the 

following times: 

Saturday 1 April 12.00-18.30 

Sunday 2-Tuesday 4 April 07.00-18.30 

Wednesday 5 April 07.00-16.00 

Slide preview room 

The Gala room will be the slide preview room and 

speakers' lounge. This room will be available for speakers 

throughout the congress. Speakers will be directed to 

this room to drop off their presentations. Please note you 

will not be able to use your own laptop for your 

presentation. 

Transport links 

Glasgow has an excellent public transport network. The 

SECC is served by a low-level train from Glasgow Central 

Station, with a 5-minute journey time. Visit 

www.spt.co.uk for local travel information. 

Further information regarding travel to Glasgow and 

from the airport can be found on our web site at 

www.ece2006.com. 

Venue 

Scottish Exhibition and Conference Centre, Glasgow G3 

8YW, UK (Tel: +44 (0)141 2483000; Fax: +44 (0)141 

2263423; Email: info@secc.co.uk). 

The SECC is one of the world's finest conference venues. 

All sessions will be held within one compact site, with 

first-rate auditoria, meeting rooms and exhibition space. 


Congress Information Prize Lectures and Awards 

Geoffrey Harris Prize 

This prestigious prize is intended for established workers 

in the field of basic or clinical neuroendocrinology, and is 

generously supported by Ipsen Ltd. The winner of the 

2006 prize, Felipe Casanueva (Santiago de Compostela, 

Spain), will deliver a lecture at ECE 2006 from 17.30 to 

18.15 on Saturday 1 April in the Clyde Auditorium. 

European Journal of Endocrinology Prize 

This prize is awarded to a candidate who has significantly 

contributed to the advancement of knowledge in 

endocrinology through publication. The recipient of this 

prize, Sabine Costagliola (Brussels, Belgium) will give a 

lecture at ECE 2006 from 16.30 to 17.15 on Saturday 1 

April in the Clyde Auditorium, and will also write a 

review paper to be published in European Journal of 

Endocrinology. 

Novartis Oncology Young Investigator Awards 

Six European Society of Endocrinology (ESE) Young 

Investigator Awards of €3000, generously sponsored by 

Novartis Pharmaceuticals, will be presented to 

researchers who have submitted abstracts (basic or 

clinical) to ECE 2006. Recipients are the first and 

presenting authors of the abstracts, and will be less than 

35 years of age at the time of the meeting. The awards 

are based on the achieved abstract scores, as determined 

by the ECE Abstract Review Committee. The final 

decision has been made by the ECE Programme 

Organising Committee. Successful applicants will present 

their abstracts as oral communications during the 

programme and will be presented with their award 

certificates during the closing ceremony. 

The six ESE Young Investigator Award recipients for 2006 

are as follows: 

Dr C Eller-Vainicher (Milan, Italy) for OC49 

Dr SR James (Birmingham, UK) for OC62 

Dr E Karteris (Coventry, UK) for OC10 

Mrs D Markovic (Coventry, UK) for OC2 

Dr E Murphy (London, UK) for OC51 

Mr AV Patchev (Berlin, Germany) for OC1 

These are marked in the programme book with an 

asterix. 

British Thyroid Association Award 

The BES and the British Thyroid Association are awarding 

a prize of £500 to the young researcher at the ECE 2006 

meeting who submits the highest scoring abstract in the 

thyroid field. Abstracts eligible for the award were 

submitted under the thyroid category, with a first author 

under the age of 35. 

The 2006 recipient is Dr JA Gilbert (London, UK). 

The abstract will be presented as part of Oral 

Communications 8 on Wednesday 5 April at 13.35 in the 

Forth Room. The prize will be awarded on Wednesday 5 

April at 15.35 during the closing ceremony. 

www.ece2006.com 5 

CONGRESS INFORMATION / PRIZE LECTURES AND AW ARDS

SOCIAL EVENTS 

6 


Social Events 

Golf Tournament 

SATURDAY 1 APRIL 2006 

A golf tournament will be held at Glasgow Golf Club and 

is open to everyone who indicated their interest on the 

registration form. If you require any further information 

please contact Colin Perry (Tel: +44 (0)141 2112108; 

Email: colin@fulcrum.u-net.com). 

Five-a-side Football Tournament 


A five-a-side football tournament is taking place at 

Drumchapel, Great Western Road, Glasgow and is open 

to everyone who indicated their interest on the 

registration form. If you require further information 

please contact Colin Perry (Tel: +44 (0)141 2112108; 

Email: colin@fulcrum.u-net.com). 

Tennis Tournament 


A tennis tournament will be held at the Scotstoun Leisure 

Centre and is open to everyone who indicated their 

interest on the registration form. If you require any 

further information please contact Maggie Carson (Tel: 

+44 (0)131 2421378; Email: m.n.carson@ed.ac.uk). 

Welcome Reception 

SATURDAY 1 APRIL 2006, 18.30-20.00, 

GLASGOW SCIENCE CENTRE 

Join your colleagues for this welcome reception at 

Glasgow Science Centre and follow the piper from the 

auditorium to the venue. An example of contemporary 

excellence in a unique setting, Glasgow Science Centre is 

a £75m collection of attractions to illuminate, intrigue, 

inspire and fire your imagination. The welcome reception 

gives delegates an opportunity to network with one 

another after the first day of sessions. Glasgow's Lord 

Provost will welcome you to the city over a glass of 

something bubbly! (See www.glasgowsciencecentre.org.) 

The Sunday Social 

SUNDAY 2 APRIL 2006, 19.00, 

TIGER TIGER, GLASGOW 

(Tickets €15/£11 each) 

For those of you wishing to enjoy a relaxed evening with 

colleagues, enjoying a drink and maybe a dance, why 

not buy a ticket for the social event at Tiger Tiger? 

Set over several floors, the contemporary restaurant, 

laid-back lounge, funky Kaz bar and upbeat club each 

have their own distinct style, décor and soundtrack. 

Ticket price includes a complimentary drink and finger 

buffet. Please show ticket to gain entry. (See 

www.tigertiger-glasgow.co.uk.) 

Congress Banquet and Ceilidh 

TUESDAY 4 APRIL 2006, 19.30, 

HILTON HOTEL, GLASGOW 

(Tickets €90/£65 each; sold on a first-come first-served basis) 

Mention 'Scotland' and 'dance' in the same breath and, 

for many, you'll immediately conjure up mental pictures 

of swinging kilts, the 'Highland Fling' and even crossed 

swords (danced over on the floor, that is!). But these 

aren't just clichés: dance has always had an important 

place at all levels of Scottish society and, even today, it is 

still very much a living tradition. So why not join your 

fellow delegates in some exuberant dancing at the 

ceilidh? This will follow the three-course gala dinner, 

served with wine, and Diagoe's will also kindly provide an 

after dinner drink. (See www.hilton.co.uk/glasgow.) 

www.ece2006.com

Satellite Sessions 

Novartis Pharmaceuticals 

SUNDAY 2 APRIL 12.20-13.50 FORTH ROOM 

From controversy to clarity in 

acromegaly management 

Chair: M Sheppard (Birmingham, UK) 

Acromegaly is a clinical condition in which there is still a 

vigorous debate as to optimal management options and 

outcomes. This satellite symposium distils the conflicting 

science and delivers practical treatment guidance. 

Professor Michael Sheppard (Birmingham, UK) will chair 

the meeting and will conclude with an overview of the 

issues raised and a summary of practical advice on 

treatment strategies for the clinical endocrinologist. 

Does surgery enhance the role of somatostatin 

analogues or do somatostatin analogues enhance the 

role of surgery? 

R Cozzi (Milan, Italy) 

Medical therapy as primary therapy – how successful 

is it? 

M Reincke (Munich, Germany) 

Target objectives – practical markers or academic debate? 

S Webb (Barcelona, Spain) 

Controversies or consensus? 

M Sheppard (Birmingham, UK) 

Ipsen 

SUNDAY 2 APRIL 18.30-20.00 CLYDE AUDITORIUM 

Tailoring therapies for patients with 

endocrine disorders 

Chairs: S Lamberts (Rotterdam, The Netherlands) & 

M Sheppard (Birmingham, UK) 

Self administration and longer injection interval 

with Autogel 

J Bevan (Aberdeen, UK) 

Cardiac safety of SST analogs for acromegaly treatment: 

new data comparing Lanreotide to Octreotide 

G Lombardi (Naples, Italy) 

Choice of testosterone preparation for substitution 

therapy 

E Nieschlag (Münster, Germany) 

Transition from child to adult therapy 

W Drake (London, UK) 

Shire Pharmaceuticals 

MONDAY 3 APRIL 12.20-13.50 FORTH ROOM 

PCOS - the cruel face of a complex disease 

Chair: S Atkin (Hull, UK) 

The symposium will investigate the dermatological 

manifestations with which PCOS patients present. 


Understanding the underlying pathophysiology has led 

to an increased number of successful treatment 

regimens. 

The complex collection of symptoms that make up PCOS 

will be discussed by our next speaker especially in relation 

to adolescents. How we diagnose, treat and manage this 

particular group of patients will also be addressed. 

Canapes will be served prior to the commencement of 

the symposia. 

Pfizer 1 

MONDAY 3 APRIL 12.20-13.50 CLYDE AUDITORIUM 

Young, middle-aged and elderly patients with 

GH deficiency: insights into age-related responses 

to GH replacement 

Chair: J Sandahl Christiansen (Aarhus, Denmark) 

More than 10 years of experience in GH replacement 

has guided us to understand individual needs of adult 

patients with GH deficiency, not only in terms of dose 

adjustment, but also the ways they benefit most from 

treatment. The picture that emerges indicates different 

age-related patterns of treatment response. This session 

will provide insights that may help endocrinologists 

expect different responses and benefits depending on 

the individual patient's phase of life. 

The transition: reaching full somatic development 

P Clayton (Manchester, UK) 

The middle-aged: securing cardiovascular health 

J Monson (London, UK) 

The third age: restoration of normality and ability 

to enjoy it 

S Shalet (Manchester, UK) 

Pfizer 2 

MONDAY 3 APRIL 18.30-20.00 CLYDE AUDITORIUM 

Clinical management of acromegaly: applying 

10 years of human experience with pegvisomant 

Chair: E Ghigo (Turin, Italy) 

It has now been 10 years since the first human studies with 

pegvisomant began. Initial safety and efficacy findings 

continue to be borne out in its use as a single medical 

therapy with unique benefits in the treatment of acromegaly. 

Acrostudy: learnings from the pegvisomant 

surveillance program 

C Strasburger (Berlin, Germany) 

The importance of dose titration in normalising 

IGF-I levels 

P Trainer (Manchester, UK) 

Pegvisomant actions and glucose homeostasis 

D Dunger (Cambridge, UK) 


SATELLITE SESSIONS

Overview Programme 

Saturday 1 April 2006 

From 12.00 Registration 

HALL 3 

16.15-16.30 Opening Ceremony 

CLYDE AUDITORIUM 

16.30-17.15 European Journal of Endocrinology 

Prize Lecture 


17.30-18.15 Geoffrey Harris Prize Lecture 


18.30-20.00 Welcome Reception 




OVERVIEW PROGRAMME

OVERVIEW PROGRAMME 

10 


Sunday 2 April 2006 

07.15-08.00 Meet the Expert 1: 

Macroprolactinaemia 



Gestational diabetes 

LOMOND AUDITORIUM 


Chips, arrays and biosensors: 

bioinformatics in endocrine 

research 

HALL 1 


Cell immortalisation in 

endocrine research 

FORTH ROOM 

08.10-10.10 Symposium 1: 

Thyroid and the heart 


08.10-10.10 Symposium 2: 

The endocrinology of 

psychiatric disease 


08.10-10.10 Clinical Management Workshop 1: 

Green over-the-counter 

endocrinology 

HALL 1 

08.10-10.10 Oral Communications 1: 

Signal transduction 

ALSH ROOM 

08.10-10.10 Young Endocrinologists Session: 

Presenting your research - 

getting your work known 

FORTH ROOM 

10.10-10.40 COFFEE 

HALL 3 

10.40-11.25 Society for Endocrinology 

Transatlantic Medal Lecture 











research 

HALL 1 




FORTH ROOM 

12.20-13.50 Novartis Pharmaceuticals 

Satellite Symposium 



FORTH ROOM 

13.50-14.50 POSTERS AND LUNCH 

HALL 3 

14.50-16.50 Symposium 3: 

Cancer and the skeleton 


14.50-16.50 Symposium 4: 

Cannabinoid signalling 



Management of complex genital 

anomalies and the transition from 

childhood to adulthood 

FORTH ROOM 


Steroids and reproductive 

endocrinology 

HALL 1 

16.50-17.30 TEA 

HALL 3 

17.30-18.15 Plenary 1: 

Vitamin D action 


18.30-20.00 Ipsen Satellite Symposium 

Tailoring therapies for patients 

with endocrine disorders 


From 19.00 The Sunday Social 

TIGER TIGER 

www.ece2006.com



Papillary thyroid cancer 

management 



Adrenal carcinoma 



Transgenic techniques 

HALL 1 


Pitfalls in signal transduction 

research 

FORTH ROOM 

08.10-10.10 Symposium 5: 

Novel peptides in reproduction 



Clinical endocrinology 

HALL 1 

08.10-10.10 Symposium 6: 

Hot topics 


08.10-10.10 Symposium 7: 

Flies, worms and fish: 

use in endocrine research 

FORTH ROOM 

10.10-10.40 COFFEE 

HALL 3 

10.40-11.25 Clinical Endocrinology Trust 

Visiting Professor Lecture 




management 







HALL 1 



research 

FORTH ROOM 


12.20-13.50 Shire Pharmaceuticals 


PCOS - the cruel face of 

a complex disease 

FORTH ROOM 

12.20-13.50 Pfizer Satellite Symposium 1 

Young, middle-aged and elderly 

patients with GH deficiency: 

insights into age-related responses 

to GH replacement 


13.50-14.00 Society for Endocrinology EGM 


14.00-14.45 British Thyroid Association AGM 

ALSH ROOM 


HALL 3 

14.50-16.50 Symposium 8: 

Clinical lessons from novel aspects 

of G protein-coupled receptors 

signalling 



Management of Graves' 

ophthalmopathy 


14.50-16.50 Basic Science Workshop: 

In vivo imaging of signalling 

HALL 1 


Diabetes and metabolism 

16.50-17.30 TEA 

FORTH ROOM 

HALL 3 

17.30-18.15 Plenary 2: 

Statins and rhabdomyolysis 



Clinical management of 

acromegaly: applying 10 years 

of human experience with 

pegvisomant 


FREE EVENING 


OVERVIEW PROGRAMME



Medical management of 

Cushing's disease 



Graves' ophthalmopathy 



Metabolic, functional and 

oncological consequences of 

altered GH/IGF expression 

HALL 1 


Growth hormone deficiency 

in adults 

FORTH ROOM 

08.10-10.10 Symposium 9: 

Stromal cell-matrix interactions 


08.10-10.10 Symposium 10: 

Controversies in male health 



Neuroendocrinology and neoplasia 

FORTH ROOM 

08.10-10.10 Nurses Session: 

Metabolic syndrome 

ALSH ROOM 

10.10-10.40 COFFEE 

HALL 3 

10.40-11.25 British Thyroid Association 

Pitt-Rivers Lecture 



Medical management of 








Metabolic, functional and 

oncological consequences of 

altered GH/IGF expression 

HALL 1 



in adults 

FORTH ROOM 

12.20-13.50 European Society of Endocrinology 

AGM 


followed by a drinks reception for attendees in 

the Gala Foyer 


HALL 3 

14.50-16.50 Symposium 11: 

How hormones get into cells 


14.50-16.50 Symposium 12: 

Endocrinology in the fetus 

HALL 1 


Contrasting practices in 

European endocrinology 



Endocrine genetics 

FORTH ROOM 

16.50-17.30 TEA 

HALL 3 


Dale Medal Lecture 


From 19.30 Congress Banquet and Ceilidh 

HILTON HOTEL 


OVERVIEW PROGRAMME

OVERVIEW PROGRAMME 

14 




Pregnancy-related pituitary 

disorders 



Hypoglycaemia and insulinoma 



Interference in hormone assays 

HALL 1 


Mouse genetics in the identification 

of quantitative traits 

FORTH ROOM 

08.10-10.10 Symposium 13: 

Monogenic disorders illuminate 

metabolic disease 


08.10-10.10 Symposium 14: 

Steroid hormone receptors 

HALL 1 

08.10-10.10 Symposium 15: 

Anabolic hormones in sport 



Calcium and bone 

FORTH ROOM 

10.10-10.40 COFFEE 

HALL 3 

10.40-11.25 Clinical Endocrinology Trust Lecture 


11.35-12.20 Plenary 3: 

Stem cells: regeneration 

in type 1 diabetes 


11.35-12.20 Debate: 

Metformin is the treatment of 

choice for polycystic ovarian 

syndrome 




disorders 







HALL 1 




FORTH ROOM 

13.05-13.35 LUNCH 

HALL 3 

13.35-15.35 Symposium 16: 

Disorders of melanocortin receptor 

functions 


13.35-15.35 Symposium 17: 

Endocrine oncogenesis and 

management of hereditary 

endocrine tumours 



Research management workshop 

HALL 1 


Thyroid 

FORTH ROOM 

15.35 Novartis Oncology Young Investigator 

Award and BTA Award Announcements 

and Close of Meeting 


www.ece2006.com

Programme 

Saturday 1 April 2006 Sunday 2 April 2006 

From 12.00 Registration 

HALL 3 

16.15-16.30 Opening Ceremony 


J Wass (Oxford, UK) 

16.30-17.15 European Journal of Endocrinology 

Prize Lecture 


Chair: P Beck Peccoz (Milan, Italy) 

S1 Evolutionary mechanisms of glycoprotein 

hormone receptors (TSHr, LH/CGr and 

FSHr) to cope with hCG in humans 

S Costagliola (Brussels, Belgium) 

17.30-18.15 Geoffrey Harris Prize Lecture 

GENEROUSLY SUPPORTED BY IPSEN LTD 


Chair: S Lamberts 

(Rotterdam, The Netherlands) 

S2 Ghrelin: a tale of modern endocrinology 

F Casanueva 

(Santiago de Compostela, Spain) 

18.30-20.00 Welcome Reception 






Chair: TBA 

P Chanson (Paris, France) 




Chair: D Johnston (London, UK) 

R Corcoy (Barcelona, Spain) 




research 

HALL 1 

Chair: V Pirags (Riga, Latvia) 

A Turner (Leicester, UK) 


Cell immortalisation in endocrine 

research 

FORTH ROOM 

Chair: TBA 

S Kim (London, UK) 

08.10-10.10 Symposium 1: 

Thyroid and the heart 


Chairs: A Tsatsoulis (Ioannina, Greece) & 

J Franklyn (Birmingham, UK) 

S11 08.10 Cardiac repercussions of thyroid 

hormones 

J Franklyn (Birmingham, UK) 

S12 08.40 The assessment of cardiovascular risk 

factors in thyroid disease 

B Biondi (Naples, Italy) 

S13 09.10 Iodothyronamines: rapid-acting thyroid 

hormone metabolites 

T Scanlan (San Francisco, USA) 

S14 09.40 Role of thyroid hormone receptor 

isoforms in development and function of 

heart and other tissues 

J Samarut (Lyon, France) 

08.10-10.10 Symposium 2: 

The endocrinology of psychiatric 

disease 


Chair: P Bouloux (London, UK) 

S15 08.10 Glucocorticoids, enzymes and memory 

impairments with ageing 

J Seckl (Edinburgh, UK) 


PROGRAMME

PROGRAMME 

16 


Sunday 2 April 2006 - continued 

S16 08.40 Effects of hypothyroidism on brain 

metabolism and its associations with 

neuropsychiatric impairments 

M Bauer (Berlin, Germany) 

S17 09.10 Overview of neuroendocrine side-effects 

R Tandon (Ann Arbor, USA) 

S18 09.40 Endocrinology of post-traumatic stress 

C Kirshbaum (Dresden, Germany) 


Green over-the-counter 

endocrinology 

HALL 1 

Chair: R Sharpe (Edinburgh, UK) 

S75 08.10 Regulation of steroid receptor expression 

and proliferation in prostate cancer by 

genistein and other flavonoids 

H Klocker (Innsbruck, Austria) 

S76 08.40 Soy, flavonoids and osteoporosis 

E Lydeking-Olsen (Copenhagen, Denmark) 

S77 09.10 Aftermath of WHI: the risks or benefits of 

red clover and soy extracts in 

postmenopausal OTC HRT 

W Wuttke (Göttingen, Germany) 


Signal transduction 

ALSH ROOM 

Chairs: M Tena Sempere (Cordoba, Spain) & 

W Knepel (Göttingen, Germany) 

OC1* 08.10 Stress response after TIF-2 disruption: loss 

of grip on feedback control or 

adrenocortical impairment? 

AV Patchev, D Fischer, M Herkenham, F Götz, 

SS Wolf, M Gehin, P Chambon, VK Patchev & 

OFX Almeida 

OC2* 08.25 Signalling and internalisation 

characteristics of corticotropin-releasing 

hormone (CRH) receptors 

D Markovic & D Grammatopoulos 

OC3 08.40 Activation of cyclic AMP (cAMP) binding 

protein (CREB) by gonadotrophinreleasing 

hormone (GnRH) requires 

calcium influx and PKC activity in 

gonadotroph cell lines 

KC Jonas, IA Thompson, JM Burrin & RC Fowkes 

OC4 08.55 The role of MRAP in the functional 

expression of the melanocortin 2 

receptor 

SN Cooray, JP Chapple, LA Metherell, 

ME Cheetham & AJL Clark 

OC5 09.10 The overexpression Pit-1 pathway, switch 

on by Ret, get into apoptosis fate 

CM Cañibano Acebes, A Vidal, MG Borrello, 

C Diéguez & CV Alcarez 

OC6 09.25 Activation of androgen membrane 

binding sites induces potent regression of 

prostate cancer cells in vitro and in vivo 

N Papadopoulou, M Kampa, A Gravanis, 

E Castanas & C Stournaras 

OC7 09.40 The effect of bone marrow stem cell 

(BMSC) differentiation on growth 

hormone receptor (GHR)-associated 

signalling pathways 

MD Lewis, TE Easter, C Elford, ME Ludgate, 

BAJ Evans, DA Rees & MF Scanlon 

OC8 09.55 Role of the calcium-calmodulin 

dependent kinase II in oncogenic 

ras-induced proliferation 

AL Cavallo, M Illario, E Di Vito, S Monaco, 

G Fenzi, G Rossi & M Vitale 

08.10-10.10 Young Endocrinologists Session: 

Presenting your research - 

getting your work known 

FORTH ROOM 

Chair: W Arlt (Birmingham, UK) 

S102 08.10 Giving talks 

A McNeilly (Edinburgh, UK) 

S103 08.35 Practical tips for a perfect poster 

A Mostyn (Nottingham, UK) 

S104 09.00 Papers for peer-reviewed journals 

S Pearce (Newcastle upon Tyne, UK) 

S105 09.25 PhD/MD thesis: a recipe for success 

D Abayasekara (London, UK) 

S106 09.50 Talking to a lay audience 

T Parkhill (Bristol, UK) 

10.10-10.40 COFFEE 

HALL 3 




Chair: J Wass (Oxford, UK) 

S3 Nuclear receptors and transcriptional 

control of lipid metabolism 

D Mangelsdorf (Dallas, USA) 




Chair: TBA 

P Chanson (Paris, France) 





R Corcoy (Barcelona, Spain) 

www.ece2006.com




bioinformatics in endocrine research 

HALL 1 

Chair: V Pirags (Riga, Latvia) 

A Turner (Leicester, UK) 




FORTH ROOM 

Chair: TBA 

S Kim (London, UK) 

12.20-13.50 Novartis Pharmaceuticals 




FORTH ROOM 


HALL 3 

14.50-16.50 Symposium 3: 

Cancer and the skeleton 


Chair: L Gennari (Sienna, Italy) 

S19 14.50 Mechanisms of malignant hypercalcaemia 

P Clezardin (Lyon, France) 

S20 15.20 The management of malignant 

hypercalcaemia 

P Selby (Manchester, UK) 

S21 15.50 Oncogenic osteomalacia: novel insights 

into the regulation of phosphate 

homeostasis 

H Jueppner (Boston, USA) 

S22 16.20 Why does thyroid carcinoma metastasise 

to bone? 

J Smit (Leiden, The Netherlands) 

14.50-16.50 Symposium 4: 

Cannabinoid signalling 


Chairs: C Tsigos (Athens, Greece) & 

M Korbonitz (London, UK) 

S23 14.50 Cannabinoids as modulators of 

neuroendocrine signalling 

U Pagotto (Bologna, Italy) 

S24 15.30 Cannabinoids and feeding behaviour 

T Kirkham (Liverpool, UK) 

S25 16.10 Clinical applications of manipulation of 

cannabinoid receptors (agonists) 

R Ross (Aberdeen, UK) 



Management of complex genital 


childhood to adulthood 

FORTH ROOM 

Chair: A Grüters-Kieslich (Berlin, Germany) 

S78 14.50 Management of the infant with 

ambiguous external genitalia. The 

pediatric endocrinologist's approach 

C Dacou-Voutetakis (Athens, Greece) 

S79 15.30 Surgical management of ambiguous 

genitalia in the infant 

C N Fékété (Paris, France) 

S80 16.10 Management of complex genital 


childhood to adulthood: a patient's 

perspective 

P Carmichael (London, UK) 


Steroids and reproductive 

endocrinology 

HALL 1 

Chair: I Huhtaniemi (London, UK) 

OC9 14.50 11β HSD1: anti-inflammatory mechanism 

in acute and chronic inflammation? 

AE Coutinho, M Gray, DA Sawatzky, 

D Brownstein, J Mullins, JR Seckl, JS Savill & 

KE Chapman 

OC10*15.05 Progesterone signaling in human 

myometrium is mediated through two 

novel membrane G protein-coupled 

receptors 

E Karteris, S Zervou, Y Pang, J Dong, 

EW Hillhouse, HS Randeva & P Thomas 

OC11 15.20 The adrenal X-zone is involved in 

progesterone inactivation 

F Beuschlein, L Heshkovitz, S Klammer, 

U Lichtenauer, I Shapiro, M Krup & 

Y Weinstein 

OC12 15.35 Expression profiling of genes in the testis 

of rhesus macaques during development 

and aging 

HF Urbanski, VT Garyfallou, DR Lemos, 

JL Downs & DI Brown 

OC13 15.50 Anti-mullerian hormone (AMH) 

production by granulosa cells from 

anovulatory PCO is 100 times higher 

than from normal ovaries, but is inhibited 

by metformin 

L Pellatt, L Hanna, D Feldman, P Malloy, 

H Brain, S Whitehead & H Mason 


PROGRAMME

PROGRAMME 

18 



OC14 16.05 Endometrial intracrinology: expression of 

3β-hydroxysteroid dehydrogenase 

(3βHSD), and 17β-hydroxysteroid 

dehydrogenase type 5 (17βHSD-5) 

SE McDonald, JI Mason & HOD Critchley 

OC15 16.20 Role of the Hu proteins, HuR and HuD, 

and αCP1 in the regulation of androgen 

receptor expression and activity in 

prostate cancer cells 

CF Down, RR Lareu, B Granath, DJ Beveridge, 

H Furneaux, J Bentel & PJ Leedman 

OC16 16.35 17β-estradiol regulates pituitary AnxA1 

expression and externalization in vivo and 

in vitro 

EL Davies, HC Christian, S Omer, 

JC Buckingham & JF Morris 

16.50-17.30 TEA 

HALL 3 

17.30-18.15 Plenary 1 


Chair: S Webb (Barcelona, Spain) 

S8 Vitamin D action 

R Bouillon (Leuven, Belgium) 

18.30-20.00 Ipsen Satellite Symposium 

Tailoring therapies for patients 

with endocrine disorders 


From 19.00 The Sunday Social 

TIGER TIGER 

www.ece2006.com




management 


Chair: I Szabolcz (Hungary) 

I Hay (Rochester, USA) 




Chair: M Terzolo (Orbassano, Italy) 




HALL 1 

Chair: I Robinson (London, UK) 

M Poutanen (Turku, Finland) 



research 

FORTH ROOM 

Chair: L Hunyady (Budapest, Hungary) 


08.10-10.10 Symposium 5: 

Novel peptides in reproduction 


Chairs: R Millar (Edinburgh, UK) & 

A Milewicz (Wroclaw, Poland) 

S26 08.10 The kisspeptin-GPR54 axis 

in reproduction 

M Tena-Sempere (Cordoba, Spain) 

S27 08.40 Use of recombinant leptin in women 

with hypothalamic amenorrhea 

C Welt (Boston, USA) 

S28 09.10 A genomic analysis of polypeptide 

ligands and their receptors: examples 

of relaxin and LGR families 

T Hsu (Stanford, USA) 

S29 09.40 Novel recombinant gonadotropin 

molecules in human reproductive 

dysfunction 

B Mannaerts (Oss, The Netherlands) 


Clinical endocrinology 

HALL 1 

Chairs: M Grussendorf (Stuttgart, Germany) & 

S Lamberts (Rotterdam, The Netherlands) 

OC17 08.10 Copeptin, a precursor of vasopressin, in 

critically ill patients - an observational 

study 

M Christ-Crain, N Morgenthaler, J Struck, 

A Bergmann & B Mueller 


OC18 08.25 Endoscope-assisted pituitary surgery for 

functioning and non-functioning pituitary 

adenomas. The experience of the first 80 

patients in a single centre 

PL Hanson, SM Joshi, G Alusi, HI Sabin, 

WM Drake & JP Monson 

OC19 08.40 Disease remission in long term treated 

acromegalic patients after somatostatin 

analogs withdrawal 

C L Ronchi, V Varca, A Lania, M Arosio, 

A Spada & P Beck-Peccoz 

OC20 08.55 A European prospective real-life 

observational study of quality of life in 

patients with acromegaly 

SM Webb, A Colao, P Caron, M Carvalheiro, 

E Ertürk, A Pokrajac-Simeunovic, J Schopohl, 

S Tsagarakis, IV Pearson, X Badia, S Caglio & 

B Vincenzi 

OC21 09.10 Adjuvant radiation therapy of the tumor 

bed prevents local recurrences in 

adrenocortical carcinoma 

M Fassnacht, S Hahner, B Polat, AC Koschker, 

M Flentje & B Allolio 

OC22 09.25 Detection of phaeochromocytoma: the 

emerging role of plasma metanephrines 

RT Peaston, SG Ball, R Quinton, RA James, 

S Pearce, TWJ Lennard & RDG Neely 

OC23 09.40 Improved prognosis in midgut carcinoid 

patients by treating raised circulating 

neurokinin A (NKA) 

JES Ardill, BJ Johnston, GB Turner, A McGinty 

& DR McCance 

OC24 09.55 Low testosterone and atherogenic 

lipid profile in aging men 

JI Mäkinen, A Perheentupa, K Irjala, 

P Pöllänen, J Mäkinen, I Huhtaniemi & 

O Raitakari 

08.10-10.10 Symposium 6: 

Hot topics 


Chairs: Pierre Bouloux (London, UK) & 

J Köhrle (Berlin, Germany) 

08.10 The obesity epidemic glutamate and 

umami regulation of food intake 

J Tresguerres (Madrid, Spain) 

08.35 Transthyretin and neuropeptide processing 

M Mendes Sousa (Porto, Portugal) 

09.00 Tissue specific effects of a novel plant 

derived SERM: 8-prenyl-naringenin 

WD Schleuning (Berlin, Germany) 

09.25 Genetic polymorphism redefine setpoints 

of the pituitary thyroid axis 

R Peeters (Rotterdam, The Netherlands) 


PROGRAMME

PROGRAMME 

20 


Monday 3 April 2006 - continued 

09.50 Oligonucleotide microarrays and their 

applications in thyroid cancer 

B Jarzab (Gliwice, Poland) 

08.10-10.10 Symposium 7: 

Flies, worms and fish: use in 


FORTH ROOM 

Chair: K Docherty (Aberdeen, UK) 

S30 08.10 Long live the worm: C. elgeans, insulin 

and aging 

D Gems (London, UK) 

S31 08.40 Dietary restriction and altered insulin/Igf1 

signalling: conserved mechanisms 

regulating lifespan in worms, flies and 

rodents 

D Withers (London, UK) 

S32 09.10 Giant flies and more: probing the 

functions and genetics of insulin 

signalling in Drosophila 

C Wilson (Oxford, UK) 

S33 09.40 Specifying the cellular responses to IGF 

signalling by IGF binding proteins: new 

lessons from the zebrafish model 

C Duan (Ann Arbor, USA) 

10.10-10.40 COFFEE 

HALL 3 

10.40-11.25 Clinical Endocrinology Trust Visiting 

Professor Lecture 


Chair: L Rees (London, UK) 

S4 Understanding the genetic control of 

puberty in the human 

W Crowley (Boston, USA) 



management 


Chair: I Szabolcz (Hungary) 

I Hay (Rochester, USA) 




Chair: M Terzolo (Orbassano, Italy) 




HALL 1 

Chair: I Robinson (London, UK) 

M Poutanen (Turku, Finland) 



research 

FORTH ROOM 

Chair: L Hunyady (Budapest, Hungary) 


12.20-13.50 Shire Pharmaceuticals Satellite 

Symposium 

PCOS - The cruel face of a complex 

disease 

FORTH ROOM 


Young, middle-aged and elderly 

patients with GHD: insights into 

age-related responses to GH 

replacement 


13.50-14.00 Society for Endocrinology EGM 


14.00-14.45 British Thyroid Association AGM 

ALSH ROOM 


HALL 3 

14.50-16.50 Symposium 8: 

Clinical lessons from novel aspects 

of G protein-coupled receptors 

signalling 


Chairs: A Spada (Milan, Italy) & 

A Breit (Marburg, Germany) 

S34 14.50 How the pattern of GPCR co-expression 

can regulate function 

G Milligan (Glasgow, UK) 

S35 15.20 Alpha- and beta-adrenoceptor 

dysfunction 

L Hein (Würzburg, Germany) 

S36 15.50 Molecular pathology of the FSH receptor 

M Misrahi (Paris, France) 

S37 16.20 Therapeutic implications from new 

aspects in V2 vasopressin receptor 

dysfunction 

T Schöneberg (Leipzig, Germany) 


Management of Graves' 



Chair: W Wiersinga (Amsterdam, The 

Netherlands) 

S81 14.50 Prevention of thyroid eye disease 

G Krassas (Thessaloniki, Greece) 

www.ece2006.com

Monday 3 April 2006 - continued 

S82 15.20 Medical treatment 

C Marcocci (Pisa, Italy) 

S83 15.50 Alternative immunomodulatory therapies 

for Graves' ophthalmopathy 

J Banga (London, UK) 

S84 16.20 Ophthalmic management of thyroid eye 

disease 

G Rose (London, UK) 

14.50-16.50 Basic Workshop: 

In vivo imaging of signalling 

HALL 1 

Chair: TBA 

S85 14.50 OPT: a novel wholemount imaging 

technology for visualising gene and 

protein expression 

S Wedden (Edinburgh, UK) 

S86 15.30 A mouse reporting on estrogen receptor 

(ER) transcriptional activity to understand 

the complexities of female physiology in 

mammals 

A Maggi (Milan, Italy) 

S87 16.10 Micro PET-ing in mice 

M Kreissl (Wuerzburg, Germany) 


Diabetes and metabolism 

FORTH ROOM 

Chairs: R Corcoy (Barcelona, Spain) & 

H Romijn (Leiden, The Netherlands) 

OC25 14.50 Cannabinoids increase AMP-activated 

protein kinase (AMPK) enzyme activity in 

the hypothalamus and heart via different 

signalling pathways - studies in CB1 

knockout animals 

B Kola, M Christ-Crain, G Wittman, 

C Leontiou, A Grossman, C Fekete & 

M Korbonits 

OC26 15.05 Neuropeptide S is a novel peptide, which 

potently stimulates the hypothalamopituitary-adrenal 

axis and inhibits food 

intake 

KL Smith, M Patterson, WS Dhillo, SR Patel, 

NM Semjonous, JV Gardiner, MA Ghatei & 

SR Bloom 

OC27 15.20 A selective increase in adipose 11β-HSD1 

expression in corticosterone-treated 

POMC-null mice is associated with 

development of metabolic syndrome 

ZM Michailidou, APC Coll, NMM Morton, 

CJ Kenyon, S O'Rahilly, JR Seckl & 

KE Chapman 


OC28 15.35 11β-Hydroxysteroid dehydrogenase type 

1 oxoreductase activity is increased in 

patients with alcoholic chronic liver 

disease: the key to the phenotype of the 

alcoholic pseudo-Cushing's state? 

A Ahmed, S Saksena, E Elias & PM Stewart 

OC29 15.50 A choline deficient diet in mice prevents 

high fat diet-induced insulin resistance in 

spite of more severe fatty liver disease 

PJ Raubenheimer, MJ Nyirenda & BR Walker 

OC30 16.05 The release of the adipocytokine visfatin 

is regulated by glucose and insulin 

DG Haider, G Schaller, S Kapiotis, C Maier, 

A Luger & M Wolzt 

OC31 16.20 Comparative analysis of the effects of 

dehydroepiandrosterone (DHEA) on 

white and brown pre-adipocyte 

proliferation/differentiation 

SPL Rice, E Wang, MF Scanlon, M Ludgate & 

DA Rees 

OC32 16.35 The in vitro effects of resistin on the 

innate immune signalling pathway in 

isolated human subcutaneous adipocytes 

CM Kusminski, NF da Silva, AL Harte, S Kumar 

& PG McTernan 

16.50-17.30 TEA 

HALL 3 

17.30-18.15 Plenary 2 


Chair: B Ake Bengtsson (Sweden) 

S9 Statins and rhabdomyolysis 

M Law (London, UK) 


Clinical management of 

acromegaly: applying 10 years 

of human experience with 

pegvisomant 


FREE EVENING 


PROGRAMME

PROGRAMME 

22 




Medical management of Cushing's 

disease 


Chair: J Newell Price (Sheffield, UK) 

G Chrousos (Athens, Greece) 




Chair: P Perros (Newcastle upon Tyne, UK) 

W Wiersinga (Amsterdam, The Netherlands) 


Metabolic, functional and oncologic 

consequences of altered GH/IGF 

expression 

HALL 1 

Chair: G Brockman (Berlin, Germany) 

P Jenkins (London, UK) 



in adults 

FORTH ROOM 


E-M Erfurth (Uppsala, Sweden) 

08.10-10.10 Symposium 9: 

Stromal cell-matrix interactions 


Chair: G Williams (London, UK) 

S38 08.10 Role of heparan sulphates in neuronal 

stem cell differentiation 

J Turnbull (Liverpool, UK) 

S39 08.40 Hormonal regulation of mesenchymal 

stem cell differentiation in bone 

F Jakob (Würzburg, Germany) 

S40 09.10 Cell adhesion molecules and osteoclast 

function 

M Helfrich (Aberdeen, UK) 

S41 09.40 Wnt signalling in the stem cell niche 

A Clark (Cardiff, UK) 

08.10-10.10 Symposium 10: 

Controversies in male health 


Chair: M Maggi (Florence, Italy) 

S42 08.10 Does andropause exist? 

A Perheentupa (Turku, Finland) 

S43 08.40 Cardiovascular effects of androgens 

F Wu (Manchester, UK) 

S44 09.10 Endocrine regulation of prostatic growth 

Z Culig (Innsbruck, Austria) 

S45 09.40 Stem cell therapeutic approaches to male 

infertility 

S Schlatt (Pittsburgh, USA) 


Neuroendocrinology and neoplasia 

FORTH ROOM 

Chairs: S Tsagarakis (Athens, Greece) & 

I Gerendai (Budapest, Hungary) 

OC33 08.10 Effect of overexpression of GH 

secretagogue receptor (GHSR) in the 

pituitary of transgenic mice 

LM Seoane, D Carmignac, FF Casanueva & 

ICAF Robinson 

OC34 08.25 Transgenic mice overexpressing urocortin 

3 show increased anxiety and depressive 

like behaviours but a hyporesponsive 

ACTH response to stress 

P M Jamieson, A Chen & W Vale 

OC35 08.40 Immunocytochemical colocalisation of 

hormones in the human fetal pituitary 

ARM Chirculescu, C Badiu, JF Morris & 

M Coculescu 

OC36 08.55 Somatostatin analogues in the treatment 

of acromegaly: correlation between 

somatostatin receptor subtype expression 

levels and clinical response 

S Petersenn, A Redmann, DK Luedecke & 

K Mann 

OC37 09.10 90Y-dotatate in the treatment of 

neuroendocrine tumours 

D Handkiewicz-Junak, K Hasse-Lazar, 

B Jurecka-Lubieniecka, J Krajewska, J Roskosz, 

A Kukulska, S Szpak, A Krawczyk & B Jarzab 

OC38 09.25 Germline mutations in patients with 

apparently sporadic pheochromocytomas/ 

paragangliomas 

M Mannelli, MS Gaglianò, L Simi, T Ercolino, 

L Becherini, P Pinzani, R Sestini, GP Bernini, 

M Mascalchi & M Genuardi 

OC39 09.40 11β-hydroxysteroid dehydrogense 

modulation of HPA function - importance 

of genetic background 

RN Carter, U Tworowska, JR Seckl & 

MC Holmes 

OC40 09.55 Expression of IGF-I and IGF-IR in 

tamoxifen-sensitive and tamoxifenresistant 

breast cancer 

CJ McVittie, S Khalaf, W Ogunkolade, 

R Carpenter, SA Bustin & PJ Jenkins 

08.10-10.10 Nurses Session: 

Metabolic syndrome 

ALSH ROOM 

Chairs: D Greenfield (Sheffield, UK) & 

S Shalet (Manchester, UK) 

S97 08.10 Leptin expands function 

H Randeva (Coventry, UK) 

www.ece2006.com

Tuesday 4 April 2006 - continued 

S98 08.35 Ghrelin update 

V Popovic (Belgrade, Serbia and Montenegro) 

S99 09.00 Insulin resistance and type 2 diabetes - 

insights from the study of extreme 

human phenotypes 

D Savage (Cambridge, UK) 

S100 09.25 Metabolic syndrome 

N Finer (Cambridge, UK) 

S101 09.50 Nurse-led weight management: 

the Counterweight Programme 

L McCombie (Glasgow, UK) 

10.10-10.40 COFFEE 

HALL 3 

10.40-11.25 British Thyroid Association Pitt-Rivers 

Lecture 


Chair: A Weetman (Sheffield, UK) 

S5 Neurological abnormalities in mice with a 

dominant negative thyroid hormone α1 

B Vennström (Stockholm, Sweden) 


Medical management of Cushing's 

disease 


Chair: J Newell Price (Sheffield, UK) 

G Chrousos (Athens, Greece) 




Chair: P Perros (Newcastle upon Tyne, UK) 

W Wiersinga (Amsterdam, The Netherlands) 


Metabolic, functional and oncologic 

consequences of altered GH/IGF 

expression 

HALL 1 

Chair: G Brockman (Berlin, Germany) 

P Jenkins (London, UK) 



in adults 

FORTH ROOM 


E-M Erfurth (Uppsala, Sweden) 

12.20-13.50 European Society of Endocrinology 

AGM 


followed by a drinks reception for attendees in 

the Gala Foyer 


HALL 3 


14.50-16.50 Symposium 11: 

How hormones get into cells 


Chair: K Chapman (Edinburgh, UK) 

S46 14.50 Specific thyroid hormone transporters 

T Visser (Rotterdam, The Netherlands) 

S47 15.20 The spectrum of MCT8 gene mutations 

H Krude (Berlin, Germany) 

S48 15.50 Multidrug resistance p-glycoprotein 

(Mdr-1): excluding corticosteroids from 

brain 

E de Kloet (Leiden, The Netherlands) 

S49 16.20 Cell surface carrier-mediated transport of 

steroid hormones 

J Steffgen (Biberach, Germany) 

14.50-16.50 Symposium 12: 

Endocrinology in the fetus 

HALL 1 

Chair: TBA 

S50 14.50 Maternal thyroid function and cognitive 

impairment in childhood 

A van Wassenaer (Amsterdam, 

The Netherlands) 

S51 15.20 Molecular basis of programming of 

renin-secreting cells 

S Pennings (Edinburgh, UK) 

S52 15.50 Birth weight and later disease: 

genes and maternal diabetes 

R Lindsay (Glasgow, UK) 

S53 16.20 Endocrine therapy of the fetus 

A Grüters-Kieslich (Berlin, Germany) 


Contrasting practices in European 

endocrinology 


Chair: B Allolio (Wurzburg, Germany) 

S88/ 14.50 Diagnosis of hypercortisolism 

S89 R Feelders (Rotterdam, The Netherlands) & 

A Atkinson (Belfast, UK) 

S90/ 15.30 New endocrinology medicines: 

S91 when are they good value? 

A Walker (Glasgow, UK) & 

J Sandahl Christiansen (Aarhus, Denmark) 

S92/ 16.10 Contrasting practices in European 

S93 endocrinology - radio-iodine therapy 

A Toft (Edinburgh, UK) & 

L Hegedüs (Odense, Denmark) 


PROGRAMME

PROGRAMME 

24 


Tuesday 4 April 2006 - continued 


Endocrine genetics 

FORTH ROOM 

Chairs: K Chatterjee (Cambridge, UK) & 

W de Herder (Rotterdam, The Netherlands) 

OC41 14.50 Mutations in cullin 7, a cofactor for 

ubiquitination, cause the 3M intra-uterine 

growth retardation syndrome 

PE Clayton, L O'Sullivan, A Glaser, 

MH Oliveira, MRS de Alacantara, 

ES de Almeida Barretto, H Kingston, A Read, 

V Cormier-Daire, PJ Scambler & G Black 

OC42 15.05 Linkage of a fourth gene for familial 

glucocorticoid deficiency to chromosome 

13q 

LA Metherell, C Becker, F Ruschendorf, 

D Naville, M Begeot, P Nurnberg, A Huebner, 

MO Savage & AJL Clark 

OC43 15.20 Mutation screening of SLC26A4 (PDS) 

gene in patients with Pendred syndrome 

and non-syndromic enlarged vestibular 

aqueduct 

M Ladsous, V Vlaeminck-Guillem, C Vincent, 

F Dubrulle, V Dumur & JL Wémeau 

OC44 15.35 Functional impact of polymorphic 

variation in the gene encoding 11βhydroxylase 

(CYP11B1): reduced adrenal 

11-hydroxylase efficiency identifies a key 

intermediate phenotype in hypertension 

M Barr, E Friel, SM MacKenzie, CD Holloway, 

EM Freel, NJR Brain, DM Wilkinson, M Ingram, 

R Fraser, AF Dominiczak, JMC Connell & 

E Davies 

OC45 15.50 Genotype/phenotype correlation of 

PRKAR1A mutations in patients with 

Carney complex (CNC) and/or sporadic 

primary pigmented nodular 

adrenocortical disease (PPNAD) from the 

CNC network 

L Groussin, F Rene-Corail, L Cazabat, E Jullian, 

E Clauser, X Bertagna & J Bertherat 

OC46 16.05 Predictors and prevalence of 

paraganglioma syndrome associated with 

mutations of the SDHC-gene 

HP Neumann 

OC47 16.20 Frequent involvement of BMP15 gene 

variants in women with premature 

ovarian failure 

E Di Pasquale, R Rossetti, A Marozzi, S Borgato, 

L Cavallo, F de Luca, S Einaudi, G Radetti, G 

Russo, M Sacco, P Beck-Peccoz & L Persani 

OC48 16.25 Progressive osseous heteroplasia: a 

phenotype associated with mutations of 

the GNAS1 gene 

N Richard, G Abeguile & ML Kottler 

16.50-17.30 TEA 

HALL 3 




Chair: J Wass (Oxford, UK) 

S6 The actions of inhibin in endocrine tissues 

J Findlay (Clayton, Australia) 

From 19.30 Congress Banquet and Ceilidh 

HILTON HOTEL 

www.ece2006.com




disorders 


Chair: TBA 

F Kelestimur (Kayseri, Turkey) 




Chair: TBA 

B Eriksson (Uppsala, Sweden) 



HALL 1 

Chair: J Barth (Leeds, UK) 

N Goncharov (Moscow, Russia) 




FORTH ROOM 

Chair: S Kim (London, UK) 

G Brockman (Berlin, Germany) 

08.10-10.10 Symposium 13: 

Monogenic disorders illuminate 

metabolic disease 


Chair: P Froguel (Lille, France) 

S54 08.10 Epidemic obesity in humans 

S O'Rahilly (Cambridge, UK) 

S55 08.40 Specific metabolic features in Prader- 

Labhart-Willi syndome (PWS) as indicators 

of the underlying genetic defect 

U Eiholzer (Zurich, Switzerland) 

S56 09.10 PPAR gamma and human metabolic 

disease 

V Chatterjee (Cambridge, UK) 

S57 09.40 Learning from monogenic diabetes: 

insights into the fetal and adult β-cell 

A Hattersley (Exeter, UK) 

08.10-10.10 Symposium 14: 

Steroid hormone receptors 

HALL 1 

Chairs: H Klocker (Innsbruck, Austria) & 

F Claessens (Leuven, Belgium) 

S58 08.10 The ups and downs of nuclear receptor 

action in fat and fertility 

M Parker (London, UK) 

S59 08.40 Chromatin remodeling 

F Gannon (Heidelberg, Germany) 

S60 09.10 Cell membrane receptors of steroid 

hormones 

J Brosens (London, UK) 


S61 09.40 Lysine modifications in transcriptional 

regulation by steroid receptors 

J Palvimo (Helsinki, Finland) 

08.10-10.10 Symposium 15: 

Anabolic hormones in sport 


Chairs: G Tolis (Athens, Greece) & 


S62 08.10 Overview of anabolic steroids in sport 

K Kuoppasalmi (Helsinki, Finland) 

S63 08.40 Detecting growth hormone abuse in 

athletes 


S64 09.10 Gene doping: will the age of gene 

therapy usher in the age of genetic 

enhancement? 

H Sweeney (Pennsylvania, USA) 

S65 09.40 Erythropoietin 

D Cowan (London, UK) 


Calcium and bone 

FORTH ROOM 

Chair: TBA 

OC49*08.10 The A990G polymorphism of calcium 

sensing receptor gene (CASR) is 

associated with nephrolithiasis in patients 

with primary hyperparathyroidism (PHPT) 

C Eller-Vainicher, M Filopanti, G Vezzoli, 

L Soldati, P Saeli, P Beck-Peccoz, A Spada & 

S Corbetta 

OC50 08.25 Congenitally hypothyroid mice with 

(Pax8-/-) or without (hyt/hyt) functional 

TSH receptors (TSHR) display equivalent 

skeletal phenotypes 

GR Williams, R Swinhoe, E Murphy, 

AJ Williams, S Costagliola, G Vassart, 

PGT Howell, A Boyde, F Flamant, J Samarut, 

R Weiss, S Refetoff & JHD Bassett 

OC51*08.40 TSH receptor action in osteoblasts and 

osteoclasts in vitro 

E Murphy, AJ Williams, TM Galliford, 

S Costagliola, G Vassart, JHD Bassett & 

GR Williams 

OC52 08.55 In acromegaly, bone mineral density 

depends on gonadal function 

M Kochman, W Zgliczynski, W Misiorowski, 

P Zdunowski, L Papierska & S Zgliczynski 

OC53 09.10 Bone involvement in patients with 

adrenal incidentalomas: role of subclinical 

hypercortisolism 

I Chiodini, F Coletti, P Epaminonda, 

S Di Lembo, V Morelli, B Masserini, G Adda & 

M Arosio 


PROGRAMME

PROGRAMME 

26 


Wednesday 5 April 2006 - continued 

OC54 09.25 Adult mice harbouring a dominant 

negative R384C mutation of TRα1 have a 

marked increase in trabecular bone and 

micro-mineralisation density 

JHD Bassett, K Nordstrom, B Vennstrom, 

PGT Howell, A Boyde & GR Williams 

OC55 09.40 Thyroid hormones stimulate osteoblast 

differentiation but inhibit mineralization 

of bone nodules in vitro 

AJ Williams, JC Barnard, JHD Bassett & 

GR Williams 

OC56 09.55 The Scandinavian investigation of primary 

hyperparathyroidism (pHPT) - end of 

inclusion and preliminary results 

JB Bollerslev, SJ Jansson, CLM Mollerup, 

JN Nordenström, EL Lungren, OT Tørring, 

CF Franco, JEV Varhaug, GAI Isaksen & 

TR Rosen 

10.10-10.40 COFFEE 

HALL 3 

10.40-11.25 Clinical Endocrinology Trust Lecture 


Chair: L Rees (London, UK) 

S7 Thyroid disease paradigms and problems 

A Weetman (Sheffield, UK) 

11.35-12.20 Plenary 3 


Chair: P Bouchard (Paris, France) 

S10 Stem cells: regeneration in type 1 

diabetes 

M Trucco (Pittsburgh, USA) 

11.35-12.20 Debate: 

Metformin is the treatment of 

choice for polycystic ovarian 

syndrome 


Chair: S Franks (London, UK) 

For the motion: R Fleming (Glasgow, UK) 

Against the motion: A Balen (Leeds, UK) 



disorders 


Chair: TBA 

F Kelestimur (Kayseri, Turkey) 




Chair: TBA 

B Eriksson (Uppsala, Sweden) 



HALL 1 

Chair: J Barth (Leeds, UK) 

N Goncharov (Moscow, Russia) 




FORTH ROOM 

Chair: S Kim (London, UK) 

G Brockman (Berlin, Germany) 

13.05-13.35 LUNCH 

HALL 3 

13.35-15.35 Symposium 16: 

Disorders of melanocortin 

receptor functions 


Chair: H Biebermann (Berlin, Germany) 

S66 13.35 MC1R variants: Mendle is quite complex 

enough 

J Rees (Edinburgh, UK) 

S67 14.05 Identification of the genes causing ACTH 

insensitivity 

A Clark (London, UK) 

S68 14.35 Melanocortin receptor mutations in 

humans 

P Froguel (Lille, France) 

S69 15.05 Gs-independent signalling of 

melanocortin-4 receptors 

A Breit (Marburg, Germany) 

13.35-15.35 Symposium 17: 

Endocrine oncogenesis and 

management of hereditary 

endocrine tumours 


Chairs: B Kos Kudla (Zabrze, Poland) & 

E Rossella (Pisa, Italy) 

S70 13.35 RET function and dysfunction 

L Fugazzola (Milan, Italy) 

S71 14.05 Novel management strategies in 

medullary carcinoma of the thyroid 

J Feldkamp (Bielefeld, Germany) 

S72 14.35 Hypoxia inducible factor (HIF) and 

phaeochromocytoma 

C Pugh (Oxford, UK) 

S73 15.05 Familial phaeochromocytomas 

P Plouin (Paris, France) 

www.ece2006.com

Wednesday 5 April 2006 - continued 


Research management workshop 

HALL 1 

Chair: C Meir (Geneva, Switzerland) 

S94 13.35 Better management of ethical review in 

European medicine development 

I Klingmann (Brussels, Belgium) 

S95 14.15 Impact of the EU Clinical Trials Directive 

on academic research 

B Moulton (Dublin, Ireland) 

S96 14.55 Funding for commercialisation of research 

after the biotech bubble 

RN Seabrook (London, UK) 


Thyroid 

FORTH ROOM 

Chairs: M Alevizaki (Athens, Greece) & 

M Colculescu (Bucharest, Romania) 

OC57 13.35 Treatment of experimental hyperthyroid 

Graves' disease with decoy TNF-family 

ligand receptors suggests an essential role 

for BAFF in production of thyroid 

stimulating antibodies 

JA Gilbert, SL Kalled, J Moorhead, D Hess, 

P Rennert, Z Li, Z Khan & J-P Banga 

OC64 13.50 Thyroid hormone receptor TRβ1 mediates 

Akt activation by T3 in pancreatic β cells 

SM Misiti, CV Verga Falzacappa, VP Patriarca, 

SM Michienzi, AS Stigliano, EB Brunetti & 

VT Toscano 

OC59 14.05 Tri-iodothyronine improves 

haemodynamic performance and is 

associated with improved myocardial 

protection post on-pump coronary artery 

bypass grafting 

AM Ranasinghe, DW Quinn, TR Graham, 

BE Keogh, CJ Mascaro, SJ Rooney, IC Wilson, 

D Pagano, JA Franklyn & RS Bonser 

OC60 14.20 4-Methylbenzylidene-camphor (4MBC) 

causes pituitary effects comparable to 

hypothyroidism 

IH Hamann, C Schmutzler, P Kirschmeyer, 

H Jarry & J Köhrle 

OC61 14.35 Phosphodiesterase-resistant PKA I 

agonists inhibit thyroid cancer cell 

growth 

S Lucchi, D Calebiro, T de Filippis, P Porazzi, 

P Beck-Peccoz & L Persani 

OC62*14.50 The role of the thyroid hormone 

transporter monocarboxylate transporter 

8 (MCT8) in fetal brain development 

SR James, CJ McCabe, VE Smith, SY Chan, 

TG Barrett, JA Franklyn & MD Kilby 


OC63 15.05 Gender-specific differences in the 

expression of deiodinase I (Dio1) in 

mammals 

C Riese, U Schweizer, J Köhrle & L Schomburg 

OC58 15.20 Interleukin 1: the optimal cytokine target 

in thyroid-associated ophthalmopathy? 

TJ Cawood, P Moriaty, C O'Farrelly & 

D O'Shea 

15.35 Novartis Oncology Young Investigator 


and Close of Meeting 


Chair: S Lamberts (Rotterdam, The 

Netherlands) 


PROGRAMME

IN TREATING ACROMEGALY 

What Matters Most 

ABBREVIATED PRESCRIBING INFORMATION 

Indications: Treatment of patients with acromegaly: 

For symptomatic control and reduction of GH and IGF 1 levels 

in patients with acromegaly: 

• who are adequately controlled on s.c. treatment with 

Sandostatin, in whom surgery, or radiotherapy is 

inappropriate or ineffective, or in the interim period until 

radiotherapy becomes fully effective. 

• In short term (3-12 months) treatment prior to pituitary surgery 

GEP Tumours: Relief of symptoms of gastroenteropancreatic 

(GEP) tumours including carcinoid tumours, VIPomas 

and glucagonomas, in patients whose symptoms are 

adequately controlled on s.c. treatment with Sandostatin. 

Sandostatin is not antitumour therapy and is not curative in these 

patients. 

Presentation: Long-acting depot injection form of octreotide 

(as acetate): 10, 20 or 30 mg per vial each supplied with 

vehicle. 

Dosage and Administration: Sandostatin LAR may only be 

administered by deep intragluteal injection. The site of repeat 

intragluteal injections should be alternated between the left and 

right gluteal muscle. 

Acromegaly 

Adults: Deep intragluteal injection starting with 20 mg at 4 

weekly intervals for 3 months in patients who have had 

a test dose of s.c. Sandostatin or who are adequately controlled 

with s.c. Sandostatin. Adjust according to clinical and 

biochemical response. Dose can be increased to 30 mg every 

4 weeks. 

GEP tumours 

Adults: Deep intragluteal injection starting with 20 mg at 4 

weekly intervals for 3 months in patients adequately controlled 

GH Control 

IGF-I Control 

Tumour Shrinkage 

Symptom Control 

on usual therapeutic range of s.c. Sandostatin. Treatment with 

s.c. Sandostatin should be continued at the previously effective 

dosage for 2 weeks after the first injection of Sandostatin LAR. 

Assess response after 3 months. Adjust according to clinical and 

biochemical response (range 10 mg to 30 mg every 4 weeks). 

Children: Limited data available. 

Contra-Indications: Hypersensitivity to octreotide or any 

components of formulation. 

Precautions: Monitor glucose tolerance and antidiabetic 

treatment in patients with diabetes mellitus. The depth and 

duration of hypoglycaemia may be increased in patients with 

insulinoma. As GH-secreting pituitary tumours may sometimes 

expand, causing serious complications (e.g. visual field defects), 

it is essential that all patients are carefully monitored. Ultrasonic 

examination of the gallbladder before and at about 6 monthly 

intervals during Sandostatin LAR therapy is recommended. Do 

not use during pregnancy or lactation. 

Interactions: Cyclosporine, cimetidine, bromocriptine. 

Somatostatin analogues may decrease the clearance of drugs 

metabolised by CYP3A4, particularly those which have a low 

therapeutic index (e.g. carbamazepine, digoxin, warfarin and 

terfenadine). Caution should be exercised during coadministration 

of octreotide and these drugs. 

Side-Effects: Pain and rarely, swelling and rash at injection 

site. Anorexia, nausea, vomiting, abdominal pain or bloating, 

flatulence, loose stools, diarrhoea and steatorrhoea. In rare 

instances, gastrointestinal side-effects may resemble acute 

intestinal obstruction, with progressive abdominal distension, 

severe epigastric pain, abdominal tenderness and guarding. 

Gallstones can develop during long-term treatment. Persistent 

hyperglycaemia, hepatic dysfunction, hypoglycaemia, transient 

alopecia and acute pancreatitis have been reported rarely. Very 

rare cases of hypersensitivity have been reported. Refer to the 

SPC for a full list of all side-effects. 

©2006 Novartis Pharma AG 2/06 SAN06000004–February 2006

Attended Posters 


Posters will be displayed throughout the conference, and will be presented at 14.00-14.50 on the following dates: 

Topic Poster numbers Date 

Bone P1-P46 Sunday 2 April 

Clinical case reports P47-P89 Sunday 2 April 

Clinical case reports P90-P132 Monday 3 April 

Clinical case reports P133-P174 Tuesday 4 April 

Clinical practice and governance P175-P210 Monday 3 April 

Comparative endocrinology P211-P217 Tuesday 4 April 

Cytokines and growth factors P218-P250 Tuesday 4 April 

Diabetes, metabolism and cardiovascular P251-P308 Sunday 2 April 

Diabetes, metabolism and cardiovascular P309-P367 Monday 3 April 

Diabetes, metabolism and cardiovascular P368-P425 Tuesday 4 April 

Endocrine disruptors P426-P436 Tuesday 4 April 

Endocrine tumours and neoplasia P437-P475 Sunday 2 April 

Endocrine tumours and neoplasia P476-P513 Monday 3 April 

Endocrine tumours and neoplasia P514-P552 Tuesday 4 April 

Growth and development P553-P574 Sunday 2 April 

Neuroendocrinology and behaviour P575-P609 Monday 3 April 

Neuroendocrinology and behaviour P610-P644 Tuesday 4 April 

Reproduction P645-P686 Sunday 2 April 

Reproduction P687-P726 Tuesday 4 April 

Steroids P727-P770 Monday 3 April 

Thyroid P771-P828 Sunday 2 April 

Thyroid P829-P886 Tuesday 4 April 

Thyroid P887-P944 Monday 3 April 


POSTERS

POSTERS 

30 


Bone 

P1 An audit of the role of Sestimibi imaging of 

the parathyroid glands in the management of 

parathyroid disease 

D Gable, J Bomanji & G Conway 

P2 Does adrenal function influence bone status in 

primary hyperparathyroidism? Preliminary 

results in a large series of patients at the time 

of the diagnosis 

L Gianotti, F Tassone, A Pia, P Razzore, F Cesario, 

G Magro & G Borretta 

P3 The effect of local radiotherapy on 

osteoprotegerin levels in patients with bone 

metastases 

A Abdulkhaliq, C Foo, G Baffoe, P Anand, SI Girgis 

& C Quigley 

P4 Clinical aspects of diabetic osteoarthropathy in 

type 1 and type 2 diabetes mellitus patients 

AP Shepelkevich & DI Romeiko 

P5 Osteoporotic fractures in old subjects: role of 

functional and nutritional status and therapy 

effects during one year after fracture 

F Magri, V Valdes, V Guazzoni, M Cupri, L Chiovato 

& E Ferrari 

P6 Circulating osteoprotegerin and receptor 

activator of NF-κB ligand system in patients 

with beta-thalassemia major 

N Angelopoulos, G Rombopoulos, D Kaltsas, 

V Kaltzidou, E Katounda & G Tolis 

P7 The role of genetic individuality and 

phytoestrogens with minerals in prevention 

and treatment of postmenopausal 

osteoporosis 

I-O Vaasa, M Roosalu, S Teesalu & I Kalits 

P8 Is there any combined influence of the N363S 

polymorphism in the glucocorticoid receptor 

gene and the BsmI polymorphism in the 

vitamin D receptor gene on the occurrence of 

glucocorticoid-induced osteoporosis in 

patients with bronchial asthma? 

U Tworowska, B Bidzinska-Speichert, A Obojski, 

M Demissie, JW Koper & R Slezak 

P9 Bone mineral density in patients with type 1 

diabetes 

E Giorgadze, M Tsagareli, N Jikurauli & N Svani 

P10 Thyroid hormone receptor alpha has a critical 

negative role in maintenance of the adult 

skeleton 

JHD Bassett, PJ O'Shea, A Boyde, PGT Howell, 

J Samarut, O Chassande & GR Williams 

P11 PTH and phosphate circadian rhythms are 

altered in adult growth hormone deficient 

patients with low bone mineral density 

HD White, AM Ahmad, BH Durham, WD Fraser & 

JP Vora 

P12 Oral phosphate therapy used as an adjunct to 

growth hormone in adult growth hormone 

deficiency results in greater changes in bone 

mineral density compared with growth 

hormone replacement alone 

HD White, AM Ahmad, BH Durham, WD Fraser & 

JP Vora 

P13 Polymorphism in farnesyl pyrophosphatesynthase 

(FDPS) gene and relation with BMD 

and response to aminobisphosphonate 

treatment 

S Silvestri, S Carbonell, AB Thomsen, Y Bagger, 

C Christiansen & ML Brandi 

P14 Do different generations of PTH assay induce 

different diagnosis in renal bone disease? 

A Gendrot, A Georges, C Lasseur, L Bordenave & 

J-B Corcuff 

P15 Management of primary hyperparathyroidism 

- are we following consensus guidelines? 

KK Gangopadhyay, A Gurubili, D Nair & P De 

P16 Value of qualitative bone histology assessment 

in the evaluation of subjects with primary 

osteoporosis 

CE Georgescu, T Seck, HW Minne, R Ziegler, 

I Duncea, L Gozariu & J Pfeilschifter 

P17 Hearing impairment increases risk of bone 

fractures in women with Turner's syndrome 

TS Han, GS Conway & B Cadge 

P18 Evaluation of bone mineral density and 

markers of bone turnover in haemodialysis 

patients 

A Zygmunt, I Kurnatowska, J Fijalkowska- 

Morawska, J Bialkowska, M Jablkowski, M Nowicki 

& A Lewinski 

P19 The effect of ceramide on IGF-I induced 

proliferation in growth plate chondrocytes 

VE MacRae, SF Ahmed & C Farquharson 

P20 Treatment and follow-up of primary 

hyperparathyroidism: 50 cases 

H Cheikhrouhou, I Hadj Ali, K Khiari & 

N Ben Abdallah 

P21 Is there any relationship between the BsmI 

and FokI polymorphisms in the vitamin D 

receptor gene and bone mineral density in 

men? 

J Kuliczkowska-Płaksej, A Trzmiel, A Filus, 

U Tworowska, D Jedrzejuk & A Milewicz 

P22 Mutational analysis of the PHEX gene in 

familial and sporadic cases of X-linked 

hypophosphatemia (XLH) 

S Clausmeyer, PC Clemens, E Schulze & F Raue 

www.ece2006.com

P23 The reduction of bone mineral density in 

post-menopausal women with primary 

hyperparathyroidism is higher in the presence 

of concomitant GH hormone secretion 

impairment 

E Cecconi, M Genovesi, F Bogazzi, L Grasso, 

M Procopio, C Marcocci, A Pinchera, L Bartalena, 

E Martino & M Gasperi 

P24 Effect of melatonin on gene expression and 

mineralization in mouse osteoblast culture 

D Manda, C Busu, O Ianas, G Stefanovici, 

R Calarasu, D Grigorie & C Dumitrache 

P25 Effects of growth hormone administration on 

parathyroid hormone sensitivity and bone 

mineral metabolism in established 

osteoporosis 

F Joseph, A Ahmad, HD White, A Joshi, B Durham, 

S Vinjamuri, K Ashawesh, WD Fraser & JP Vora 

P26 Is 1g of calcium and 800IU of vitamin D 

sufficient to replenish vitamin D stores in 

postmenopausal women with low bone 

density? 

T Sathyapalan, M Bottazzi, C Walton & 

P Albertazzi 

P27 Synergistic induction of osteoblastic local 

glucocorticoid metabolism by inflammatory 

cytokines and glucocorticoids: a novel 

mechanism for glucocorticoid-induced bone 

disease 

K Kaur, R Hardy, PM Stewart, EH Rabbitt, 

M Hewison & MS Cooper 

P28 Evidence for high prevalence of hormonal 

irregularities in male osteoporosis 

S Goebel, C Riegel, L Seefried, B Saller & F Jakob 

P29 Evaluation of bone markers and structure in 

subclinical Cushing's syndrome 

M Monesi, MR Ambrosio, S Taroni, M Bondanelli, 

MC Zatelli & EC degli Uberti 

P30 Asymptomatic primary hyperparathyroidism: 

preliminary results of a prospective 

randomized study on the effect of 

parathyroidectomy 

E Ambrogini, L Cianferotti, E Vignali, F Cetani, 

G Viccica, A Picone, P Miccoli, A Pinchera & 

C Marcocci 

P31 Brown tumors in a patient with gluten 

enteropathy and masked primary (or tertiary) 

hyperparathyroidism 

K Jacob, J Sudagani, M Davies & P Selby 

P32 Baseline characteristics of postmenopausal 

Greek women with osteoporosis who had an 

inadequate response to antiresorptive 

medications 

A Ginis, E Charalampidou & N Thalassinos and the 

Hellenic OSSO Study Group 


P33 Effect of grape procyanidins on TNF alpha 

mRNA expression and cell DNA damage in 

MC3T3-E1 osteoblast-like cells in vitro 

JY Zhong & LH Zhang 

P34 The effects of dexamethasone and 

dehydroepiandrosterone (DHEA) on cytokines 

and receptor expression in a human 

osteoblastic cell line: potential steroid-sparing 

role for DHEA 

G Harding, YT Mak, B Evans, J Cheung, 

D MacDonald & G Hampson 

P35 Assessment of bone health and body 

composition in Glasgow school children 

R Rashid & SF Ahmed 

P36 Assessment of bone mineral density (BMD) in 

patients with adrenal incidentaloma (AI): 

comparison between dual-energy X-ray 

absorptiometry (DEXA) and quantitative 

ultrasonometry (QUS) 

G Reimondo, S Bovio, M Ventura, G Osella, A Angeli 

& M Terzolo 

P37 A comparative study of neck ultrasonography, 

Sestamibi scan and parathyroid surgery 

findings 

KCS Dixit, AJ Norris, PG Wiles, MW Savage, 

AN Khan & A Gandhi 

P38 Glucocorticoid metabolism in mouse 

osteoblasts: a model for the effects of local 

glucocorticoid generation on bone 

R Crook, K Hewitt, PM Stewart, EH Rabbitt & 

MS Cooper 

P39 Long-term growth hormone (GH) replacement 

in GH deficient adults - favourable effect on 

bone and body composition 

V Hána, J Cáp, T Vas˘átko & JJ Stepán 

P40 Does parathyroidectomy reduce the risk of 

fractures and renal stones? Results of a 

systematic review and meta analysis 

BE Sanders, M Davies & PL Selby 

P41 Brown tumors in hyperparathyroidism may be 

mistaken for primitive bone neoplasia: report 

of two cases 

CA Rota, F Ingraudo, RM Paragliola, MP Ricciato, 

AL Bilotta, F Ianni, F Gallo, G Ubertini, SM Corsello 

& A Pontecorvi 

P42 The effect of once-weekly risedronate on 

biochemical markers of bone turnover after 

three months of treatment 

D Paun, D Grigorie, A Ghemigian, F Cofaru & 

C Dumitrache 

P43 Quantitative ultrasound at the hand phalanges 

in patients with acromegaly 

M Bolanowski, W Pluskiewicz & J Daroszewski 


POSTERS

POSTERS 

32 


P44 Selenium supplementation restores the 

antioxidative capacity and prevents cell 

damage in mesenchymal stem cells in vitro 

R Ebert, M Ulmer, S Zeck, J Meissner-Weigl, 

D Schneider, H Stopper, N Schupp, M Kassem & 

F Jakob 

P45 Expression of the membrane-associated 

hormone-sensitive protein UO-44 in hMSC- 

TERT immortalized mesenchymal stem cells 

L Seefried, R Ebert, M Kassem & F Jakob 

P46 The effect of once-weekly risedronate on 

biochemical markers of bone turnover after 

three months of treatment 

D Paun, D Grigorie, A Ghemigian, F Cofaru & 

C Dumitrache 

Clinical case reports 

P47 Forced conservative management of a patient 

with pituitary tumour apoplexy and reduced 

conscious level 

A Advani, RA James, A Jenkins, JH Parr, J Scott, 

R Cooper & ST Wahid 

P48 An unusual presentation of 'fits' 

S Dissanayake, M Lazdam, V Basker, A Fryer, 

RC Strange, M Deaken & F Hanna 

P49 An unusual cause of confusion 

A Tahrani & P Moulik 

P50 Recurrent congenital neonatal 

hyperthyroidism in a mother with Graves' 

disease (post radio-ablation) on thyroxine 

replacement 

J Kumar, P Rajendran, R Lapworth, C Buchanan & 

C Williams 

P51 Isolated ACTH deficiency following long-term 

benzodiazepine treatment 

K Müssig, E Friess, K Mörike, H-U Häring & 

D Overkamp 

P52 Infertility and bilateral testicular masses due to 

21-hydroxylase deficiency 

K Müssig, S Kaltenbach, C Maser-Gluth, 

MF Hartmann, SA Wudy, M Horger, B Gallwitz, 

F Raue, H-U Häring & E Schulze 

P53 Graves' eye disease following radioiodine 

treatment for toxic nodular goitre 

A Tahrani & P Moulik 

P54 Recurrent hypoglycaemia: an unusual 

association of islet cell hyperplasia and coeliac 

disease 

RS Moisey, D Wright & SR Peacey 

P55 Screening of osteoporosis in a small Romanian 

town 

S Mandasescu & MM Trisca 

P56 Acute myocardial infarction and Graves' 

thyrotoxicosis 

RA Chudleigh, PJD Owen, S Bhattachrya & 

JS Davies 

P57 Acromegaly, pregnancy and diabetes mellitus - 

a successful maternal and foetal outcome 

SS Seshadri, D Wright, DC Whitelaw & SR Peacey 

P58 Surgical management of metastatic 

phaeochromocytoma: review of 2 cases 

TH El-Tawil, KH Darzy, R Carpenter, S Bhattacharya, 

S Edmondson & JP Monson 

P59 The coincidence of mucoepidermoid and 

papillary thyroid carcinoma. A case report 

GL Kovacs, F Salamon, Z Gorombey, L Kovacs, 

E Hubina, MI Goth & I Szabolcs 

P60 DIre Straits - hypothalamic diabetes insipidus, 

acute myeloid leukaemia and high risk 

cytogenetics: 45,XX,t(3;3)(q21q26),-7 

KS Myint, M Besser, J Craig, D Halsall, H Simpson, 

DF Wood, VKK Chatterjee & M Gurnell 

P61 Metastatic insulinoma or not? 

KS Myint, RK Semple, I MacFarlane, D Appleton, 

RK Praseedom, H Simpson, DF Wood, 

VKK Chatterjee & M Gurnell 

P62 APECED (autoimmune polyendocrinopathycandidiasis-ectodermal 

dystrophy) syndrome 

with atypical or incomplete presentation: 

report of 4 cases with AIRE gene mutations in 

heterozygosity 

C Mazza, I Sparapani, L Costa, S Zanola, 

M Filisetti, A Pilotta, F Lombardi, MI Spagnuolo, 

G Valerio, A Franzese, G Radetti & F Buzi 

P63 Relationship between age of onset, natural 

course and therapeutic approach in patients 

with acromegaly 

EI Marova, VS Pronin, SE Agadzanjan, 

NN Molitvoslovova, MB Antsiferov & TM Alexeeva 

P64 Sweet's syndrome and thyroid diseases: 

is there a link? 

F Magri, E Gabellieri, AR Sorrentino, MI Rizza, 

L Chiovato & E Ferrari 

P65 Bone marrow hypoplasia in a patient with 

panhypopituitarism responsive to sex 

hormone therapy. The importance of 

compliance with testosterone therapy 

MA Badawi, FS Farah, MY Elkhalifa, A Al-Humaidi & 

TA Elhadd 

P66 Multiple endocrine neoplasia type 1 (MEN1) 

in a patient with systemic mastocytosis 

A Jönsson, C Grännö, J Järhult & G Roupe 

P67 Brown tumour of the maxilla as the presenting 

feature of parathyroid carcinoma 

AJ Watt, T Gruning & DEH Flanagan 

P68 Unexpected detection of thyroid cancer in a 

patient with presumed Graves' thyrotoxicosis 

AJ Watt, T Gruning & DEH Flanagan 

P69 Primary hyperparathyroidism (PHPT): still a 

cause of hypertension resistant to therapy 

AP Baptista, EC Morgado, AP Silva & PL Neves 

www.ece2006.com

P70 Spontaneous pregnancy after trans-sphenoidal 

surgery in a patient with pituitary hypophysitis 

- a case report 

H Siddique, V Baskar, S Dissanayeke, RN Clayton & 

FWF Hanna 

P71 Adipsic diabetes insipidus following pituitary 

surgery for a macroprolactinoma 

M Sherlock, A Agha, D Smith, R Crowley & 

C Thompson 

P72 Regression of somatotropinoma in the course 

of treatment with octreotide in a female 

patient with acromegaly 

B Matuszek, M Lenart-Lipińska & A Nowakowski 

P73 Familial hyperparathyroidism with a mutation 

in the HRPT2 gene 

P Goulden, G Bano, VK Ajith Kumar, SV Hodgson & 

SS Nussey 

P74 Pendred's syndrome with three mutations 

P Goulden, G Bano, VK Ajith Kumar, SV Hodgson & 

SS Nussey 

P75 About three cases of Riedel thyroiditis 

MC Vantyghem, S Marcelli-Tourvieille, J Schmidt, 

B Néraud, P Perimenis, E Leteurtre, C Cardot- 

Bauters, F Pattou, B Carnaille & JL Wémeau 

P76 Parathyroid carcinoma in a patient with 

chronic renal failure on long-term dialysis 

MR Diaconescu, M Glod & I Costea 

P77 Should prophylactic thyroidectomy be carried 

out in mucosal neuroma syndrome? 

G Spyer, S Ellard, P Turnpenny, A Hattersley & 

B Vaidya 

P78 Synchronous malignant para-aortic 

phaeochromocytoma and vagal nerve 

paraganglioma in a patient with germline 

SDHB mutation 

RW McCallum, P Stanton, S Walker, 

V Parameswaran & T Greenaway 

P79 Ophthalmic presentations of Cushing's 

syndrome 

IM Ibrahim, A Al-Bermani & RA James 

P80 Long-term outcome of untreated Cushing's 

syndrome due to pituitary microadenoma 

L Nduwayo, J Othmani & P Rousseaux 

P81 Invasive prolactinoma with multiple 

recurrences: pituitary atypical adenoma or 

pituitary carcinoma? Report of a case 

L Gomes, I Paiva, C Ribeiro, F Gomes, M Rito, 

O Rebelo & M Carvalheiro 

P82 A case of primary pigmented micronodular 

hyperplasia as a cause of Cushing's syndrome 

A Akalin, O Son, S Isiksoy, N Kebapci & B Efe 

P83 Endocrine evaluation in a man with restrictive 

eating disorder 

M Moro, L Danesi, N Polli, E Rasi, B Filippini, 

M Andrioli, M Scacchi & F Cavagnini 


P84 Hypopituitarism in an adult thalassemic 

patient. Effects of different replacement 

therapies 

L Danesi, A Cattaneo, E Lavezzi, M Scacchi & 

F Cavagnini 

P85 Langerhans cell histiocytosis; management 

dilemma for the adult endocrinologist! 

IM Ibrahim, E-L Lim, S Razvi, SHS Pearce, N Leach, 

R Quinton, D Mitra, J Wilsdon, A Baborie, 

S Johnson, AD Burt, K Wood, G Jones, K Windebank, 

J Pritchard, CO Record & SMM Bennett 

P86 A case of bacterial endocarditis in a patient 

with acromegaly 

G Bassotti, D Di Sarra, D Pietrobono, T D'Amico, 

P Gargiulo & G Tamburrano 

P87 Gitelman's syndrome in pregnant, type 1 

diabetic patient presented with foetal growth 

retardation, and bilateral hydronephrosis and 

hydroureter 

MA Elrishi, A Kilvert, B Sirnivasan & I Lawrence 

P88 The prolonged progressive course of 

acromegaly, complicated with diabetes 

mellitus, bilateral gonarthropathy, thyroid 

pathology and severe papillomatosis (clinical 

observation) 

TS Kamynina, AV Dreval & JG Pokramovich 

P89 A case of adult GH deficit in a woman with 

autoimmune polyendocrine syndrome type II 

D Pietrobono, G Bassotti, F Diacono, R Iuorio, 

V Mercuri & P Gargiulo 

P90 Spontaneous thrombosis of ophthalmic artery 

aneurysm causing isolated cortisol deficiency 

A Zia, F Joseph, S Basu, TRK Varma & JP Vora 

P91 Aortic involvement in Turner syndrome 

M Ilyas, SL Atkin, V Mathew, C Chu & D Ettles 

P92 Purely adrenaline-secreting 

phaeochromocytoma: a classical presentation 

of a rare entity 

A Merghani, KH Darzy, D Morris, R Carpenter, 

A Deaner & JP Monson 

P93 A scary awakening - acute paralysis in a young 

man 

LV Forrest & JK Platts 

P94 Systemic amyloidosis presenting with 

thyrotoxicosis: a case report 

G Fegan, S Rasbridge & M Taylor 

P95 Unusual case of pseudohypoparathyroidism 

type IB 

LCH Ciin & T Dornan 

P96 A case of Cushing's syndrome and rapid 

course of illness 

J Sudagani, K Jacob, S Anwar, C Gibson, JRE Davis 

& FCW Wu 

P97 Primary adrenal insufficiency, gonadal failure 

and weak legs 

J Sudagani, K Jacob, S Anwar, C Gibson, JRE Davis 

& FCW Wu 


POSTERS

POSTERS 

34 


P98 Hypocalcemic cardiomyopathy in a patient 

with primary hypoparathyroidism and Fahr's 

disease 

S Azzoug & F Chentli 

P99 An unusual case of panhypopituitarism 

associated with positive ANCA: atypical 

presentation of Wegener's disease or 

lymphocytic hypophysitis? 

F Medici & P Kelly 

P100 Isolated secondary hypothyroidism in identical 

twins 

PJ Weston, AK Annamalai & S Bandyopadhyay 

P101 Adrenal-insufficiency manifesting as 

hyperkalaemic paralysis 

AS Kashyap, KP Anand & S Kashyap 

P102 Hypercalcaemia and hypereosinophilic 

syndrome in a patient with 

cholangiocarcinoma 

KP Papatheodorou, DP Papazoglou, NP Papanas, 

CI Iakovidis & EM Maltezos 

P103 Di-George syndrome presenting with 

hypocalcaemia and personality disorder in 

adulthood - a case report 

M Jose, N Iqbal, P Gaut, D Balakrishnan & 

H Maksoud 

P104 Phaeochromocytoma presenting as gestational 

diabetes 

KM Evans, I Montague, BA Millward & DE Flanagan 

P105 Conn's syndrome associated with 

hyperprolactinaemia: two case reports. 

Hypertension was cured by surgery in both 

cases despite a 10- and 16-year history 

I Talapatra, S Ghosh & DJ Tymms 

P106 Parathyroid carcinoma in multiple endocrine 

neoplasia (MEN) type 1: two case reports 

A Agha, R Carpenter, S Bhattacharya & JP Monson 

P107 Co-existing hypoparathyroidism and vitamin D 

deficiency causing life-threatening 

hypocalcaemia 

L Edwards & M Abubaker 

P108 A rare case of metastatic choroidal melanoma 

to the thyroid gland: the importance of 

cytology 

C Vezzosi, C La Magra, P Pedaccini, M Bernardini, 

S Silvestri & R Nassi 

P109 A complex case of pregnancy and 

pegvisamont treated acromegaly 

AI Qureshi, G Ramanathan, A Walton, L Seal, 

G Bano, I Manyonda & A Panahloo 

P110 Post-partum thyroiditis (PPT): colour-Doppler 

ultrasonography evaluation 

P De Remigis, A De Remigis & L Vianale 

P111 The challenges of managing metabolic 

derangements 

N Iqbal, A Gruber & G Thomson 

P112 Three generations of generalised resistance to 

thyroid hormone (GRTH) 

SC McGeoch, WA Watson, E Stephen, H Watson, 

A Mayo, P Abraham & JS Bevan 

P113 Mineral-rich baths - an unusual source of 

exposure to excess iodine 

KD Hopkins & S Ibrahim 

P114 Biochemical screening for RET negative 

medullary thyroid carcinoma (MTC): a case 

report highlighting difficulties in the 

interpretation of pentagastrin stimulated 

calcitonin testing 

DR Webb, N Seevaratnam, M Suri & P King 

P115 A long-standing lump in the neck proving 

troublesome for the surgeons 

S Bandyopadhyay & JP Vora 

P116 A case of isolated ACTH deficiency who 

developed autoimmune-mediated 

hypothyroidism and hepatitis 

SY Kim, JH Kim & HY Bae 

P117 Cushing's disease presenting as a 

schizophreniform psychosis 

RW McCallum, V Parameswaran, A Duffield, 

L Hoffman, JR Burgess & T Greenaway 

P118 Obesity, hypertension and elevated 

catecholamines 

AA Joshi, VKB Prabhakar, HD White, MJ Diver & 

JP Vora 

P119 Cushing's syndrome in an adolescent with 

MEN1: where is the lesion? 

F Smeeton, JS Davies, MF Scanlon & DA Rees 

P120 Glucagonoma: does the clinical expression 

depend on the presence of inherited disease? 

F Smeeton, JS Davies, MF Scanlon & DA Rees 

P121 A rare cause of gynaecomastia 

C Ravikumar, M-F Kong, MJ Levy & TA Howlett 

P122 Is the continuation of lithium treatment safe 

during peri-operative periods? 

A Tan, S Bandyopadhyay & JP Vora 

P123 An unusual cause of jaundice 

PJD Owen, SS Lakra, LDKE Premawardhana, 

A Baghomian, A Godkin & JH Lazarus 

P124 Severe thyrotoxicosis and pregnancy 

JH Parr, A James Jones, K Wynne & S Wahid 

P125 Identification of two novel GALNT3 mutations 

in a patient with familial tumoral calcinosis 

(FTC) 

AM Barbieri, M Filopanti, G Bua & P Beck-Peccoz 

P126 Megadenoma 

BCT Field, SC Barnes, MJ Wheeler, MP Powell, 

SM Thomas & PV Carroll 

P127 Autoimmune hypophysitis causing permanent 

diabetes insipidus - a case report 

D Grant, K Campbell & J Connell 

www.ece2006.com

P128 Time course of neuroendocrine dysfunction 

after aneurysmal subarachnoid hemorrhage - 

need for reassessment even years after the 

hemorrhage? 

A Reineke, E Poll, S Levasseur, E Yagmur, 

JM Gilsbach & I Kreitschmann-Andermahr 

P129 A case of late onset congenital adrenal 

hyperplasia in a female epileptic patient: 

implications for clinical practice 

E Davies, J Kisalu, PM Bouloux & M Thomas 

P130 Adult-onset nesidioblastosis- a rare clinical case 

T Martins, L Gomes, J Guimarães, M Melo & 

M Carvalheiro 

P131 Seeking an appropriate sex of rearing in 

5α-reductase deficiency 

S Iyer, RM Thomas & T Cheetham 

P132 49,XXXXY syndrome connected with 


B Wikiera, R Slezak, E Glab, E Barg & A Noczynska 

P133 Giant labia majora in familial partial 

lipodystrophy 

T Kyaw Tun, N Correia, NA Phelan, M Shahid, 

O Buckley, W Prendeville & J Gibney 

P134 Pituitary apoplexy and acromegaly: a case 

report 

K Jacob, J Sudagani, S Anwar, C Gibson, FCW Wu, 

DW Ray & JRE Davis 

P135 The effects of lanreotide administration vs 

unilateral adrenalectomy on disease activity in 

GIP-dependent Cushing's syndrome 

M Robaczyk, B Krzyzanowska-Swiniarska, G Kulig & 

K Pilarska 

P136 Epilepsy at presentation of macroprolactinoma 

D Deepak, N Bashir, P Foy & IA MacFarlane 

P137 Difficulty to distinguish hyperandrogenia due 

to a tumoral formation or to polycystic ovary 

syndrome: a case report 

MP Teissier, C Combes, A Drutel & S Lopez 

P138 Resolution of diagnostic uncertainties with 

DAX-1 gene mutation analysis 

P Arundel, R Fisher, C Chu & S Alvi 

P139 Multihormonal disorders in 17-year-old girl 

with congenital hypoplastic anemia and 

secondary hemochromatosis 

E Glab, B Wikiera & E Barg 

P140 Carcinoid tumour: spontaneous regression 

following pregnancy 

EL Lim, I Macleod, D Carr, D Manas, R Quinton & 

A James 

P141 A rare cause of thyrotoxicosis and 

hypercalcemia 

NPN Murthy, Y Prasad, M Thomas & T Fiad 

P142 Maternal virilization and female fetal 

pseudohermaphroditism caused by 

exaggerating androgen secretion of 

pregnancy leutomas 

C Chen & Y Wang 


P143 Two unusual cases of extra-adrenal 

phaeochromocytoma 

PK Singh, N Iqbal, P Strouhal, BM Singh & 

HN Buch 

P144 Prolonged hungry bone syndrome in a patient 

with Wolfram syndrome: a case report 

O Basat, S Ucak, AB Oncul, S Seber, N Eren & 

Y Altuntas 

P145 Postmenopausal androgen excess: a clinical 

perspective 

SA Ritchie, A Collier, M McIntyre & JMC Connell 

P146 Use of pulse methylprednisolone therapy in 


O Nechaeva, Y Bardeeva, O Perepelova, 

T Shestakova & I Chikh 

P147 Acute suprarenal impairment because of an 

adrenal bilateral necrosis with 

antiphospholipids' syndrome 

J Combes, S Chabroux & JP Ory 

P148 Challenges in the management of an 

uncommon cause of diabetes insipidus 

K Kaushal, K Jacob & SM Shalet 

P149 Psychiatric and movement disorders in 

primary hypoparathyroidism 

S Chatterjee 

P150 A case report of malignant insulinoma 

N Jeandidier, S Boullu, L Ciarloni, S Drui, B Louis, 

M Pinget, JE Kurtz & G Chabrier 

P151 Malignant paraganglioma in young patient 

without symptoms - a case report 

Z Velija-Asimi 

P152 Secondary amenorrhoea induced by 

dihydrocodeine ingestion resolves following 

opiate withdrawal 

S González & RD Murray 

P153 Combined cortisol and aldosterone 

hypersecretion in two unusual cases of 

hypertension due to adrenocortical neoplasia 

SCM Miller & JMC Connell 

P154 Endocrine disorders in a high secure hospital 

IA MacFarlane, D Deepak & GV Gill 

P155 Acromegaly with a double pituitary adenoma 

S Chandran & C Parkinson 

P156 17β-Hydroxysteroid dehydrogenase deficiency 

caused by homozygous H271R mutation 

A Bachelot, Z Chakhtoura, F Kuttenn, Y Morel & 

PH Touraine 

P157 Small intragenic somatic mutation associated 

with a germline mutation of HRPT2 gene in a 

patient with sporadic primary 

hyperparathyroidism 

E Pardi, F Cetani, E Ambrogini, S Borsari, M Lemmi, 

A Pinchera & C Marcocci 


POSTERS

POSTERS 

36 


P158 Plasma exchange for the prevention of severe 

thyrotoxic exacerbation following radioactive 

iodine therapy for Graves' hyperthyroidism 

A Wee, V DeSilva & MG Prentice 

P159 Not-so-silent, silent corticotroph adenomas 

SGI Suliman, SE Baldeweg, O Ansorge, A Clark, 

M Powell & JAH Wass 

P160 Cushing's syndrome presenting with 

palpitations 

NG Lessan 

P161 An unusual case of PTHrPoma with coexistent 

secondary hyperparathyroidism 

MO Sharfi, E Hardy, AA Panahloo, F Lofts & LJ Seal 

P162 False positive newborn screen for congenital 

hypothyroidism due to a TSH-IgG (macro-TSH) 

complex 

DJ Halsall, SK Hall, P Barker, J Anderson, 

M Fahie-Wilson, R Gama & VK Chatterjee 

P163 Familial hypocalciuric hypercalcemia (FHH) 

caused by P748L mutation in the calcium 

sensing receptor (CaSR) gene 

R Mahto, A Tahrani, A Macleod & RV Thakker 

P164 Importance of complex evaluation of the 

changes in ST-segment in ECG: case report of 

the patient with Addison disease and Brugada 

syndrome 

M Pura & P Vanuga 

P165 Metformin-associated lactic acidosis in a 

Caucasian woman precipitated by acute renal 

failure treated with bicarbonate haemodialysis 

T González Losada, L Del Olmo García, P Martinez 

de Icaya, V Alcázar Lázaro, T López del Val, 

M Pérez Pelayo & S Herranz Antolín 

P166 Dysgerminoma and gonadoblastoma in 

children with complete androgen insensibility 

A Noczynska, T Zak & B Salmonowicz 

P167 Unexpected features in Prader-Willi syndrome 

- case report 

C Vulpoi, C Rusu, MC Ungureanu, C Preda, 

O Stoica & E Zbranca 

P168 Three extreme cases of electrolyte imbalanceinduced 

seizures 

AG Gruber, N Iqbal & GA Thomson 

P169 Two cases of idiopathic primary 

hypoparathyroidism 

C Badiu, D Cristofor & M Coculescu 

P170 Cushing's syndrome due to medullary thyroid 

carcinoma - a case report 

A Sousa, E Rodrigues, A Varela, E Vinha, D Braga, 

P Couto, J Lopes, M Cardoso-Oliveira & JL Medina 

P171 Polymyalgia rheumatica and Hashimoto 

thyroiditis 

GN Karachalios, I Kostoglou-Athanassiou, 

P Athanassiou & PH Kaldrymidis 

P172 Addison's disease: soy sauce - a life-saving 

concoction 

B Bhattacharya, A Ullah, WSA Smellie, A McCulloch 

& AH Heald 

P173 Pretibial myxoedema: is this a marker for 

occult thyroid ophthalmopathy? 

B Bhattacharya, A Ullah, AJ McCulloch & AH Heald 

P174 An unusual carcinoid tumor in a case of 

Cushing syndrome 

ZT Turki, FA Aouididi, HS Smida, LBS Ben Salem, 

RB Bouguerra & CBS Ben Slama 

Clinical practice and governance 

P175 Audit on management of chronic adrenal 

insufficiency 

RK Rao, A Brahma & H Gray 

P176 Salivary cortisol daycurve and quality of life 

assessment in optimizing glucocorticoid 

replacement therapy in patients with 

Addison's disease 

LCCJ Smans, EGWM Lentjes & PMJ Zelissen 

P177 Symptom-specific thresholds for testosterone 

deficiency modulate complaints and metabolic 

risk in 434 aging male patients 

M Zitzmann, S Faber & E Nieschlag 

P178 Long-term experience of more than 8 years 

with a novel formulation of testosterone 

undecanoate (nebido) in substitution therapy 

of hypogonadal men 

M Zitzmann, F Saad & E Nieschlag 

P179 Improvements for patients and nurses using 

2.5ml prefilled syringes as the vehicle solution 

for suspension of sandostatin LAR 

microspheres 

KT Maher, WM Drake, GM Besser, AB Grossman, 

SL Chew, PJ Jenkins, LA Kalingag, FK Fode, 

MT O'Sullivan-Hawketts, DM Walker & JP Monson 

P180 Impaired thirst and AVP release in a patient 

with partial cranial diabetes insipidus (CDI) 

and subtle pituitary disease 

WHMS Chandrasekara, S Khan, SS Lakra, 

MD Penney & LDKE Premawardhana 

P181 Reactive hypoglycaemia - can measuring 

insulin concentrations help understand the 

pathophysiology and support diagnosis? 

RB Poole, AJ Brooks & JSW Li Voon Chong 

P182 Impaired quality of life in patients with adrenal 

insufficiency - evidence that improved 

glucocorticoid replacement strategies are 

needed 

S Hahner, M Loeffler, W Arlt, O Decker, AC 

Koschker, D Weismann, M Fassnacht & B Allolio 

P183 Long-acting, intramuscular testosterone 

undecanoate (TU, NEBIDO) in the treatment 

of female-to-male transgender individuals 

JW Jaobeit, M Epe, U Hugo, M Ludwig & 

HM Schulte 

www.ece2006.com

P184 Long-acting intramuscular testosterone 

undecanoate (TU, NEBIDO) in treatment of 

hypogonadal aging males 

JW Jacobeit & HM Schulte 

P185 Screening in primary care using fasting 

glucose uncovers significant hypoglycaemia 

including an asymptomatic insulinoma 

S Wordsworth, M Hassanein & J Platts 

P186 Comparison of the effect of sibutramine 

monotherapy with sibutramine-metformin 

combination therapy in nondiabetic obese 

women 

M Sargin, H Sargin, H Gozu, M Tuna, F Erkal, 

M Tekce & A Yayla 

P187 Torbay adrenal and pituitary project 

S Cox 

P188 Autoimmune hypoadrenalism: the profile of 

related conditions 

JAH Wass, KG White & A Elliott 

P189 Recombinant hGH therapy in males with 

organic GHD: should we trust in total 

testosterone levels for diagnosis of central 

hypogonadism? 

C Giavoli, AG Lania, E Ferrante, F Ermetici, 

S Bergamaschi, CL Ronchi, B Ambrosi, A Spada & 

P Beck-Peccoz 

P190 Survey of steroid replacement therapy 

S Gorick, RH Greenwood, PJ Heyburn, MJ Sampson, 

KK Dhatariya & RC Temple 

P191 Concordance between GH determination and 

IGF-I in acromegaly using two IGF-I methods 

S Hepburn, SM Chambers, JA Gilbert, 

AM McGregor, JP Miell & SJB Aylwin 

P192 Adult Turner syndrome clinic: what are the 

patients' perceptions of this specialist service? 

LE Smethurst 

P193 Adequacy of post-glucose GH nadir 20 000mU/l - 

review of presentation, management and 

outcome 

N Seevaratnam, E Khoo, R Rea & P Mansell 

P195 Long term outcome in men with 

microprolactinoma 

R Rea & W Jeffcoate 

P196 Ophthalmic findings in Turner syndrome 

B Wikiera, M Mulak, E Barg & B Reniewska 

P197 Early detection of diabetic autonomic 

neuropathy with a new device 

M Fevre-Genoulaz, MJ Lafitte, SS Srikanta, 

L Punitha & S Vidyanand 


P198 Adult growth hormone replacement therapy 

after the institution of NICE guidelines 

S Curran, P Lowdell, A Webb, C Holmes, M Gurnell, 

DF Wood, VKK Chatterjee & HL Simpson 

P199 Clinical evaluation of Sheehan syndrome 

A Kubat Uzum, M Mert, Y Orhan, N Ozbey & 

F Aral 

P200 Is a repeat or resting prolactin necessary in the 

investigation of hyperprolactinaemia? 

R Agarwal, S Pramodh, P Durroch, S Chambers, 

A McGregor & SJB Aylwin 

P201 Knowledge of testosterone replacement 

therapy is significantly correlated with patient 

satisfaction, suggesting greater need for 

education 

SV Llahana & GS Conway 

P202 Cushing's disease - an audit of outcomes 

following pituitary surgery from a single 

centre 

V Baskar, G Varugheese, V Carlin & RN Clayton 

P203 Clinical characterization of patients with 

hyperprolactinaemia due to macroprolactin 

F Donadio, AR Angioni, A Lania, E Orsi, 

P Beck-Peccoz & A Spada 

P204 Total cortisol and calculated free cortisol 

during the 250µg ACTH test 

M Klose, M Lange, A Krogh-Rasmussen, E Haug & 

U Feldt-Rasmussen 

P205 Comparison of the effects of transdermal and 

oral oestrogen treatments on serum and 

salivary cortisol concentrations 

A Bahri, L Breen, S Barnes, JK Powrie, SM Thomas & 

PV Carroll 

P206 A survey of gender dysphoria (transsexual) 

patients attending an endocrine clinic 

G Scull, C Gibson, L Webster, DW Ray, FCW Wu & 

JRE Davis 

P207 Osteoporosis, osteopaenia and osteoarthritis in 

autoimmune hypoadrenalism 

JAH Wass, KG White & A Elliott 

P208 Autoimmune hypoadrenalism: symptoms at 

diagnosis 

KG White, JAH Wass & A Elliott 

P209 Does HT still have a place? The impact on 

menopausal-related symptoms 

C Cristea, C Vulpoi, MC Ungureanu, L Leustean, 

C Concita, V Mogos & E Zbranca 

P210 High mortality rate in hospital in-patients with 

hyponatraemia 

LCH Ciin, P Narayanan, F Stewart, A Heald & 

T Dornan 


POSTERS

POSTERS 

38 


Comparative endocrinology 

P211 The patients with HIV lipodystrophy syndrome 

have lower total fat mass but similar free fat 

mass 

P Freitas, D Carvalho, F Correia, T Faria, B Perez, 

R Marques, R Serrão, J Pereira, A Mota Miranda & 

JL Medina 

P212 Dynamic macroprolactin and adjusted 

prolactin responses in hyperprolactinaemic 

patients 

S Bandyopadhyay, MJ Diver & JP Vora 

P213 Retrospective study of usefulness of Sestamibi 

scans in primary hyperparathyroidism 

K John, S Blackburn, J Miell & C Diaz 

P214 Assessment of oxidative stress in patients with 

polycystic ovarian syndrome treated with 

either orlistat or metformin 

J Shepherd, V Jayagopal, ES Kilpatrick & SL Atkin 

P215 Prognostication in canine parvoviral diarrhoea 

using basal serum cortisol concentrations 

JP Schoeman, LJ Venter, A Goddard, AL Leisewitz & 

ME Herrtage 

P216 Short-term effects of propionate on the leptin 

system and on G protein-coupled receptor 

GPR41 mRNA levels in adipose tissue of goats 

MM Mielenz, CS Seybold & HS Sauerwein 

P217 Ontogeny of galanin and vasotocin 

immunoreactivity in the supraoptic nucleus 

(SON) and the bed nucleus of the stria 

terminalis (BSTM) in chickens 

S Klein & R Grossmann 

Cytokines and growth factors 

P218 The role of IL-4 and IFN-gamma as prognostic 

factors of major adverse cardiac events in 

patients with ST-elevation myocardial 

infarction assigned primary percutaneous 

coronary intervention 

M Osuch, B Szygula-Jurkiewicz, J Szkodzinski, 

R Wojnicz, A Lekston, L Polonski, A Blazelonis & 

B Zubelewicz-Szkodzinska 

P219 Adiponectin and resistin concentrations during 

oral glucose tolerance test (OGTT) in insulinresistant 

subjects 

K Szosland, K Lewandowski, H Randeva & 

A Lewinski 

P220 Effects of IGF-II on glucose metabolism 

S Zachariah, A Brackenbridge & D Russell Jones 

P221 Interleukin-6 and transforming growth factor 

beta-1 concentration in serum in patients with 

coronary vessels restenosis 

AB Blazelonis, J Szkodzinski, W Romanowski, 

A Danikiewicz, M Gasior, L Polonski, A Kaszuba, 

M Muc-Wierzgon & B Zubelewicz-Szkodzinska 

P222 Immunosuppressive effect of recombinant 

human erythropoietin 

A Vahdati, M Adib & S Kashfi 

P223 Low dose dexamethasone does not alter 

serum adiponectin or resistin concentrations 

KC Lewandowski, K Szosland & A Lewinski 

P224 Interleukin-6 and TNF-alpha in hemodialysis 

patients: association with obesity and 

metabolic syndrome 

Z Rasic, G Perunicic, Z Gluvic, J Tica & M Pavicevic 

P225 VEGF and sVCAM in patients with adrenal 

gland tumors 

TA Britvin, NE Kushlinsky, IA Kazantseva, 

MA Sivtsova & AP Kalinin 

P226 Prolactin deficiency is independently 

associated with reduced IGF-I status in 

severely GHD adults 

A Mukherjee, WDJ Ryder, A Jostel & SM Shalet 

P227 GH/IGF-I axis and haematological alterations 

in anorexia nervosa 

N Polli & F Cavagnini 

P228 Selected hormones serum levels in 

dependence on BMI and sex 

M Tajtáková, Z Semanová, D Petrás˘ová, 

J Petrovičová & M Pytliak 

P229 Abnormalities of humoral immunity with 

reduced immunogenicity to pneumococcal 

vaccine in panhypopituitarism 

A Mukherjee, M Helbert, JRE Davis & SM Shalet 

P230 Lack of influence of an IGF-I gene 

polymorphism on circulating IGF-I levels in 

severely GHD adults 

JAMJL Janssen, A Mukherjee, HK Gleeson, 

S Lamberts & SM Shalet 

P231 Serum TGF-beta-1 levels in non-alcoholic 

steatohepatitis 

S Yener, B Akinci, F Bayraktar, T Demir, M Akarsu, 

MA Özcan, M Yalcin, L Kebapcilar, A Comlekci & 

S Yesil 

P232 Subclinical hypothyroidism could be regarded 

as a benign condition in oxidative stress but 

not in atherosclerosis 

L Kebapcilar, B Akinci, F Bayraktar, A Comlekci, 

A Solak, T Demir, S Yener, T Kume, A Ozkaya & 

S Yesil 

P233 Low TGF-beta-1 levels in idiopathic male 

osteoporosis 

B Akinci, F Bayraktar, A Saklamaz, T Demir, S Yener, 

A Comlekci, MA Ozcan, L Kebapcilar, F Yuksel & 

S Yesil 

P234 Possible predictive value of IGF-II mRNA 

expression in breast cancer (BC) 

CG Giani, EG Giustarini, PF Fierabracci, DC 

Campani & MEL Lippman 

P235 IGF-II protein expression in breast cancer. 

Relationship with the most important 

predictive parameters in breast malignancy 

EG Giustarini, AP Pinchera, DC Campani, 

PF Fierabracci, KC Cullen & CG Giani 

www.ece2006.com

P236 The effect of growth hormone replacement on 

the diurnal and ultradian dynamics of ghrelin 

and leptin in adult growth hormone deficiency 

F Joseph, G Brabant, A Ahmad, B Durham, 

WD Fraser & JP Vora 

P237 Growth hormone receptor extracellular 

domain linked to glycophosphatidyl inositol 

(GHR-GPI); a potential growth hormone 

receptor antagonist 

CE Bowles, I Wilkinson, N Gavalas, P Watson, 

D Watts & R Ross 

P238 The depot specific expression of NPY in 

human adipose tissue and its upregulation 

under hyperinsulinaemic conditions in isolated 

human adipocytes 

K Kos, AL Harte, P Gupta, P O'Hare, PG McTernan 

& S Kumar 

P239 The role of BMPs in the establishment of zona 

glomerulosa in the adrenal gland 

A Bakmanidis & PJ King 

P240 Anosmin-1: a novel cofactor for fibroblast 

growth factor receptor-1 

Y Hu, S Kim, S Cadman, S Guimond, J Turnbull & 

P Bouloux 

P241 Effect of growth hormone deficiency in adults 

on insulin action and gene expression of 

selected adipokines in subcutaneous adipose 

tissue 

A Penesova, M Skopkova, M Pura, M Vlcek, 

Z Radikova, I Vorzakova, M Tajtakova, P Vanuga, 

V Belan, J Koska, J Payer, I Klimes & D Gasperikova 

P242 Soluble interleukin 2 receptor is elevated in 

sera of women with Graves' disease and has 

relation to serum free thyroxine and thyroid 

volume 

J Jiskra, M Antosova, E Potlukova, Z Lacinova, 

H Mareckova, P Sandova, D Smutek & Z Limanova 

P243 Molecular mechanisms of idiopathic muscle 

hypertrophy in humans 

AM Solomon, EP Hoffman, SD Ghimbovschi, 

Z Wang, RW Orrell, G Goldspink, SD Harridge & 

PMG Bouloux 

P244 CD4 T-cell count improves during sustained 

IGF-I response following low dose growth 

hormone therapy in HIV-infected patients on 

stable antiretroviral regimens. A pilot study 

O Andersen, BR Hansen, A Flyvbjerg, S Madsbad, 

H Ørskov, JO Nielsen, J Iversen & SB Haugaard 

P245 The differential influence of specific plant 

lectins on insulin and IGFs binding to 

solubilised placental membrane IGF and 

insulin receptors 

R Masnikosa, I Baricevic & O Nedic 

P246 GH and GH antagonist B2036 effect on the 

immune system 

M Maamra, F Perna, A Colao, R Pivonello, 

S Zappacosta, RJM Ross & G Matarese 


P247 IGF-I modulates HIF-1alpha and HIF-2alpha in 

Kaposi sarcoma 

SB Catrina, IR Botusan, A Rantanen, AI Catrina, 

P Pyakurel, M Axelson, P Biberfeld, L Poellinger & 

K Brismar 

P248 Proinflammatory cytokine gene expression 

shows intrinsic circadian oscillation in 

peripheral cells 

A McMaster, J Lebiecki, A Loudon, R Donn & 

DW Ray 

P249 Plasma interleukin 1α in patients with 

polycystic ovary syndrome - relation to insulin 

resistance 

I Kowalska, M Straczkowski, A Nikolajuk, 

A Kozlowska, M Karczewska-Kupczewska, 

A Adamska, S Wolczynski, I Kinalska & M Gorska 

P250 Expression of functional toll-like receptors in 

adipocytes 

KM Oeff & SR Bornstein 

Diabetes, metabolism and cardiovascular 

P251 The involvement of GH-IGF-I axis in a mouse 

model of type II diabetic nephropathy 

R Eshet, D Landau, L Wachsmann & Y Segev 

P252 Sodium bicarbonate reacts with 

polysaccharides, starch, to enhance exercise 

TSM Arbab 

P253 New function for the enzyme amylase 

discovered. Amylase works as a 

catalyst/hydrolyzing agent to break down 

disaccharides (sucrose, lactose, maltose etc), 

and polysaccharides (starch) 

TSM Arbab 

P254 Liver GH receptor signaling in type I diabetic 

mice 

L Wachsman, R Eshet, D Landau & Y Segev 

P255 The effects of changes in insulin sensitivity on 

androgen supply values in diabetic men at 

different age 

MD Tronko & OV Korpacheva-Zinych 

P256 The effect, in clinical practice, of long-acting 

fluvastatin (LAF) on low density lipoproteincholesterol 

(LDL-Ch) in patients with type 2 

diabetes mellitus (T2DM) in which other 

statins have failed to achieve the goals 

FJ del Cañizo-Gómez 

P257 Nutritional outcome in end-stage renal disease 

diabetic patients: short term follow-up of 

patients initiating/escaping dialysis 

C Raffaitin, P Chauveau, C Lasseur, N Barthe, 

H Gin, C Combe, JB Corcuff & V Rigalleau 

P258 Improvement of nutritional status in nondialysed 

uremic diabetic patients 

C Raffaitin, P Chauveau, C Lasseur, N Barthe, 

H Gin, C Combe, JB Corcuff & V Rigalleau 


POSTERS

POSTERS 

40 


P259 Subthalamic nucleus stimulation in 

Parkinsonian patients does not increase serum 

ghrelin levels 

JB Corcuff, C Perlemoine, F Macia, F Tison, I Coman, 

D Guehl, P Burbaud, E Cuny, L Baillet, H Gin & 

V Rigalleau 

P260 Hyperandrogenism as a risk factor of coronary 

artery disease in young women 

Z Sablik, A Samborska-Sablik, JH Goch & K Kula 

P261 Comparison of urinary N-acytyl 

β-D-glucoseaminidase activity in diabetic 

patients and controls 

ZB Hesabi & S Salimi 

P262 Association of hypogonadism and type 2 

diabetes in men attending an outpatient 

erectile dysfunction clinic 

G Corona, E Mannucci, L Petrone, R Mansani, 

G Balercia, R Giommi, V Chiarini, G Forti & 

M Maggi 

P263 Estimation of the lipid metabolism in women 

with gestational diabetes mellitus (part 2). 

Differences resulting from the method of 

treatment 

A Bronisz, M Sobis-Zmudzinska, M Pujanek & 

R Junik 

P264 Estimation of some parameters of lipid 

metabolism in pregnant women with 

gestational diabetes mellitus 

M Sobis-Zmudzinska, A Bronisz, M Pujanek & 

R Junik 

P265 The role of a lifestyle modification in 

preventing type II diabetes mellitus in subjects 

with high-risk factors 

EI Shishko & TV Mokhort 

P266 The effect of Greek mediterranean diet on 

trace elements and blood coagulation factors 

in type 2 diabetes patients 

A Ginis, C Tzioras, N Panayotou & C Phenekos 

P267 12-month audit of insulin glargine use in the 

diabetic clinic 

D Ghosh & M Elsheikh 

P268 Increased expression of the adipokines resistin 

and FIAF in hypoxic/ischemic mouse brain 

G Wiesner, RE Brown, GS Robertson, E Ur & 

M Wilkinson 

P269 Prevalence of chronic cardiovascular 

complications in newly diagnosed type 2 

diabetic patients 

D Metreveli, N Bibilashvili, I Gudushauri, 

N Gambashidze, Z Robitashvili, K Mikadze, 

L Tigishvili & C Sajaia 

P270 Hormonal profile associated with the insulin 

sensitive obese subjects 

DH St-Pierre, AK Karelis, JF Henry, FM Malita, 

J Fontaine, D Mignault, M Brochu, JP Bastard, 

E Doucet, K Cianflone & R Rabasa-Lhoret 

P271 AT1 receptor activation mediated oxidative 

stress and uncoupling protein-2 driven betacell 

dysfunction in obesity-induced type 2 

diabetes mellitus 

KY Chu & PS Leung 

P272 Effects of hyperglycemia on the AT1 receptor 

expression and secretory function in an INS-1E 

beta-cell line 

PS Leung, KK Leung & KY Chu 

P273 Evaluation of garlic extract effect on serum 

angiotensin converting enzyme (ACE) level in 

streptozotocin-diabetic rats 

SM Shafiee, SM Hosseini, A Yabesi & ZB Hesabi 

P274 Determinants of metabolic syndrome and 

insulin resistance in hemodialysis patients 

HC Chen & JY Guh 

P275 Hyperlactatidemia caused by acute myocardial 

infarction in patients with type 2 diabetes 

mellitus 

A Jovanovic, V Peric, S Sovtic, T Novakovic, R Stolic 

& S Markovic-Jovanovic 

P276 The safety and efficacy of chinese herbal 

medicine PHS-E2 (Glucoherb) in 

streptozotocin-induced diabetic Wistar rats 

TA Elhadd, AA Al-Amoudi, SMG Al-Ghamdi, 

E M Ibrahim & HA El-Shiekh 

P277 Education for diabetic patients for fasting of 

Ramadan: a questionnaire study 

AA Al-Amoudi, N Al-Ulagi, M Bashir, L Bissar, 

SMG Al-Ghamdi & TA Elhadd 

P278 Alcohol intake deteriorates insulin receptors 

and adipokines expression in rat adipose tissue 

E Pravdová, M Ficková & L Macho 

P279 Des-acyl ghrelin regulates glucose and lipid 

metabolism in HL-1 cardiomyocytes 

MJ Iglesias, R Piñeiro, S Eiras, B Rodiño, 

JR González-Juanatey & MF Lago 

P280 Regulation of brain-derived resistin and FIAF in 

a novel hypothalamic neuronal cell line 

RE Brown, A Imran, DD Belsham, E Ur & 

M Wilkinson 

P281 Myocardial ischemia in type 1 diabetic 

patients - re-examination after four years 

M Kowalczyk, B Chrapko, J Zaorska-Rajca, 

JS Tarach & A Nowakowski 

P282 The metabolic syndrome presence in 

peripheral arterial occlusive disease of diabetic 

patients 

DS Tesic, P Pantelinac, M Mitrovic, R Pejin, 

J Radosavljevic, D Naglic, D Tomic & I Obrovacki 

P283 A TCF1 mutation may cause transient 

congenital hyperinsulinism followed by 

MODY3 

K Brusgaard, HBT Christesen, T Hansen, P Njölstad, 

J Malec & B Brock Jacobsen 

www.ece2006.com

P284 Waist circumference cut-offs for categorisation 

among Tunisian adult population 

R Bouguerra, H Smida, L Ben Salem, J El Ati, 

S Gaigi, CH Ben Rayana, C Ben Slama & B Zouari 

P285 Associations between BMI and smoking with 

reference to other life style factors, the 4th 

and the 5th Tromsø studies 

M Sneve & R Jorde 

P286 Gene variants at calpain-5 locus are associated 

with obesity and other features of metabolic 

syndrome 

ME Saez, MT Martinez-Larrad, R Ramirez-Lorca, 

JL Gonzalez-Sanchez, C Zabena, A Gonzalez, 

A Ruiz & M Serrano-Rios 

P287 Plasma concentrations of asymmetric dimethyl 

arginine and total homocysteine in siblings of 

type 2 diabetes mellitus 

S Guldiken, CH Karadag, E Arikan, M Demir & 

M Kara 

P288 Mortality risks of diabetic patients who reach 

end-stage renal disease (ESRD) in the United 

States: age and gender differences 

AG Stack & L O'Shea 

P289 Hormonal profile in men suffering from 

coronary artery disease and metabolic 

syndrome 

Z Sablik, A Samborska-Sablik, JH Goch & K Kula 

P290 The impact of vitamins and/or mineral 

supplementation on blood pressure in type 2 

diabetes 

M Farvid, M Jalali & F Siassi 

P291 Pro12Ala PPAR gamma2 gene polymorphism 

in PCOS women - the role of the satiety and 

insulin activity regulating compounds 

B Bidzinska-Speichert, U Tworowska, M Demissie, 

G Bednarek-Tupikowska & R Slezak 

P292 Glucose metabolism, insulin secretion and 

insulin sensitivity in juvenile hemochromatosis 

N Angelopoulos, M Noutsou, A Goula & G Tolis 

P293 Glucocorticoids are metabolised within 

perivascular adipose: the link between 

metabolic diseases and their vascular 

consequences? 

AR Dover, CJ Huang, DE Livingstone, 

PJ Raubenheimer, PWF Hadoke, BR Walker & 

RM Reynolds 

P294 Absence of sexual dimorphism in the 

symptomatic responses to hypoglycaemia in 

adults with and without type 1 diabetes 

J Geddes, RE Warren, AJ Sommerfield, V McAulay, 

MWJ Strachan, KV Allen, IJ Deary & BM Frier 

P295 Metabolic syndrome and insulin sensitivity in 

early glycoregulation disorders 

V Dimitrijevic-Sreckovic, P Djordjevic, S Popovic, 

D Gostiljac, F Canovic, B Sreckovic, M Ilic, 

T Novakovic, E Colak, R Obrenovic, G Milic, T Nisic 

& V Panasiuk 


P296 Biochemical predictors of the cardiovascular 

complications in patients with obesity and 

type 2 diabetes 

T Doliashvili, E Giorgadze, N Tsagareli, K Asatiani & 

K Bochorishvili 

P297 Decreased cardiac and arterial noradrenaline 

and dopamine concentrations occur 

concomitantly with the development of type II 

diabetes in rats treated neonatally with 

monosodium glutamate (MSG): a possible 

basis for autonomic neuropathy? 

JFB Morrison, M Shaffiullah, S Dhanasekaran, 

R Sheen & EK Mensah-Brown 

P298 Gender distribution in Ukrainian adult insulintreated 

diabetics depending on age at 

diagnosis 

M Tronko, M Khalangot, V Kravcenko, Y Kulchinska 

& A Vaiserman 

P299 Effects of arm exercise on metabolic 

parameters in type 2 diabetic patients 

N Leelayuwat, O Tunkumnerdthai, M Donsom, 

N Punyaek, T Pratipanawatr & U Kukongviriyapan 

P300 The ethanolic extract of Combretum 

decandrum Roxb. improved glucose tolerance 

and increased glucose uptake of 

hyperinsulinemic rats 

P Pannangpetch, W Theansuwan, B Kongyingyoes, 

V Kukongviriyapan & U Kukongviriyapan 

P301 In-patients food intake and reasons of nonconsumption 

B Gatta, D Daniel-Lamazière, J-B Corcuff, F Poirier, 

M-N Petitpierre, F Morizot & H Gin 

P302 Renal expression of alpha-ENaC is increased in 

testosterone treated rats 

T Kienitz, B Allolio, CJ Strasburger & M Quinkler 

P303 Insulin resistance syndrome and non-alcoholic 

fatty liver disease in obese children: influence 

of ethnic background, sex, age and family 

history of type 2 diabetes 

DL Clough, L Watson, C Cuisick, L Tetlow, RA Amin, 

PE Clayton & CM Hall 

P304 Serum ghrelin levels during oral glucose 

challenge - new insights from gastrectomized 

patients 

D Miljic, S Pekic, P Pesko, M Djurovic, M Doknic, 

J Glodic, C Dieguez, FF Casanueva & V Popovic 

P305 A gene-gene interaction of single nucleotide 

polymorphisms within two oxidative stress 

genes affects arterial compliance in patients 

with coronary artery disease 

RS Drummond, HHC Koh-Tan, NJR Brain, 

JD McClure, LM Cherry, AJB Kirk, N Sattar, 

JMC Connell & AF Dominiczak 


POSTERS

POSTERS 

42 


P306 The variable number of tandem repeat 

polymorphism in the NOS3 gene is associated 

with arterial compliance and insulin resistance 

in coronary artery disease 

RS Drummond, HHC Koh-Tan, NJR Brain, A Kirk, 

N Sattar, JMC Connell & AF Dominiczak 

P307 Altered cholesterol and bile acid homeostasis 

in the hexose-6-phosphate dehydrogenase 

(H6PDH) knockout mouse 

KN Hewitt, IJ Bujalska, GG Lavery, PM Stewart & 

EA Walker 

P308 Insulin secretion in HBV and HCV infected 

patients with type 2 diabetes mellitus 

LY Hamnueva, LS Andreeva & AV Davydova 

P309 The pancreatic beta-cells autoantibodies in 

HBV and HCV infected patients with type 2 


AV Davydova, LY Hamnueva & LS Andreeva 

P310 Adrenomedullin increases the expression of 

CLR and RAMP2 in microvascular endothelial 

cells 

N Schwarz, K Sidhu, S Kapas & JP Hinson 

P311 Sympathetic function in carriers of MC4R 

mutations 

D Heutling, F Sayk, C Dodt, HL Fehm, T Frank, 

A Hinney, J Hebebrand & H Lehnert 

P312 A case of myocardial infarction induced by 

factitious hypoglycaemia in type 2 diabetes 

patient 

R Srinivasan, E Sanders & M Flynn 

P313 Orlistat improves postprandial triglyceride 

metabolism in obese patients with or without 

diabetes 

I Sahin, R Bentli, L Keskin, C Taskapan, S Senel & 

S Yologlu 

P314 Challenge in achieving target HbA1c in a 

relatively rare diabetes complication 

MU Haq, G Morrison & PJ Weston 

P315 Depot specific activation of inflammatory 

signalling molecules JNK and NFκB in human 

abdominal subcutaneous and omental adipose 

tissue 

NF da Silva, AE Fowler, AL Harte, AR Baker, 

CM Kusminski, SJ Creely, P O'Hare, S Kumar & 

PG McTernan 

P316 Endothelial, inflammatory and endocrine 

markers in women with PCOS before and after 

metformin treatment 

D Heutling, H Schulz, I Nickel, J Kleinstein, 

P Kaltwasser, HS Randeva, K Krzyzanowska, 

F Mittermayer, M Wolzt, G Schernthaner & 

H Lehnert 

P317 Expression and regulation of adiponectin 

receptors (AdR-1 and AdR-2) in pancreatic 

beta-cells 

JEP Brown, JE Digby, SJ Dunmore & HS Randeva 

P318 Cardiovascular risk factors and macrovascular 

complications in type 2 diabetes 

K Khiari, H Cheikhrouhou, I Hadj Ali & 


P319 Effects of ezetimibe on serum lipoproteins in 

patients with homozygous familial 

hypercholesterolemia undergoing LDL 

cholesterol apheresis and high dose 

atorvastatin therapy 

A Azezli, T Bayraktaroglu, F Kutluturk, A Cikim, 

S Tanyolac & Y Orhan 

P320 Effect of micronised fenofibrate on plasma 

levels of C-reactive protein in combined 

hyperlipidemia 

A Azezli, T Bayraktaroglu, F Kutluturk, A Cikim, 

S Tanyolac & Y Orhan 

P321 Long term safety of atorvastatin and 

fenofibrate therapy in patients with combined 

hyperlipidemia 

A Azezli, A Telci, T Bayraktaroglu, A Cikim, A Uzum, 

F Kutluturk, S Tanyolac & Y Orhan 

P322 Use of insulin glargine during pregnancy in 

women with type 1 diabetes mellitus 

D Ghosh, D Graham, P Street & M Elsheikh 

P323 Serum ferritin levels and obesity 

F Kutluturk, A Sertkaya Cikim, A Azezli & Y Orhan 

P324 Utility of continuous glucose monitoring 

(CGMS) to explore glycemic patterns in 

patients with diabetes mellitus in the UAE 

NG Lessan, A Abdullah, H AlMousavi, Q Nasir & 

S Athamneh 

P325 Dyslipidemia in premenopausal and 

postmenopausal obese women 

A Sertkaya Cikim, F Kutluturk, A Azezli & Y Orhan 

P326 The effect of moxonodine on endothelial 

dysfunction in metabolic syndrome 

A Sertkaya Cikim, E Topal, K Cikim, I Temel & 

R Ozdemir 

P327 The BsmI and FokI polymorphisms in the 

vitamin D receptor gene in relation to 

anthropometric and metabolic parameters 

describing metabolic syndrome 

A Filus, A Trzmiel, J Kuliczkowska-Płaksej, 

U Tworowska & A Milewicz 

P328 Comparison between NPH insulin and insulin 

glargine in intensive insulin therapy in type 1 


M Pes˘ic, S Radenkovic, Szˇivic, M Velojic, D Dimic & 

D Mikic 

P329 Association of C-reactive protein with insulin 

resistance in first degree relatives of type 2 


NE Gulcelik, R Serter, M Ozkaya & Y Aral 

www.ece2006.com

P330 How do glucose, insulin, potassium improve 

haemodynamic performance? Evidence for 

beta-adrenoreceptor and sarcoplasmic 

reticulum calcium ATPase up-regulation 

AM Ranasinghe, DW Quinn, CJ McCabe, D Pagano, 

JA Franklyn & RS Bonser 

P331 Effects of weight loss on the coronary risk 

profile in obese patients two years after 

bariatric surgery 

M Melo, D Rodrigues, MV Campos, J Guimaraes, 

A Fagulha, J Figueiredo, C Manso, G Tralhão, 

A Milheiro, F Castro e Sousa & M Carvalheiro 

P332 The severity of cardiovascular disease in 

women is modified by estrogen receptor alpha 

polymorphic variants 

M Alevizaki, K Saltiki, I Kanakakis, A Cimponeriu, 

C Alevizaki, I Georgiou & E Anastasiou 

P333 Adult pancreatic islet progenitor cells exhibit 

plasticity in vitro 

WE Leadbeater, MR Summerfield, DJ Hill, M Berry & 

A Logan 

P334 Regulation of hexose-6-phosphate 

dehydrogenase (H6PDH) in human fetal liver 

WRL-68 cells 

A Swali, I Bujalska, PM Stewart & EA Walker 

P335 Relationships between plasma adiponectin and 

testosterone concentrations in middle-aged 

men and women 

J Zhang, RIG Holt, SH Wild, H Holt, RB Poole, 

QX Zeng & CD Byrne 

P336 Relationship between testosterone and in vivo 

expression of adipoR1 in skeletal muscle in 

middle aged Caucasian men 

J Zhang, H Holt & CD Byrne 

P337 Testosterone secretion and melatonin rhythm 

in men with the metabolic syndrome 

R Robeva, G Kirilov & PH Kumanov 

P338 Mortality and morbidity of diabetes patients 

IV Misnikova, YA Kovaleva & AV Dreval 

P339 Prevalence of diabetic foot syndrome among 

diabetes patients 

IV Bakharev, IV Misnikova & AV Dreval 

P340 Decreased cutaneous vasomotor responses in 

patients with insulin resistance 

P Tretjakovs, A Jurka, K Geldenere, A Stifts, JI Aivars 

& V Pirags 

P341 Lipid profile in normal weight and obese 

women with polycystic ovary syndrome 

M Stojkovic, M Zarkovic, J Ciric, B Beleslin, S Savic, 

M Drezgic & B Trbojevic 

P342 Is ghrelin a potential signal of decreased fatfree 

mass in elderly subjects? 

P Magni, S Bertoli, M Ruscica, E Dozio, V Krogh, 

M Motta, G Testolin & A Battezzati 


P343 Obesity and expression of serotonin 

transporter (SERT) in human platelets 

A Marsili, F Santini, C Pelosini, L Betti, L Fabbrini, 

G Galli, I Ricco, S Baroni, P Italiani, P Fierabracci, 

G Giannaccini & A Pinchera 

P344 Acute and chronic effect of teriparatide on 

glucose metabolism in women with 

established osteoporosis 

A Anastasilakis, DG Goulis, G Koukoulis, A Slavakis, 

M Kita & A Avramidis 

P345 Adipose glucocorticoid synthesis: transcription 

of the 11β-hydroxylase gene in omental but 

not subcutaneous adipose tissue 

SM MacKenzie, CJ Kenyon, DEW Livingstone, 

R Andrew, R Fraser, JMC Connell & E Davies 

P346 Metabolic syndrome among patients with 

primary aldosteronism: a common feature? 

G Giacchetti, V Ronconi, F Turchi, L Agostinelli, 

S Rilli & M Boscaro 

P347 Metabolic parameters in patients with primary 

aldosteronism: relation to SNPs of the 

adiponectin gene 

V Ronconi, L Agostinelli, F Turchi, S Rilli, M Boscaro 

& G Giacchetti 

P348 Coronary artery disease and heart failure in 

diabetic patients in the north of Portugal 

C Neves, JL Medina & F Lopes 

P349 Physiological concentrations of testosterone 

inhibit extracellular calcium entry via voltagegated 

calcium channels in the A7r5 vascular 

smooth muscle cell line - a non-genomic 

effect 

J Hall, RD Jones, KS Channer, C Peers & TH Jones 

P350 Comparison between premixed insulin as part 

30 vs premixed human insulin 30/70 in 

combination with metformin in obese type 2 


D Mikic, MV Golubovic, M Pesic, R Kocic, 

S Radenkovic, D Dimic & S Antic 

P351 Effect of repaglinide vs glimepirid on 

glycaemic control in overweight and obese 


uncontrolled by metformin 

MV Golubovic, D Mikic, M Pesic, D Dimic, 

S Radenkovic & R Kocic 

P352 Association of an insertion/deletion 

polymorphism in the alpha 2B adrenergic 

receptor with essential hypertension in 


DP Papazoglou, KP Papatheodorou, NP Papanas, 

LP Papazoglou, PP Papathanasiou, TE Exiara, 

DC Christakidis & EM Maltezos 

P353 The metabolic syndrome and insulin resistance 

in polycystic ovary syndrome - study of over 

40 cases 

C Neamtu, I Gherlan, C Boanta, 

A Caragheorgheopol & C Dumitrache 


POSTERS

POSTERS 

44 


P354 Prevalence of registered diabetic nephropathy 

and its terminal stages 

VA Gubkina, IV Misnikova, AV Dreval & 

ON Vetchinnikova 

P356 Non-insulinoma pancreatogenous 

hypoglycaemia syndrome (NIPHS) caused by 

an activating glucokinase mutation 

HBT Christesen, K Brusgaard, H Beck-Nielsen, 

J Malec & B Brock Jacobsen 

P357 Relationship between plasma visfatin levels 

and the metabolic variables in metabolic 

syndrome 

A Sonmez, T Dogru, I Tasci, I Yilmaz, M Pinar, 

I Naharci, N Bingol, S Kilic, A Demirtas, S Bingol, 

U Musabak, T Ozgurtas, K Erbil & S Erikci 

P358 The vasodilatory action of oestrogen in 

isolated human pulmonary arteries 

AM Smith, RK Sandher, RD Jones, TH Jones & 

KS Channer 

P359 The effect of fluvastatin on adiponectin and 

insulin sensitivity 

A Sonmez, T Dogru, I Tasci, I Yilmaz, M Pinar, 

I Naharci, N Bingol, S Kilic, A Demirtas, S Bingol, 

U Musabak, T Ozgurtas, K Erbil & S Erikci 

P360 Leptin as a regulator of serum acylated ghrelin 

in normal-weight and obese premenopausal 

women 

A Kempa, B Krzyz˙anowska-S´winiarska, 

T Miazgowski & K Pilarska 

P361 Insulin receptoropathies are distinguished 

from other syndromes of severe insulin 

resistance by elevated plasma adiponectin 

levels 

RK Semple, MA Soos, CM Mitchell, JC Wilson, 

J Luan, EK Cochran, NJ Wareham, P Gorden, VKK 

Chatterjee & S O'Rahilly 

P362 Impaired endothelial function in young nonobese 

women with polycystic ovary syndrome: 

normalization after therapy with ethinyl 

estradiol-cyproterone acetate 

M Kravariti, KK Naka, N Kazakos, LK Michalis, 

A Tsatsoulis & S Kalantaridou 

P363 Carbohydrate metabolism in children with 

Down's syndrome 

E Wojcik, E Barg, M Gromkowska, B Wikiera & 

E Maslowska 

P364 Anti-oxidative effect of 17beta-estradiol in 

human endothelial cells: the role of Bcl-2 

W Zhong & SL Atkin 

P365 Emergence of new addictions following gastric 

reduction surgery for morbid obesity 

J O'Connell, R Yoder, O Fogarty, J Geoghegan & 

D O'Shea 

P366 Is the male androgenetic alopecia the sign of 

male equivalent of polycystic ovary syndrome 

or metabolic syndrome? 

M Duskova, L Starka, M Hill, M Dolezal, 

K Simunkova & I Cermakova 

P367 Increased prevalence of the metabolic 

syndrome by NCEP, WHO and IDF criteria in 

women with PCOS 

AJ Cussons, J Shaw, BGA Stuckey, GF Watts & 

P Zimmet 

P368 Estrogen receptor alpha (ER'alpha') gene 

polymorphisms and first-ever primary 

intracerebral hemorrhage (PICH) 

M Strand, I Söderström, P-G Wiklund, G Hallmans, 

L Weinehall, S Söderberg & T Olsson 

P369 The metabolic control levels of 548 diabetic 

outpatients compared with the current 

guidelines of Polish Diabetes Association (PDA) 

J Malicka, M Kurowska, JS Tarach & A Nowakowski 

P370 Increased sub-clinical inflammation and 

markers of vascular injury in obese children 

AL Harte, AR Baker, ML Hill, L Gilardini, A Girola, 

NF da Silva, C Invitti, S Kumar & PG McTernan 

P371 Clinical, functional and polysomnographics 

parameters in severely obese patients 

M Giannetti, F Santini, M Di Giorgio, G Scartabelli, 

P Fierabracci, A Marsili, R Valeriano, I Ricco, G Galli, 

A Pucci, N Carpenè, P Vitti, A Palla & A Pinchera 

P372 The role of tumour necrosis factor-alpha in 

insulin-stimulated endothelial nitric oxide 

production 

SA Ritchie, JMC Connell & IP Salt 

P373 Correlation of WBC and PLT count with 

parameters of type 2 diabetes mellitus 

KP Papatheodorou, NP Papanas, DP Papazoglou, 

GD Dimitriadis, LP Papazoglou, EN Ntakomyti, 

SK Kotsiou & EM Maltezos 

P374 Field evaluation of a multi-sensor armband in 

Greek women 

DP Papazoglou, LP Papazoglou, TP Papadopoulos, 

NP Papanas, KP Papatheodorou, SK Kotsiou & 

EM Maltezos 

P375 The acute stimulation of nitric oxide synthesis 

by rosiglitazone in human aortic endothelial 

cells is independent of the PPAR gamma 

receptor but is dependant on the fuel sensing 

enzyme AMPK 

JG Boyle, IP Salt, SJ Cleland & JMC Connell 

P376 Dehydroepiandrosterone in relation to obesity, 

insulin resistance and lipid spectra in Czech 

non-diabetic population 

B Bendlova, J Vcelak, D Vejrazkova, M Vankova, 

K Dvorakova, J Vrbikova, M Hill, L Starka & 

K Vondra 

P377 Frequency of dyslipidaemias in children - 

results of lifestyle intervention 

VA Petrou, AK Tertipi, E Posnaghidou, ED Kostakioti, 

VT Skarpa, M Anastasakou & C Hadjiathanasiou 

P378 SiRNA-mediated depletion of synaptotagmin- 

11 abrogates insulin-stimulated glucose 

uptake in 3T3-L1 adipocytes 

SCM Miller, P Mitra, JMC Connell & GW Gould 

www.ece2006.com

P379 Chromosome 1p shows significant linkage to 

steroid metabolism in hypertension in the 

British Genetics of Hypertension Study 

S Padmanabhan, R Fraser, M Ingram, E Davies, 

PB Munroe, R Dobson, M Brown, N Samani, 

D Clayton, M Farrall, J Webster, M Lathop, 

M Caulfield, AF Dominczak & JM Connell 

P380 Impaired glucose metabolism in patients with 

Cushing's syndrome 

GA Arnaldi, TM Mancini, BP Polenta, 

MC Cardinaletti, PC Canibus, EF Faloia & 

MB Boscaro 

P381 Effects of bariatric surgery on preclinical 

myocardial alterations in severe obesity and 

the related role of insulin resistance 

A Pucci, F Santini, V Di Bello, A Marsili, 

P Fierabracci, A Di Cori, C Palagi, MG Delle Donne, 

M Giannetti, M Anselmino, P Vitti, A Balbarini & 

A Pinchera 

P382 The effect of an 18 week group exercise 

education program on weight, physical 

activity, cardiovascular fitness, quality of life 

and attitudes to exercise in obese Irish female 

adults 

A Quinn, E Fogarty & D O'Shea 

P383 Direct effect of cannabinoids and ghrelin on 

liver and adipose cell metabolism via the AMPactivated 

protein kinase (AMPK) enzyme 

P Dalino, D Aguilar, AM Isidori, E Hubina, 

EA Garcia, B Kola, AB Grossman & M Korbonits 

P384 Expression and localisation of human tissue 

kallikrein in transfected human embryonic 

kidney cells (HEK-293). Development of a 

novel panel of monoclonal antibodies (mAbs) 

against human tissue kallikrein 

YC Pham, PA Meadows & JN Harvey 

P385 Dietary regulation of peripheral glucocorticoid 

action: comparison of saturated and 

unsaturated fats 

TY Man, L Ramage, A Gokcel, Z Michailidou, 

CJ Kenyon, K Chapman, JR Seckl & NM Morton 

P386 The KCNJ11 E23K and UCP2 G-866A SNPs in 

relation to DM2 in Czech population 

D Vejrazkova, M Vankova, P Lukasova, J Vcelak, 

H Kvasnickova, K Vondra & B Bendlova 

P387 Androgen regulation of hepatic glucocorticoid 

metabolism in obese Zucker rats 

DEW Livingstone, P Barat, CR McDonnell, BR Walker 

& R Andrew 

P388 Plasma N-terminal pro-brain natriuretic 

peptide and adiponectin levels increases 

during weight loss 

C Kistorp, H Bliddal, A Flyvbjerg, J Frystyk, 

P Hildebrandt & J Faber 


P389 Multiple signalling pathways are involved in 

the phosphorylation of ERK1/2 upon 

activation of human OX1R and OX2R: 

evidence for differential modulation by orexin- 

A and orexin-B 

J Tang, J Chen, H Lehnert & HS Randeva 

P390 Association among individual deprivation 

using the EPICES score and anthropometric 

factors linked to abdominal and metabolic 

markers 

H Bihan, G Nguyen, R Cohen, C Menu, K Soufi, 

G Reach & H LeClésiau 

P391 Mapping of adiponectin and adiponectin 

receptors in the human adult and fetal heart 

J Chen, M Lencioni, E Karteris, H Lehnert & 

HS Randeva 

P392 Testosterone replacement therapy reduces 

insulin resistance and improves glycaemic 

control in hypogonadal men with type 2 

diabetes 

D Kapoor, E Goodwin, KS Channer & TH Jones 

P393 Functional analysis of cardiac orexin receptors: 

preferential activation by OR-B 

J Chen, E Karteris, G Rodrigo, P Stanfield, A Ng & 

HS Randeva 

P394 Orexin receptor expression in human adipose 

tissue: differential effects of orexins 

JE Digby, J Chen & HS Randeva 

P395 Insulin sensitivity and lipid profile in obese and 

normal weight hypertensive subjects 

S Ognjanovic, M Petakov, DJ Macut, T Isailovic, 

B Popovic, I Bozic & S Damjanovic 

P396 Human adipocytes attenuate cardiomyocyte 

contraction. A direct link between heart failure 

and obesity 

V Lamounier-Zepter, M Ehrhart-Bornstein, 

P Karczewski, SR Bornstein & I Morano 

P397 Dietary potassium driven responses in the 

renal WNK kinase pathway in vivo 

M O'Reilly, E Marshall, T MacGillvray, M Mittal, 

CJ Kenyon & RW Brown 

P398 The in vitro and in vivo role of diabetic status 

and insulin sensitisers on the novel 

adipocytokine, visfatin 

KC McGee, NF da Silva, AR Baker, AL Harte, 

SJ Creely, MJ Hill, M Khanolkar, M Evans, S Kumar 

& PG McTernan 

P399 Adrenocortical function in obese Zucker rats 

CJ Kenyon, DEW Livingstone, AD McNeilly, E Davies, 

R Andrew & SM MacKenzie 

P400 Recurrence rate of atrial fibrillation in 

amiodarone-induced hyperthyroidism 

RA Trifanescu, S Fica, D Dimulescu, C Barbu, 

I Coman, C Ceck, R Bunghez & M Coculescu 


POSTERS

POSTERS 

46 


P401 The effect of hyperthyroidia on glycemic 

control in patients with diabetes mellitus 

S Fica, C Barbu, A Lazar, M Grigorescu, A Albu & 

R Bunghez 

P402 Flow mediated dilatation and sVCAM 

concentration as the markers of endothelial 

dysfunction in patients with acromegaly 

M Bolanowski, M Kaluzny, J Daroszewski & A Szuba 

P403 Low endogenous testosterone induces fatty 

streak formation following cholesterol feeding 

in the testosterone deficient testicular 

feminised mouse and castrated male 

JE Nettleship, RD Jones, CM Biggins, KS Channer & 

TH Jones 

P404 Testosterone replacement reduces aortic fatty 

streak formation in testosterone deficient Tfm 

mice following feeding on a cholesterolenriched 

diet 

JE Nettleship, RD Jones, CM Biggins, KS Channer & 

TH Jones 

P405 Growth hormone and IGFBP-3 but not IGF-I 

are independent predictors for insulin 

sensitivity in healthy subjects: on the role of 

hGH in the metabolic syndrome 

MA Arafat, F Perschel, C Schöfl, M Weickert, 

J Purschwitz, H Rochlitz, J Spranger, M Möhlig & 

AFH Pfeiffer 

P406 Dehydroepiandrosterone inhibits 

differentiation, proliferation and 11βhydroxysteroid 

dehydrogenase type 1 activity 

in human preadipocytes 

J McNelis, IJ Bujalska, PM Stewart & W Arlt 

P407 Urocortin 2 mediates glucose utilization and 

insulin sensitivity in skeletal muscle 

A Chen, B Brar, CS Choi, D Rousso, J Vaughan, 

C Donaldson, S Smith, C Li, SN Kim, T Nagy, 

G Shulman, KF Lee & W Vale 

P408 Elevated serum hs-CRP in the obese - still 

much to be explained 

M Koziolek, B Krzyzanowska-Swiniarska, 

M Robaczyk, A Szczerkowska, A Kempa, G Kulig, 

E Andrysiak-Mamos & K Pilarska 

P409 Lipoprotein Lp(a) in patients with systemic 

lupus erythematosus 

P Athanassiou, I Kostoglou-Athanassiou, A Kordalis, 

TH Kalogirou, CH Galanaki, E Bastakis & 

PH Kaldrymidis 

P410 Effects of alcoholic extract of walnut (Juglans 

regia L.) septum on serum lipids and activites 

of aminotransferase enzymes in streptozocin 

induced diabetic rats 

R Hadjikhani & J Solati 

P411 The ways in which zinc enters beta cells in the 

pancreas and the influence of zinc blockers on 

the development of type 1 diabetes 

T Priel, M Hershfinkel & I Sekler 

P412 Lipoprotein Lp(a) in patients with rheumatoid 

arthritis 

P Athanassiou, I Kostoglou-Athanassiou, A Kordalis, 

TH Kalogirou, CH Galanaki, E Bastakis & 


P413 Polymorphisms in insulin-like growth factor 

binding protein-1 (IGFBP-1) are associated 

with altered circulating IGF-I and lower body 

mass index in type-2 diabetes mellitus 

AH Heald, RH Stephens, P McElduff, K Kaushal, 

K Siddals, JP New, J Worthington, WE Ollier & 

JM Gibson 

P414 Polymorphisms in insulin-like growth factor 

binding protein-1 (IGFBP-1) are associated 

with increased type-2 diabetes mellitus 

prevalence 

AH Heald, RH Stephens, P McElduff, K Kaushal, 

JP New, J Worthington, WE Ollier, N Pendleton, 

M Horan, A Payton & JM Gibson 

P415 Cardiac autonomic neuropathy in relation to 

some components of metabolic syndrome in 

newly diagnosed type 2 diabetic patients 

MA Nishnianidze, RB Kurashvili, MG Khelashvili, 

E Shelestova, LR Tsutskiridze & MG Bekaia 

P416 Severity of depression in patients with type 1 

and type 2 diabetes and its relation to the 

level of glycemia control and anti-depressive 

therapy 

LR Tsutskiridze, RB Kurashvili, GR Kurashvili, 

MG Khelashvili, MA Nishnianidze, EL Shelestova & 

MG Dundua 

P417 Cardiac autonomic and peripheral neuropathy 

in newly diagnosed type 2 diabetic patients 

GR Kurashvili, RB Kurashvili, MG Khelashvili, 

LR Tsutskiridze, EL Shelestova & MN Kobaidze 

P418 Rapid effect of repaglinide in combination 

with metformin in poorly controlled obese 


RB Kurashvili, NG Asatiani, MG Nishnianidze & 

EL Shelestova 

P419 Impact of migration on circulating 

adipocytokines in an Asian Indian population 

AH Heald, J Patel, D Prabharakan, S Anderson, 

E Hughes, A Vyas, D Bhatnagar, S Reddy, 

P Durrington & JK Cruickshank 

P420 Migration to the UK results in significantly 

lower testosterone levels in South Asian men 

JV Patel, N Panja, D Prabharakan, S Anderson, 

A Vyas, D Bhatnagar, P Durrington, JM Gibson, 

E Hughes, S Reddy, JK Cruickshank & AH Heald 

P421 Prevalence of skin manifestation in diabetic 

patients in Ahvaz University Diabetes Center 

H Shahbazian, R Yaghoobi & R Meamari 

P422 Correlations between leptin, insulin resistance 

and lipid profile in postmenopausal women 

C Poiana, L Stoian & AM Stefanescu 

www.ece2006.com

P423 Correlation between glycemia levels and 

mortality rate in patients with type 2 diabetes 

and prior myocardial infarction 

M Dundua, N Asatiani, R Kurashvili, M Khelashvili, 

L Tsutskiridze & E Shelestova 

P424 Left ventricular geometry and contractile 

ability in type 2 diabetes and non-diabetic 

patients with mild hypertension 

N Beridze, I Bochorishvili, M Iashvili, R Kurashvili & 

M Dundua 

P425 Effect of lacidipine on left ventricular mass and 

blood pressure circadian rhythm in 

hypertensive diabetic patients 

T Akhobadze, R Kurashvili, M Khelashvili, 

L Tsutskiridze, E Shelestova, M Dundua, K Paghava, 

T Kajaia & T Khidesheli 

Endocrine disruptors 

P426 Prevalence of the phyto-oestrogen urinary 

metabolites enterodiol and enterolactone in 

patients under endocrine investigation 

L Reilly, L Scobbie, CA Dorrian & AM Wallace 

P427 Comparative review of primary and secondary 

empty sella syndrome 

MB Babarina, IA Gracheva & EI Marova 

P428 Adult's primary empty sella 

M Rezzoug, L Zadoud, L Cherf & F Chentli 

P429 The UV filter benzophenone 2 inactivates 

human recombinant thyroperoxidase in vitro 

and disturbs thyroid hormone homeostasis in 

rats 

C Schmutzler, A Bacinski, P Ambrugger, H Klammer, 

W Wuttke, A Grüters, H Jarry & J Köhrle 

P430 Endocrine disorders in thalassaemia - local 

experience in an inner city hospital in 

Birmingham, England 

KK Gangopadhyay, G Das, W Burbridge, C Wright 

& P De 

P431 Extracts of black cohosh (Actaea racemosa) 

inhibit growth of MCF-7 and MDA-MB-231 

breast cancer cells and dose-dependently 

inhibit oestrone sulphatase activity 

SA Whitehead, C Kotalla, S Rice & HD Mason 

P432 Androgen-dependent Sertoli cell proliferation 

as a target for endocrine disruptors relevant to 

human male reproductive health 

H Scott, N Hallmark, PTK Saunders, G Verhoeven, 

K De Gendt, G Hutchison & RM Sharpe 

P433 A randomized, open-label, multicenter study 

to evaluate octreotide LAR with surgical 

therapy as primary therapy in patients with 

acromegaly 

A Colao, H Bouterfa, P Cappabianca, P Caron, 

E De Menis, A Farrall, M Gadelha, A Reed, 

M Reincke, M Safari, G T'Sjoen & R Cuneo 


P434 Origin of dysgenetic areas in testes of rats 

exposed to di-n-butyl phthalate (DBP) during 

fetal life: a model of human testicular 

dysgenesis syndrome 

IK Mahood, HM Scott, N Hallmark, C McKinnell, 

M Walker, JS Fisher & RM Sharpe 

P435 Endocrine disruptors and idiopathic 

gynecomastia with aromatase gene 

polymorphism 

IK Czajka, S Zgliczynski & W Zgliczynski 

P436 Loss and resumption of ovarian function after 

mitotane administration 

I Kostoglou-Athanassiou, M Goula, P Athanassiou & 


Endocrine tumours and neoplasia 

P437 Estrogen receptor alpha and beta (ERα and -β) 

gene and protein expression in breast cancer 

cell lines: verification by RT-PCR and Western 

blotting 

MD Al-Bader, CHJ Ford, J Jacob, LJ Jacob & 

SS Mohan 

P438 Challenges associated with the diagnosis, 

differential diagnosis and treatment of 4 cases 

of ACTH-dependent Cushing's syndrome due 

to intermittent hypercortisolism 

JR Lindsay & LK Nieman 

P439 Hyperprolactinaemia in a series of adults with 

craniopharyngiomas and Rathke's cleft cysts: 

what are the upper limits? 

G Thanabalasingham, N Karavitaki, N Meston, 

HE Turner & JAH Wass 

P440 Parathyroid scintigraphy for 

hyperparathyroidism, an assessment of 

performance 

T Vizhalil Paul, N Thomas, M Seshadri, 

S Rajaratinam, K Sudeep & J Jubbin Jagan 

P441 Insulinomas - an experience from a tertiary 

care institution in South India 

T Vizhalil Paul, N Thomas, M Seshadri, 

K Senthilvasan, E Esther & K Sudeep 

P442 Biological diagnosis of 63 

pheochromocytomas and/or paragangliomas 

M d'Herbomez, C Bauters, N Rouaix, G Forzy, 

C Do Cao, B Carnaille & JL Wemeau 

P443 Dedifferentiated papillary thyroid cancer. Use 

of array CGH in searching for prognostic 

markers 

A Gazdag, G Pocsay, R Pocsay, L Puskas, L Feher, 

E Tarko & M Tarko 

P444 Stereotactic conformal radiotherapy in 

pituitary adenomas - outcome in 36 

consecutive patients during years 1996-2004 

C Schalin-Jäntti, L Valanne, M Kouri & T Sane 

P445 Intra-ovarian adrenocortical carcinoma 

F Chentli, F Yesli, N Meziani, S Alem, N Kesri & 

S Fedala 


POSTERS

POSTERS 

48 


P446 Comparative efficacy of therapy by 

sandostatin and parlodel of patients with 

acromegalia 

ZY Khaimova & AA Khalikova 

P447 Pituitary tumors in Republic of Croatia 

M Vrkljan, A Maric, M Matovinovic, V Cerina, 

D Herman & HI Pecina 

P448 Histological pecularities of pituitary adenomas 

ZY Khalimova & ER Magdieva 

P449 Surgical treatment in acromegaly: predictors 

of outcome 

PV Iushkov, NN Molitvoslovova, EG Luljeva & 

EI Marova 

P450 Pituitary mass and hypothyroidism. A case 

report 

H Smida, R Bouguerra, L Ben Salem, N Younsi, 

CH Saidi & C Ben Slama 

P451 Incidence rate of thyroid cancer in Olsztyn 

region in the years 1993-2004 

E Bandurska-Stankiewicz & E Aksamit-Białoszewska 

P452 A typical clinical picture of four insulinoma 

cases 

M Kurowska, J Malicka, JS Tarach & A Nowakowski 

P453 What is the best glycaemic index for diagnosis 

of insulinoma? 

JM Andrieu, DB Bassiri, RM Ramdani, EG Guzman, 

JF Fabre, EA Aboud & JC Courreges 

P454 Sustained correction of hypercortisolism with a 

low dose mitotane regimen in a young 

woman with PPNAD and Carney Complex 

M Campo, G Picca, ED Laudadio, O Lamacchia & 

M Cignarelli 

P455 Hypocorticism after radiosurgery 

(protonotherapy) in patients with normal MRI 

and in patients with confirmed tumor for 


OV Manchenko & EI Marova 

P456 Prognostic value of Ki-67 expression in the 

cytologic identification of pancreatic 

endocrine tumors: preliminary data 

MF Manzoni, GM Franchi, C Piani, C Cappelletti, 

PG Arcidiacono, L Albarello, C Doglioni & E Bosi 

P457 Difficulties in diagnosing persistent 

acromegaly using current consensus criteria 

for cure after transsphenoidal surgery 

M Petakov, M Djurovic, S Ognjanovic, DJ Macut, 

T Isailovic, B Popovic, I Bozic, M Joksimovic & 

S Damjanovic 

P458 Carbohydrate metabolism in patients with 

hypercorticism 

V Chachibaia, M Korinteli, E Giorgadze, 

B Gvadzabia & K Bochorishvili 

P459 Role of family history for diabetes mellitus in 

determining insulin resistance in acromegalic 

patients 

F Diacono, D Pietrobono, G Bassotti, L Borgognoni, 

D Di Sarra, R Iuorio, P Gargiulo & G Tamburrano 

P460 Familial acromegaly 

G Oruk, O Kucuksahin, D Soysal, E Tatar & 

C Ozdemir 

P461 Role of complex Cdk4/cyclin D1 in 

somatostatin subtype 2 receptor-mediated 

inhibition of cell proliferation of a medullary 

thyroid carcinoma cell line in vitro 

F Tagliati, MC Zatelli, A Bottoni, D Piccin, A Luchin, 

MD Culler & EC degli Uberti 

P462 Selective cyclo-oxygenase 2 inhibitors revert 

chemoresistance in medullary thyroid 

carcinoma by a mechanism mediated by P-gp 

and PGH2 

MC Zatelli, A Luchin, D Piccin, F Tagliati, A Bottoni, 

C Vignali, M Bondanelli & EC degli Uberti 

P463 An intrasellar germinoma with normal 

cerebrospinal fluid β-HCG concentration 

misdiagnosed as hypophysitis 

S Tanyolac, A Cikim, N Ozbey, A Sencer, R Kurt, 

S Sencer, I Turantan & S Molvalilar 

P464 Response to medical treatment in male 

macroprolactinomas 

F Chentli, S Azzoug & S Boudiar 

P465 Non-functioning pituitary tumors 

F Chentli, N Meziani, K Takbou, C Habbak, 

S Bendaoud, L Cherf & AEM Haddam 

P466 Diabetic retinopathy in acromegaly 

S Azzoug, A Adem & F Chentli 

P467 Malignant catecholamine-secreting 

paragangliomas of retrocardial localization 

M Sabljar-Matovinovic, I Prkacin, N Crkvencic, 

S Gracin & M Knotek 

P468 Short-term evaluation of quality of life in 

acromegalic patients 

C Sardella, C Cosci, S Gavioli, F Bogazzi & 

E Martino 

P469 Octreotide as alternative to surgical 

adrenalectomy 

D Katalinic, G Mirosevic & V Zjacic-Rotkvic 

P470 Inhibition of IGF-II signal transduction 

improves chemosensitivity in human 

adrenocortical cancer cells 

S Hahner, E Beidinger, A Stuermer, AC Koschker, 

D Weismann, M Fassnacht & B Allolio 

P471 The new TNM classification is inferior to the 

Lee classification in predicting outcome in 

patients with adrenocortical carcinoma 

M Fassnacht, AC Koschker, S Hahner, U Maeder, 

D Weismann, T Linden, M Quinckler, H Willenberg, 

P Bucsky, S Diehl, M Brauckhoff, M Schaefer, 

N Schlenz, K Muessig, M Reincke & B Allolio 

P472 Stimulated and spontaneous growth hormone 

release in irradiated acromegalic patients 

AA van der Klaauw, AM Pereira, SW van Thiel, 

JWA Smit, EPM Corssmit, NR Biermasz, M Frohlich, 

A Iranmanesh, JD Veldhuis, F Roelfsema & 

JA Romijn 

www.ece2006.com

P473 WNT4 expression in normal human adrenals 

and adrenocortical tumours 

T Kuulasmaa, J Jääskeläinen, T Pietiläinen, 

S Loimas, S Aaltomaa, P Heikkilä, V-M Kosma & 

R Voutilainen 

P474 The clinical particularities, medical possibility 

of prolactinomas in men 

LK Dzeranova, VV Vax & EN Giniatullina 

P475 Management of thyroid cancer in children 

A Mazilu, AE Ranetti, A Mihai & C Spiroiu 

P476 Diagnosis difficulties in insulinomas 

AE Ranetti, A Mazilu, C Spiroiu & A Mihai 

P477 Insulin-like growth factor-I signalling in 

tamoxifen sensitive and tamoxifen resistant 

breast cancer cells 

CJ McVittie, S Khalaf, W Ogunkolade, R Carpenter, 

SA Bustin & PJ Jenkins 

P478 Functioning adrenocortical carcinoma and the 

clinical endocrinologist: toxic treatments and 

poor prognosis 

RM Thomas, R Bliss, D Richardson, S Johnson, 

S Turner, S Bennett & R Quinton 

P479 Post-operative serum cortisol for prediction of 

long-term remission from Cushing's syndrome 

JR Lindsay, EH Oldfield & LK Nieman 

P480 An in-frame complex germline mutation in the 

juxtamembrane intracellular domain causing 

RET activation in familial medullary thyroid 

carcinoma 

L Fugazzola, D Cordella, M Muzza, L Alberti, 

P Travaglini, P Colombo, P Beck-Peccoz & L Persani 

P481 Macroprolactinoma: 5 cases 

I Hadj Ali, H Cheikhrouhou, K Khiari & 


P482 48h appears as sufficient duration of fasting in 

the diagnosis of insulinoma - a single centre 

experience with 23 cases 

M Quinkler, F Strehlow, H Biering, M Pirlich, H Gerl, 

CJ Strasburger & M Ventz 

P483 A case of a patient with differentiated thyroid 

carcinoma and metastases to the kidneys 

Z Adamczewski, J Makarewicz, M Knapska- 

Kucharska, L Oszukowska, A Karwowska & 

A Lewinski 

P484 Development of a non-isotopic immunoassay 

for the measurement of aldosterone in saliva 

J Manolopoulou & M Bidlingmaier 

P485 Thyroid autoimmunity and breast cancer (BC): 

absence of morphological autoimmune 

changes in breast malignant tissue 

EG Giustarini, AP Pinchera, PF Fierabracci, 

DC Campani & CG Giani 

P486 Pituicytoma - a case report 

P Rao-Balakrishna, C Dang, K Gnanalingam, H Reid 

& T Kearney 


P487 PTTG promotes a novel VEGF-KDR-ID3 

autocrine mitogenic pathway in thyroid 

cancer 

DS Kim, MA Buchanan, AL Stratford, R Susarla, 

JC Watkinson, MC Eggo, JA Franklyn & CJ McCabe 

P488 Multiple endocrine neoplasia type 1 (MEN 1) 

is associated with insulin resistance and an 

increased prevalence of diabetes and impaired 

fasting glucose 

RW McCallum, V Parameswaran & JR Burgess 

P489 Evaluation of a standardized protocol for the 

collection and storage of adrenal tumor 

samples - preparation for a European adrenal 

tumor bank (ENS@T) 

I Johnsen, S Hahner, M Fassnacht, J Bertherat, 

X Bertagna, PF Plouin, M Reincke, B Allolio & 

F Beuschlein 

P490 Value of overnight dexamethasone 

suppression test (1mg-DST) in subclinical 

Cushing's syndrome 

Z Penezic, M Zarkovic, M Ivovic, S Vujovic, J Ciric, 

BZ Beleslin, M Stojanovic, LJ Marina & M Drezgic 

P491 Effect of catecholamine uptake inhibition on 

catecholamine content in human adrenal 

chromaffin cells and pheochromocytes 

J Rosmaninho-Salgado, AR Álvaro, D Grand, 

A Mota, E Grouzmann & C Cavadas 

P492 PTTG binding factor (PBF) can transform cells 

independently of interaction with PTTG 

AL Stratford, K Boelaert, DS Kim, JA Franklyn & 

CJ McCabe 

P493 Carney's complex with acromegaly as the 

leading clinical condition 

LM Fatti, G Bertola, G Balza, E Lavezzi, F Pecori 

Giraldi & F Cavagnini 

P494 Daily profiles of aldosterone secretion in 

primary aldosteronism 

J Ciric, M Zarkovic, B Beleslin, Z Penezic, 

M Stojkovic, S Savic & B Trbojevic 

P495 Analysis of succinyl dehydrogenase (SDH) 

subunits gene mutations in patients with 


A Krawczyk, K Hasse-Lazar, A Pawlaczek, 

D Rusinek, S Szpak-Ulczok, M Peczkowska, 

A Preibisz, A Kubaszek, E Gubala, A Januszewicz & 

B Jarzab 

P496 Neuropeptide Y-Y1 receptors mediate the 

effects of neuropeptide Y on prostate cancer 

cell growth 

M Ruscica, E Dozio, M Motta & P Magni 

P497 Differential expression of neurogenins by 

human pituitary adenomas 

A Fratticci, R Padronetti, F Giangaspero, L Ventura, 

M Piccirilli, V Esposito, A Gulino, E Alesse & 

ML Jaffrain-Rea 


POSTERS

POSTERS 

50 


P498 Evidence for an attenuated 11betahydroxysteroid 

dehydrogenase type-1 

response to an inflammatory stimulus in 

primary cultures of epithelial ovarian cancer 

KS Fegan, MT Rae & SG Hillier 

P499 Long-term somatostatin analog octreotide 

treatment in insulinoma patients 

D Vezzosi, A Bennet, F Courbon & P Caron 

P500 Development of dopamine agonist resistance 

and progression from microadenoma to 

macroadenoma in two women with 

hyperprolactinaemia 

D McCall, SJ Hunter, RS Cooke, B Herron, 

B Sheridan & AB Atkinson 

P501 The rare RET mutation (insTTCTdelG) at 

codon 666 is associated with a low penetrance 

of medullary thyroid carcinoma and 

pheochromocytoma 

M Bex, B Decallonne, G Matthijs & E Legius 

P502 Use of TRH in addition to CRH stimulation 

during bilateral petrosal sinus sampling in 

Cushing's syndrome - long term experience 

P Sathiskumar, J Wright & TA Howlett 

P503 Glucagonoma syndrome - treatment with 

intensive insulin and high dose vitamin B 

complex 

NA Phelan, M Shahid, N Correia, T Kyaw Tun, 

KC Conlon & J Gibney 

P504 Headaches cured by surgery 

A Banerjee, M Balaratnam, W Dhillo, N Mendoza & 

K Meeran 

P505 Chromogranin-a in adrenal incidentalomas - 

marker for tumour secretion 

M Ivovic, Z Penezic, S Vujovic, Lj Marina, 

M Stojanovic & M Drezgic 

P506 A novel germ-line mutation GLY321ARG in the 

exon 5 of the RET proto-oncogene detected in 

a family with familial medullary thyroid 

carcinoma 

E Vaclavikova, S Dvorakova, J Duskova, P Vlcek, 

A Ryska & B Bendlova 

P507 Contemporary management of 

macroprolactinomas 

AI Palalau, C Miller, NJ Gittoes & AA Toogood 

P508 Cushing's paraneoplastic syndrome secondary 

to recurrent ovarian carcinoma 

J Combes, S Chabroux, D Debieuvre & JP Ory 

P509 Molecular, genetic and clinical characterisation 

of neurofibromatosis type 1-associated 


B Bausch & HP Neumann 

P510 AcroBel: a registry and survey on acromegaly 

in Belgium 

M Bex, R Abs, GT Sjoen, J Mockel, B Velkeniers & 

D Maiter 

P511 The latest safety and efficacy data of patients 

treated with pegvisomant 

I Schreiber, K Forssmann, M Buchfelder, M Droste, 

K Mann, B Saller & CJ Strasburger 

P512 Mutation at codon 804 in a Greek kindred 

detected by screening of the six RET exons in 

patients with medullary thyroid carcinoma 

N Mytakidis, E Vassiliou, V Liakos, L Papagrigoriou, 

F Hadzimarkou, I Kostoglou-Athanasiou, 

G Koutsodontis, A Ladopoulou, T Bei, 

D Yannoukakos & P Kaldrymidis 

P513 A rare RET gene mutation is found in two 

apparently unrelated Greek kindreds with 

familial medullary thyroid carcinoma 

N Mytakidis, M Zachariou, T Anagnostopoulos, 

E Vassiliou, D Thomas, A Tertipi, T Rampias, 

I Konstantopoulou, P Natsis, D Yannoukakos & 

P Kaldrymidis 

P514 Surgical cure with preserved pituitary function 

is rare in acromegalic patients. Results from 

the POTA study (preoperative octreotide 

treatment of acromegaly) 

SM Carlsen, T Schreiner, S Anderud, Ø Johannesen, 

J Svartberg & J Bollerslev 

P515 Different scintigraphic patterns between 

sympathetic and parasympathetic 


MS Gaglianò, L Simi, T Ercolino, L Becherini, 

R Sestini, M Mascalchi, M Genuardi, V Briganti, 

G La Cava, C Olianti & M Mannelli 

P516 mRNA expression of somatostatin receptor 

subtypes in pheochromocytomas/ 


M Mannelli, S Gelmini, F Malentacchi, L Simi, 

MS Gaglianò, T Ercolino, L Becherini, A Valeri, 

C Pratesi & C Orlando 

P517 A retrospective review of the effect of pituitary 

radiotherapy after trans-sphenoidal surgery for 

non-functioning pituitary adenomas 

P Chellamuthu, I Robertson, MJ Levy & TA Howlett 

P518 Biochemical characteristics of 'silent' ACTHsecreting 

pituitary adenomas: preoperative 

serum and urine studies 

C Maser-Gluth, G Artlich, A Gutenberg & 

M Buchfelder 

P519 Radiotherapy and o,p'-DDD induce an 

inhibition of growth and interfere in the cell 

cycle in H295-R adrenocortical cell line 

A Stigliano, L Cerquetti, B Bucci, P Carlini, 

D Amendola, S Misiti, R Miceli, U de Paula, 

E Brunetti & V Toscano 

P520 Role of PKA regulatory subunit 2B protein on 

cortisol-secreting adrenocortical cells 

proliferation 

A Lania, G Mantovani, S Bondioni, E Peverelli, 

S Ferrero, L Vicentini, S Bosari, P Beck-Peccoz & 

A Spada 

www.ece2006.com

P521 Outcome of management of 

craniopharyngiomas - a contemporary series 

JD Rippin, RD Mitchell, EJ McGregor, AA Toogood & 

NJ Gittoes 

P522 Anatomo-clinical features in multihormonal 

prolactinomas 

D Voicu, C Badiu, D Hortopan, C Stancu, 

A Caragheorgheopol & M Coculescu 

P523 Glucocorticoid receptor gene N363S variant in 

patients with clinically inapparent adrenal 

adenomas 

G Reimondo, I Micossi, D Giachino, S Bovio, 

B Allasino, F Daffara, A Angeli, M Terzolo & 

M De Marchi 

P524 Characteristics and follow-up of thyroid cancer 

in patients with hyperthyroidism 

M Boudina, K Pazaitou-Panayiotou, A Chrisoulidou, 

A Drimonitis, A Kaprara, E Georgiou & I Vainas 

P525 Investigation and surgical management of 

pancreatic neuroendocrine tumours 

FM Coyle, WM Drake, SL Chew, P Jenkins, 

RR Hutchins, AB Grossman, JP Monson & 

S Bhattacharya 

P526 Estrone and cortisol co-secreting 

adrenocortical carcinoma in a man presenting 

with hypogonadotrophic hypogonadism and 

painful gynaecomastia 

EL Lim, S Razvi, S Vaikkakara, IM Ibrahim, S Turner, 

S Johnson, JI Mason, TJW Lennard, R Bliss, S Elloitt, 

D Richardson, RD Neely & R Quinton 

P527 Origin and spread of the SDHD p.Y114C 

mutation causing head and neck 

paraganglioma in Trentino, Italy 

F Schiavi, Z Erlic, T Savvoukidis, S Demattè, 

A Del Piano, ME Cecchini, P Amistà, F Grego, 

F Trabalzini, M Hoffman, A Schwentek, F Mantero, 

F Branz, HPH Neumann & G Opocher 

P528 Characterization of familial non-syndromic 


G Opocher, F Schiavi, M Iacobone, S Sattarova, 

Z Erlic, M Martella, C Mian, L Zambonin, 

P De Lazzari, A Murgia, G Favia & F Mantero 

P529 Endostatin and VEGF levels in serum of 

patients with pituitary tumors 

A Gruszka, J Kunert-Radek, M Pawlikowski, 

H Stepien & A Radek 

P530 18F-deoxy-D-glucose positron emission 

tomography (FDG-PET) increases the 

detection rate of recurrent or residual 

medullary thyroid cancer 

A Faggiano, P Ferolla, LC Pezzullo, M Chiofalo, 

F Milone, N Mozzillo, G Scarpelli, F Santeusanio, 

G Angeletti, G Lombardi & A Colao 

P531 Papillary thyroid microcarcinoma: a low risk 

neoplasia? 

GA Lupoli, S Colarusso, A Panico, F Fonderico, 

F Nappi, F Marciello, A Martinelli, P Cuofano, 

F Lo Calzo, L Vicedomini & G Lupoli 


P532 The value of fluorine-18 fluorodeoxyglucose 

PET during follow-up of patients with 

medullary thyroid carcinoma 

GA Lupoli, S Colarusso, A Panico, F Fonderico, 

F Nappi, F Marciello, A Gonnella, MR Poggiano, 

E Nicolai, M Salvatore & G Lupoli 

P533 N363S and Bcl I variants in the glucocorticoid 

receptor gene and their associations in 

Cushing's syndrome and Addison's disease 

G Arnaldi, G Appolloni, C Polloni, P Romagni, 

B Polenta, M Cardinaletti, A Falorni & M Boscaro 

P534 Novel inactivating mutations in four Italian 

cases of familial hypocalciuric hypercalcemia 

F Cetani, S Borsari, M Lemmi, E Pardi, E Ambrogini, 

A Pinchera & C Marcocci 

P535 Genetic analyses of familial isolated primary 

hyperparathyroidism: implications for clinical 

assessment and surgical management 

C Marcocci, E Pardi, S Borsari, E Ambrogini, 

M Lemmi, A Picone, E Vignali, G Viccica, P Berti, 

P Miccoli & F Cetani 

P536 Non-pancreatic carcinoid tumours - 

prognostic value of proliferative index (Ki67%) 

RM Thomas, G Bernstone, S Johnson, D Manas, 

RA James & P Perros 

P537 Somatostatin receptor subtypes 1-5 in 

pituitary tumors of various etiologies: 

investigation by immunohistochemistry 

N Unger, I Serdiuk, W Saeger, H Wiedemeyer, 

J Van de Nes, S Schulz, D Stolke, K Mann & 

S Petersenn 

P538 High performance liquid chromatography 

(HPLC) in the follow-up of mitotane therapy in 

a patient with adrenal carcinoma 

D Thomas, I Kostoglou-Athanassiou, S Bournazos, 

N Mytakidis, V Liakos, E Vassiliou, P Athanassiou & 


P539 Multiple endocrine neoplasia type 1 and 

angiomyxoma 

I Kostoglou-Athanassiou, P Athanassiou, D Thomas, 

N Mytakidis, E Vassiliou, V Liakos & PH Kaldrymidis 

P540 Novel L301R heterozygous mutation of the 

menin gene in a Hungarian MEN 1 family 

P Gergics, K Balogh, M Toth, A Patocs, L Hunyadi, 

S Czirjak, J Horanyi, A Gyorkos & K Racz 

P541 Differences in the presenting biochemical and 

imaging data in patients with acromegaly 

caused by pure GH adenomas, adenomas with 

GH and PRL cell differentiation and 

plurihormonal adenomas 

A Fernandez, N Karavitaki, O Ansorge, 

V Fazal-Sanderson, HE Turner & JAH Wass 

P542 Management of thyrotrophin-secreting 

adenoma with octreotide therapy 

AEC Fountain, NM Neary, ECI Hatfield & K Meeran 


POSTERS

POSTERS 

52 


P543 Tumor size and gonadotrophin 

immunoreactivity of pituitary adenomas 

C Badiu, C Stancu, O Filip, D Hortopan, 

V Ciubotaru & M Coculescu 

P544 Carotid arterial intima-media thickness (IMT), 

a marker of atherosclerosis, does not differ in 

patients with acromegaly compared to healthy 

controls 

AN Paisley, JAL Lawrance, R Murray, SM Shalet & 

PJ Trainer 

P545 Acute biliary tract problems are common on 

discontinuation of somatostatin analogue (SA) 

therapy 

AN Paisley, ME Roberts & PJ Trainer 

P546 Cell proliferation and outcome of GHsecreting 

pituitary adenomas 

L De Marinis, A Bianchi, L Tilaro, F Doglietto, 

F Veltri, GV Vellone, F Lugli, A Fusco, V Cimino, 

A Pontecorvi & L Lauriola 

P547 Efficacy and safety of high doses of long 

acting somatostatin analogues for treatment 

of well-differentiated functioning 

neuroendocrine tumors 

P Ferolla, A Faggiano, R Pivonello, G Lombardi, 

G Angeletti, A Colao & F Santeusanio 

P548 Surgical debulking of GH secreting adenomas 

improves control of acromegaly by lanreotide 

- a prospective study 

JAH Wass, V Fazal-Sanderson, J Byrne, S Rowel, 

N Karavitaki, P Trainer & HE Turner 

P549 Diagnostic utility of dexamethazone 

suppression tests in the work-up of Cushing's 

disease 

EJ Roderick, K Collison, N Karavitaki, HE Turner, 

S Suliman & JAH Wass 

P550 Descriptive epidemiology of thyroid cancer 

occurring in the population living in the 

Rhône Alpes region: 1998-2004 

Z Nejjari, L Remontet, F Borson-Chazot, N Bossard, 

N Berger, M Decaussin-Petrucci, J Estève & 

G Sassolas 

P551 In vitro effects of SOM230 on primary cultured 

pheochromocytoma cells 

D Pasquali, G Conzo, V Rossi, G Bellastella, 

L Maione, A Bellastella & AA Sinisi 

P552 Fourier transform infrared spectroscopy (FTIR) 

of parathyroid pathology 

K Das, N Stone, C Kendall, C Fowler & 

J Christie-Brown 

Growth and development 

P553 Prevalence of the main GH receptor 

polymorphisms in GH deficient children and in 

the general population 

M Filisetti, P Mella, A Pilotta, L Costa, I Sparapani, 

S Zanola, B Guaragni, B Felappi, E Prandi & F Buzi 

P554 Developmental control of tissue deiodinases 

by cortisol in fetal sheep during late gestation 

AJ Forhead, K Curtis, E Kaptein, TJ Visser & 

AL Fowden 

P555 Significance of neonatal steroid imprinting and 

of peripubertal growth hormone excess for 

the development of prostatic hyperplasia in 

the rat 

F Goetz, A Mitroshkin, AV Patchev & W Rohde 

P556 Adrenal (interrenal) development in the 

zebrafish 

TT To, S Hahner, K Rohr, G Nica, 

M Hammerschmidt, C Winkler & B Allolio 

P557 Comparison of dietary pattern and food habit 

in urban and rural adolescent girls, Gillan, Iran 

H Pouraram & M Abtahi 

P558 Effective factors on status of nutritional 

education in primary school children, Tehran, 

Iran: a focus group discussion (FGD) 

M Abtahi, M Abdollahi, M Amini, H Kianfar, 

M Dadkhah & H Pouraram 

P559 Morphological changes of pituitary region in 

primary GH deficiency 

J Bruna & J Brunova 

P560 Growth without growth hormone: normal 

final height of four patients with multiple 

pituitary hormone deficiency 

M Doknic, D Miljic, S Pekic, M Djurovic, V Zivkovic, 

M Stojanovic, C Dieguez, FF Casanueva & 

V Popovic 

P561 RAD21-dependent effects of securin/PTTG and 

separase on fetal neuronal NT2 cells 

HN Pemberton, K Boelaert, DS Kim, SY Chan, 

MD Kilby, JA Franklyn & CJ McCabe 

P562 Leukemia inhibitory factor promotes the 

chemomigration of immature GNRH neurons 

E Dozio, M Ruscica, M Motta, R Maggi & P Magni 

P563 The study of nutrition with different salt 

concentrations in prenatal period on BP and 

tissue changes Na and aldosterone level in 

next generation 

F Heydarpour 

P564 Sodium, birth weight, adult weight and BP in 

adulthood 

F Alaee & F Heydarpour 

P565 Embryonic gene expression affected by 

different sodium concentrations 

M Heydarpour & F Heydarpour 

P566 Sodium changes autonomic nervous response 

M Heydarpour & F Heydarpour 

P567 Lipid peroxidation, activity of caspase 3 and 

apoptosis activation in low birth weight 

children 

E Barg, K Gasiorowski, B Wikiera, A Skoczynska, 

B Turczyn & E Glab 

www.ece2006.com

P568 Growth hormone induced improvement in 

quality of life does not correlate with 

reduction in vascular risk in adult 

hypopituitary patients 

RW McCallum, JR Petrie, AF Dominiczak & 

JMC Connell 

P569 The response of infant's adrenal gland and salt 

appetite, aldosterone and Na serum level to 

mother's salt consumption 

P Heydarpour & F Heydarpour 

P570 Maternal testosterone levels during pregnancy 

are associated with offspring size at birth 

SM Carlsen, G Jacobsen & P Romundstad 

P571 Mortality in growth hormone deficiency 

K Stochholm, C Gravholt, T Laursen, J Sandahl 

Christiansen & A Green 

P572 The cardiovascular risk profile and carotid IMT 

of adults with partial GH deficiency 

RD Murray, G Wieringa, JA Lawrance & SM Shalet 

P573 Double blind placebo controlled study on the 

impact of rGH replacement on quality of life in 

patients with severe growth hormone 

deficiency 

S González, S Sugunendran & SL Atkin 

P574 Prolonged expression of the ACTH receptor, 

MC2-R, during 3T3-L1 adipocyte 

differentiation is dependent upon switching 

promoter usage to an adipocyte-specific, 

C/EBP-driven, downstream promoter 

LA Noon, AJL Clark, PJ O'Shaughnessy & PJ King 

Neuroendocrinology and behaviour 

P575 Association between the LRP5 gene and serum 

post-menopausal follicle stimulating hormone 

levels 

I Zofkova, K Zajickova & M Hill 

P576 Structural analysis of somatotrophs and 

lactotrophs in annexin 1 null mice 

T Afzal, JF Morris, JC Buckingham & HC Christian 

P577 Dietary supplements for stress and obesity comorbidities 

reduction 

D Dimitrov & L Koeva 

P578 The impact of hypothalamic-pituitary (h-p) 

irradiation on the TSH bio/immuno (B/I) ratio 

in the fed and fasting states 

KH Darzy, L Persani, S Borgato, P Beck-Peccoz & 

SM Shalet 

P579 Comparison of the catecholaminergic 

response to 2 different stressors in healthy 

men 

BC Binnert, SG Seematter, SR Stettler, 

BS B Beck-Schimmer, SD Spahn & TL Tappy 

P580 Effect of gastric bypass and gastric banding on 

neurotensin levels in morbidly obese patients 

M Christ-Crain, R Stoeckli, A Ernst, N Morgenthaler, 

S Bilz, M Korbonits, A Bergmann, B Mueller & 

U Keller 


P581 Mental and neuropsychological disorders of 

children with congenital hypothyroidism 

YM Urmanova & SM Safarova 

P582 Hypopituitary patients have a high occurrence 

of metabolic syndrome markers and increased 

prevalence of cardiovascular risk factors 

B Matuszek, E Obel, M Kowalczyk & A Nowakowski 

P583 Spontaneous GH secretion in the fed and 

fasting states in cranially irradiated adult 

cancer survivors with normal peak GH 

responses to two provocative tests: does GH 

neurosecretory dysfunction exist? 

KH Darzy, RD Murray, HK Gleeson, SS Pezzoli, 

MO Thorner & SM Shalet 

P584 The long-term predictive accuracy of the short 

synacthen (corticotropin) stimulation test for 

assessment of the hypothalamic-pituitaryadrenal 

axis 

A Agha, J Tomlinson, PM Clark, G Holder & 

PM Stewart 

P585 GH secretion in amyotrophic lateral sclerosis 

LL Morselli, P Bongioanni, M Genovesi, R Licitra, 

B Rossi & E Martino 

P586 Clinical significance of macroprolactin 

P Álvarez-Vázquez, D Rodríguez Pérez, E Álvarez 

García, C Páramo Fernandez, E Hervás Abad & 

MA Andrade Olivié 

P587 ADH and thirst function in defence with 

hypernatremia formation 

F Heydarpour 

P588 The effect of garlic odor on appetite center 

F Heydarpour 

P589 Taste protective mechanism in relation with 

salt 

F Heydarpour 

P590 The effect of salt on night sleep 

F Heydarpour 

P591 Evaluation of cognitive functions by using 

P300 auditory event related potentials (ERPs) 

in patients with growth hormone (GH) 

deficiency and GH excess 

F Tanriverdi, C Suer, H Yapislar, K Unluhizarci, 

F Bayram & F Kelestimur 

P592 Appetite regulating hormones in 

constitutionally lean and anorexia nervosa 

subjects 

B Galusca, N Germain, CW le Roux, D Frere, 

MA Ghatei, SR Bloom & B Estour 

P593 Differentiation of TSH-OMA from thyroid 

hormone resistance syndrome using thyroid 

color Doppler sonography 

C Cosci, C Sardella, L Manetti, M Gasperi, 

L Tomisti, S Gavioli, E Macchia, F Bogazzi & 

E Martino 


POSTERS

POSTERS 

54 


P594 Maternal consumption of a high-meat, low 

carbohydrate diet in late pregnancy and stress 

responsiveness in the offspring 

RM Reynolds, H Simonsen, S Pearson, ME Barker, 

DJP Barker, M Campbell-Brown, KM Godfrey & 

DIW Phillips 

P595 Patients with pituitary disease who have had 

radiotherapy have reduced cerebral vasomotor 

reactivity 

N Rathbone, JS Davies & MF Scanlon 

P596 An open label, controlled study to assess the 

ability of patients with acromegaly, or their 

partners, to administer somatuline autogel 

JS Bevan, J Newell-Price & JAH Wass 

P597 The effect of dopamine on neuroendocrine 

disorders in women with PCOS under chronic 

stress conditions 

DK Virsaladze, K Natmeladze, I Topuria, 

A Natmeladze & N Paichadze 

P598 Measurement of basal cortisol in serum and 

saliva for the diagnosis of secondary adrenal 

insufficiency 

T Deutschbein, N Unger, K Mann & S Petersenn 

P599 Sensitivity and specificity of different 

provocative tests for the diagnosis of 

secondary hypoadrenalism in patients with 

hypothalamo-pituitary disorders 

A Picu, R Giordano, L Bonelli, M Balbo, 

M Pellegrino, R Berardelli, G Corneli, V Gasco, 

E Ghigo & E Arvat 

P600 Pulmonary function in Cushing's disease 

T Bayraktaroglu, F Kutluturk, E Turan, Y Orhan & 

S Tanyolac 

P601 Adenosine stimulates connexin 43 expression 

and increases intercellular communication in 

the folliculostellate cells of the anterior 

pituitary gland 

BM Lewis, K Francis, A Pexa, A Deussen, 

MF Scanlon, DA Rees & J Ham 

P602 Complement C5a inhibits the secretion of 

macrophage migration inhibitory factor (MIF) 

in anterior pituitary cell lines 

BM Lewis, K Francis, P Monk, MF Scanlon & J Ham 

P603 Unrecognized chronic hypopituitarism in 

patients who survived hemorrhagic fever with 

renal syndrome 

M Stojanovic, S Pekic, G Cvijovic, A Kendereski, 

M Doknic, D Miljic, V Zivkovic, M Djurovic, D Micic 

& V Popovic 

P604 Ghrelin test for the assessment of growth 

hormone (GH) status in successfully treated 

patients with acromegaly 

S Pekic Djurdjevic, M Doknic, D Miljic, 

M Joksimovic, J Glodic, M Djurovic, C Dieguez, 

FF Casanueva & V Popovic 

P605 The thickening of the pituitary stem in 

connection with 06 cases 

NS Fedala, AEM Haddam & F Chentli 

P606 Effectiveness of the association of 

bromocriptine and cabergoline in the 

treatment of 05 invasive and giants prolactin 

macroadenoma 

AEM Haddam, S Fedala, S Bouzidi, S Ouahid, 

NS Fedala, MS Bourouba & D Meskine 

P607 Hypothalamic-pituitary dysfunction following 

irradiation of non-pituitary brain tumours in 

adults 

A Agha, M Sherlock, S Brennan, SA O'Connor, 

E O'Sullivan, B Rogers, C Faul, D Rawluk, W Tormey 

& CJ Thompson 

P608 Bone mass and metabolism in active 

acromegaly - no impact of gonadal status. a 

study of 73 patients 

SL Fougner, K Godang, T Ueland, T Schreiner & 

J Bollerslev 

P609 Effect of pegvisomant on glucose metabolism 

S Aznar, E Boix, P Revert, O Moreno, A López-Maciá 

& A Picó 

P610 Psychological and gastrointestinal problems in 

anorexia nervosa patients 

M Djurovic, D Popovic, S Pekic, I Jovanovic, 

B Lapcevic, M Petakov, V Zivkovic, M Stojanovic, 

M Doknic, FF Casanueva, C Diguez & V Popovic 

P611 Octreotide shrinks the cellular rather than the 

vascular compartment in acromegalic tumours 

in vivo 

AM Manuchehri, M Lowry, C Rowland Hill, 

LW Turnbull & SL Atkin 

P612 Positive correlation between acroqol and SF- 

36 and negative with BDI in sample of 60 

acromegalics 

M Abreu, D Carvalho, E Vinha, S Webb & 

JL Medina 

P613 Quality of life (QoL) and psychiatric sequelae 

following aneurysmal subarachnoid 

hemorrhage (SAH): does neuroendocrine 

dysfunction play a role? 

I Kreitschmann-Andermahr, E Poll, B Saller, 

A Reineke, JM Gilsbach & BO Hütter 

P614 Pituitary function in patients with detectable 

serum pituitary autoantibodies 

LL Morselli, L Manetti, I Lupi, S Albertini, L Grasso, 

R Fessehatsion, M Genovesi, M Gasperi & E Martino 

P615 Prevalence of pituitary autoantibodies in 

thyroid disorders 

L Manetti, LL Morselli, I Lupi, S Albertini, L Grasso, 

M Genovesi, R Fessehatsion, S Mariotti & E Martino 

P616 Rate of change in size of macroprolactinomas 

with dopamine agonist therapy - is there any 

relationship to fall in prolactin concentrations? 

CL Miller, A Palalau, AA Toogood & NJL Gittoes 

P617 The levels of ghrelin and leptin and body fat 

mass in patients treated for thyroid 

dysfunction 

J Brunova, L Karasova & P Kasalicky 

www.ece2006.com

P618 Night sleep affected by salt 

R Samadie & F Heydarpour 

P619 ADH and thirst function in defence with 

hypernatremia formation 

R Samadie & F Heydarpour 

P620 Taste protective mechanism in relation to salt 

F Alaee & F Heydarpour 

P621 Cushing's syndrome as a model to investigate 

the effects on cognition of high circulating 

levels of glucocorticoid 

N Correia, S Mullally, M Shahid, NA Phelan, 

S O'Mara, T Kyaw Tun & J Gibney 

P622 The influence of growth hormone 

replacement (GHR) in adults with GH 

deficiency (GHD) on body composition, basal 

metabolic rate, physical activity and ingestive 

behaviour 

D Deepak, C Daousi, JP Wilding, J Pinkney & 

IA MacFarlane 

P623 Influence of affective changes on cortisol 

response to ACTH 

M Zarkovic, J Ciric, B Beleslin, Z Penezic, 

M Stojkovic, S Savic & B Trbojevic 

P624 Interest of a single treatment by somatostatin 

analogues in a macroadenoma secreting TSH 

and GH 

S Lopez, C Combes, A Drutel, F Archambeaud 

Mouveroux & MP Teissier 

P625 Dehydroepiandrosterone (DHEA) improves 

psychological well-being in male and female 

hypopituitary patients in addition to growth 

hormone replacement (GHR) 

AM Brooke, LA Kalingag, F Miraki-Moud, 

C Camacho-Hubner, KT Maher, DM Walker, 

JP Hinson & JP Monson 

P626 The influence of a GH receptor antagonist 

(GHRA) on the relationship between GH and 

IGF-I in adults with severe growth hormone 

deficiency (AGHD) 

A Pokrajac, CA Berg, M Bidlingmaier, 

CJ Strasburger, SM Shalet & PJ Trainer 

P627 Can adults with severe growth hormone 

deficiency (AsGHD) and a low IGF-I be 

distinguished from those with a normal IGF-I? 

CA Berg, A Pokrajac, M Bidlingmaier, 

CJ Strasburger, K Mann, SM Shalet & PJ Trainer 

P628 Sleep disorders in acromegaly: preliminary 

data demonstrating a high prevalence of 

restless leg syndrome (RLS) 

S Cannavo, R Condurso, S Squadrito, G Romanello, 

I Arico, G Mento, F Trimarchi & R Silvestri 

P629 Risk factors for the development of 

atherosclerosis in patients with acromegaly 

M Medic-Stojanoska, B Kovacev-Zavisic, LJ Popovic, 

J Radosavljevic, T Radovanov, I Bajkin, G Mitic & 

M Mitrovic 


P630 Microalbuminuria as well as insulin sensitivity 

are improved under octreotide-LAR treatment 

in acromegalic patients 

R Baldelli, V Gasco, R Pivonello, A Bianchi, 

V Cimino, F Galenca, A Pontecorvi, G Lombardi, 

E Ghigo, A Colao, L De Marinis & S Grottoli 

P631 Pro-opiomelanocortin and ACTH, precursors of 

alphaMSH, are secreted from human 

melanocytes and keratinocytes and can 

stimulate melanogenesis 

K Rousseau, S Kauser, LE Prtichard, A Warhurst, 

RL Oliver, CA Schmitz, AJ Thody, DJ Tobin & 

A White 

P632 Processing and sorting of proopiomelanocortin 

is an important checkpoint 

in regulating release of ACTH from secretory 

vesicles in pituitary cells 

A Warhurst, RL Oliver, RA Davies, LE Pritchard & 

A White 

P633 Hormone therapy effects on sleep and dreams 

in menopausal women 

C Rasanu, D Niculescu, I Botusan, O Filip & 

M Coculescu 

P634 Glucose-suppressed GH levels compared with 

IGF-I levels in patients with acromegaly 

B Steffin, B Gutt, J Roemmler, M Bidlingmaier & 

J Schopohl 

P635 Loss of rise in awakening cortisol response in 

prepubertal survivors of leukaemia post bone 

marrow transplantation and chemotherapy 

treatment 

ML Yeap, D Jessop, R Elson, J Cornish, S Lightman 

& EC Crowne 

P636 The incidence of spontaneous cerebro-spinal 

fluid rhinorrhea in a large series of patients 

with macroprolactinoma 

SGI Suliman, J Byrne, O Ansorge & JAH Wass 

P637 Gonadotropin levels in the cerebrospinal fluid 

(CSF) as a marker of the gonadotropin 

secretion from non-functioning pituitary 

adenomas 

ML Gheorghiu, C Badiu, A Caragheorgheopol, 

D Hortopan, A Dumitrascu, S Galoiu, C Capatana 

& M Coculescu 

P638 Prolonged post-operative follow-up is 

necessary for unirradiated non-functioning 

pituitary adenomata 

KV Allen & JAH Wass 

P639 Anterior pituitary hormone dysfunction after 

traumatic brain injury: less common than 

previously thought? 

N Karavitaki, JD Henderson-Slater, DT Wade & 

JAH Wass 

P640 Effects of long-term GH treatment in Prader- 

Willi adults 

C Hoybye 


POSTERS

POSTERS 

56 


P641 Endocrine abnormalities are common in 

transsexual individuals 

SJ Iqbal, H Baig, R Green, J Barrett & LJ Seal 

P642 Glucagon-induced suppression of ghrelin 

secretion is exerted at hypothalamus-pituitary 

level and is not mediated by an increase in 

catecholamine secretion 

MA Arafat, F Perschel, B Otto, M Weickert, 

H Rochlitz, C Schöfl, J Spranger, M Möhlig & 

AFH Pfeiffer 

P643 Complications of hormonal therapy in male to 

female transsexuals is uncommon 

H Baig, SJ Iqbal, R Green, J Barrett & LJ Seal 

P644 Effects of targeted ablation of GHRH neurons 

in mice on anterior pituitary somatotrophs 

and lactotrophs 

A Miller, P Le Tissier, I Robinson & HC Christian 

Reproduction 

P645 Spermatogenesis in autologous testicular 

transplants in the non-human primate 

Callithrix jacchus 

CM Luetjens, S Schlatt, E Nieschlag, M Simoni & 

J Wistuba 

P646 Hormonal status of women with benign 

endometrial hyperplastic lesions 

AA Osipova, VA Matveeva, AV Samoilova & 

AG Gunin 

P647 Dependence of semen characteristics on 

abstinence time, testicular volume and 

hormones 

F Tüttelmann, CM Luetjens, TG Cooper, M Simoni 

& E Nieschlag 

P648 Plasma endothelin-1 levels in patients with 

male hypogonadism 

A Tomova, PH Kumanov & G Kirilov 

P649 Outcome of 59 pregnancies in 43 acromegalic 

women 

PH Caron, J Bertherat, A Brac de la Périère, TH Brue, 

C Cortet-Rudelli, F Schillo & PH Chanson 

P650 Difficulties in achieving versus maintaining 

erection: organic, psychogenic and relational 

determinants 

G Corona, L Petrone, E Mannucci, M Mansani, 

G Balercia, C Krausz, R Giommi, G Forti & M Maggi 

P651 Psycho-biological correlates of smoking in 

patients with erectile dysfunction 

G Corona, L Petrone, E Mannucci, V Ricca, 

R Mansani, A Cilotti, G Balercia, R Giommi, 

V Chiarini, G Forti & M Maggi 

P652 Psycho-biological correlates of delayed 

ejaculation in male patients with sexual 

dysfunctions 

G Corona, L Petrone, E Mannucci, AD Fisher, 

G Balercia, R Giommi, V Chiarini, G Forti & 

M Maggi 

P653 Psycho-biological correlates of free-floating 

anxiety symptoms in male patients with sexual 

dysfunctions 

G Corona, E Mannucci, L Petrone, V Ricca, 

G Balercia, R Giommi, G Forti & M Maggi 

P654 Histone deacetylase inhibitors exert estradiolinduced 

proliferation and hyperplasia 

formation in the mouse uterus 

AG Gunin & AA Osipova 

P655 Aetiologies of galactorrheas 

F Chentli & D Meskine 

P656 Standardisation and validation of a sensitive 

enzyme immunoassay procedure to estimate 

13,14-dihydro-15-keto-PGF2α (PGFM) in 

mithun (Bos frontalis) plasma 

DP Mishra, A Dhali, A Mech, M Karunakaran, 

H Choudhury & C Rajkhowa 

P657 Siofor efficacy in treatment of obesity and 

reproductive disorders 

ZY Khalimova & GD Narimova 

P658 Endothelin-1 levels in men of reproductive age 

with idiopathic hypogonadism after treatment 

with tamoxifen or raloxifene 

M Tzoitou, E Papadopoulou, A Papageorgiou, 

M Kita, V Zournatzi, A Kourtis, A Avramidis & 

D Panidis 

P659 Clinical, hormonal, neuroradiological 

characteristics and response to treatment in 

29 macroprolactinomas 

R Bouguerra, L Ben Salem, Z Turki, H Smida, 

I Kammoun, C Saidi & C Ben Slama 

P660 Prevalence of macroprolactinemia during 

pregnancy of women with prolactinproducing 

pituitary microadenomas 

I Varga, C Jakab, E Toldy, P Gergics, M Toth, R Kiss, 

N Szucs, P Pusztai, A Patocs, I Adler, E Glaz & 

K Racz 

P661 Hormone replacement therapy in 

postmenopausis fails to normalize 

gonadotropins - does it matter? 

J Zmire, P Cvitkovic, P Jukic, B Colak, D Lucinger, 

L Sokolic, B Rocic & K Kljajic 

P662 All that is hypogonadal in haemochromatosis 

is not due to iron deposition 

EP O'Sullivan & CH Walsh 

P663 Nitric-oxide-cGMP and ATP-cAMP pathways in 

pregnant women with gestation diabetes 

mellitus 

ZV Zabarovskaya, OD Bichan & AP Shepelkevich 

P666 The influenace of estradiol on erythrocyte 

antioxidative enzyme system activity in preand 

postmenopausal women 

G Bednarek-Tupikowska, U Tworowska & 

B Bidzinska-Speichert 

www.ece2006.com

P667 The influence of the cimicifuga racemosa on 

the vegetovascular and psychoemotional 

disorders in women with climacteric syndrome 

E Giorgadze, M Korinteli, K Asatiani & M Tsagareli 

P668 Gonadal dysfunction in hypercortisolic men 

F Chentli, H Boudina, K Gati, S Azzoug & N 

Meziani 

P669 Role of estrogen receptor α- or β-isoforms in 

sex-specific brain organization 

F Goetz, AV Patchev & W Rohde 

P670 An immortalised cell line (SK11) derived from 

immature mouse testes express functionally 

active androgen and oestrogen receptors 

RP Hooley, SF Sneddon, F Collins & PTK Saunders 

P671 Clinical and laboratory relationships in women 

with hirsutism as a primary symptom 

I Duncea, CE Georgescu, C Ghervan, A Valea & 

L Gozariu 

P672 Bone mass density in 180 women with 

premature ovarian failure 

S Vujovic, M Stojanovic, Z Penezic, M Ivovic, 

M Kovacevic, B Barac, L Marina & M Drezgic 

P673 Oxidized low-density lipoprotein 

autoantibodies in patients with polycystic 

ovary syndrome 

A Azezli, A Telci, T Bayraktaroglu, F Kutluturk, 

A Uzum, A Cikim, S Tanyolac & Y Orhan 

P674 Transforming growth factor beta 1 and 

decidualisation of the human endometrium 

NM Kane, J Brosens, HOD Critchley & RW Kelly 

P675 Evidence for synergy of SHBG and androgen 

receptor genes in PCOS phenotype 

N Xita, I Georgiou, V Psofaki, G Kolios & 

A Tsatsoulis 

P676 Factor analysis identifies three independent 

factors within PCOS 

AJ Cussons, V Burke, BGA Stuckey & GF Watts 

P677 Impaired vascular function in hypogonadal 

males is unaltered during treatment cycle with 

intramuscular testosterone esters 

HA Lane, JC Smith, K Morris, J Cockcroft, 

J Goodfellow, MF Scanlon & JS Davies 

P678 Changes in GnRH gene expression in the 

medial basal hypothalamus of rhesus 

macaques across the menstrual cycle 

HF Urbanski, N Noriega, VT Garyfallou, JL Downs & 

SG Kohama 

P679 Mechanisms of Wolffian duct differentiation; 

development of a model for studying 

androgen-driven stromal-epithelial interactions 

M Welsh, RM Sharpe & PTK Saunders 

P680 Neonatal, but not maternal, plasma lipid 

profiles are altered in pregnancy in women 

with polycystic ovarian syndrome (PCOS), 

compared with weight matched controls 

EK Tan, M Kanagalingam, R Fleming, JMR Gill & 

DJ Freeman 


P681 Kisspeptin-54 stimulates the hypothalamicpituitary-gonadal 

axis in human males 

WS Dhillo, OB Chaudhri, M Patterson, 

EL Thompson, KG Murphy, MK Badman, 

BM McGowan, V Amber, S Patel, MA Ghatei & 

SR Bloom 

P682 Effect of chronic tadalafil administration on 

penile hypoxia induced by cavernous 

neurotomy in the rat 

L Vignozzi, A Morelli, S Filippi, S Donati, M Luconi, 

XH Zhang, S Ambrosini, GB Vannelli, V Mirone, 

G Forti & M Maggi 

P683 Neuromedin U (NMU) and neuromedin S 

(NMS) function as putative regulators of the 

gonadotropic axis in the rat 

E Vigo, J Roa, JM Castellano, R Fernandez- 

Fernandez, VM Navarro, R Pineda, E Aguilar, 

L Pinilla & M Tena-Sempere 

P684 Circadian changes in melatonin secretion and 

its relationship to gonadotropins in 

premenopausal women 

O Ianas, D Manda, R Calarasu, C Busu & 

D Campean 

P685 Serum levels of PSA do not change in healthy 

pre-menopausal and in menopausal women, 

but are increased in subjects with polycystic 

ovary syndrome (PCOS) 

A Burelli, E Rineladi, R Cionini, E Benelli, A Pinchera 

& E Pucci 

P686 Expressions of KISS1 and GPR54 are 

differentially regulated by estradiol and GnRH 

in adult female rat pituitary 

N Richard, G Galmiche, S Corvaisier & ML Kottler 

P687 Anti-Mullerian hormone (AMH) production by 

and AMH type II receptor (AMHRII) in normal 

human ovaries 

L Hanna, L Pellatt, S Rice, S Whitehead & H Mason 

P688 Identification and functional study of a new 

FSH receptor gene mutation in women 

affected by polycystic ovary syndrome (PCOS) 

E Ferrarini, FJ Orio, S Palomba, T Cascella, A 

Dimida, S di Biase, D Labella, P Agretti, G de 

Marco, E Gianetti, P Vitti, A Colao, G Lombardi, E 

Pucci, A Pinchera & M Tonacchera 

P689 Plasma kisspeptin is a novel tumour marker in 

patients with gestational trophoblastic 

neoplasia 

WS Dhillo, P Savage, KG Murphy, OB Chaudhri, 

M Patterson, VM Foggo, GS Dancey, H Mitchell, 

MJ Seckl, MA Gahtei & SR Bloom 

P690 Chronic subcutaneous administration of 

kisspeptin-54 causes testicular degeneration in 

adult male rats 

EL Thompson, KG Murphy, M Patterson, GA Bewick, 

PH Jethwa, GWH Stamp, JF Todd, MA Ghatei & 

SR Bloom 


POSTERS

POSTERS 

58 


P691 Oxidative stress, endothelial function, and 

arterial stiffness in young patients with 

polycystic ovary syndrome 

E Benelli, L Ghiadoni, D Giannini, E Rinaldi, 

Y Plantinga, C Taurino, A Burelli, GP Bernini, 

A Pinchera & E Pucci 

P692 Aldosterone and renin plasma levels in young 

patients with polycystic ovary syndrome 

GP Bernini, S Bela, R Cionini, M Bardini, A Moretti, 

E Benelli, E Rinaldi, A Burelli, P Vitti & E Pucci 

P693 Association between polymorphisms within 

the SUR1/Kir6.2 gene region and polycystic 

ovary syndrome: a case-control study 

TM Barber, E Zeggini, MJ Goh, L Webber, JAH Wass, 

S Franks & MI McCarthy 

P694 Effect of family history of type 2 diabetes on 

metabolic status of women with polycystic 


A Vryonidou, I-A Vatalas, V Loi, T Terzi, 

A Dionyssiou-Asteriou & C Phenekos 

P695 A review of cimetidine (tagamet) effects as a 

reproductive toxicant in male rat prostate and 

seminal vesicle 

E Eilati 

P696 A review of male rat genital system 

morphology following cimetidine (tagamet) 

injection 

E Eilati 

P697 A review of cimetidine (tagamet) as a 

reproductive toxicant in male rat Leydig cells 

E Eilati 

P698 Functional restoration of intact rabbit ovary 

after cryopreservation and transplantation 

C Chen, S Chen & G Wu 

P699 Effects of metformin therapy in lean subjects 

with PCOS on insulin resistance indices 

Y Altuntas, O Basat, S Ucak, S Seber, N Eren, 

CY Ersoy & K Arslan 

P700 Comparison of various insulin sensivity indices 

in idiopathic hirsutism 

S Ucak, O Basat, S Seber, E Satir & CY Ersoy 

P701 Metformin therapy decreases 

hyperandrogenism and hyperinsulinaemia in 


TME Abdalla, D Wilton, A Wilton, A Wayte, 

K Griffiths & J Huber 

P702 A unique subgroup of patients with polycystic 

ovary syndrome identified by clinical and 

biochemical features 

TME Abdalla, A Wilton, D Wilton, K Griffiths, 

A Wayte & J Huber 

P703 Obstetric hazards of maternal obesity 

S Paiva, L Ruas, M Campos, M Melo, J Guimarães, 

A Lobo, E Sobral, E Marta, A Cravo & M Carvalheiro 

P704 Cardiopulmonary impairment in young 


F Orio, F Giallauria, S Palomba, T Cascella, 

A De Lorenzo, R Lucci, F Manguso, L Vuolo, 

T Russo, G Lombardi, A Colao & C Vigorito 

P705 Metformin decreases CRP level and 

cardiovascular risk in PCOS women 

Z Velija-Asimi 

P706 Functional characterization of the folliclestimulating 

hormone receptor core promoter: 

applying a comparative approach among 

primates 

M Brune, E Kostova, E Nieschlag & J Gromoll 

P707 Testosterone restores diabetes-induced erectile 

dysfunction and sildenafil responsiveness in 

two distinct animal models of chemical 

diabetes 

S Filippi, A Morelli, L Vignozzi, XH Zhang, M Luconi, 

S Donati, G Forti & M Maggi 

P708 Androgenic status is influenced by AR 

polymorphism (CAG repeats number) 

D Canale, C Caglieresi, C Moschini, E Macchia & 

E Martino 

P709 Role of D327N sex-hormone binding globulin 

gene polymorphism in the pathogenesis of 

polycystic ovary syndrome 

J Vrbikova, J Zavadilova, M Vankova, D Vejrazkova, 

P Lukasova, J Vcelak, K Dvorakova, K Vondra & 

B Bendlova 

P710 Endocrine evaluation of a large cohort of male 

cancer survivors compared with healthy 

controls 

DM Greenfield, RE Coleman, BW Hancock, 

HA Davies, J Snowden & RJ Ross 

P711 The use of prolonged human chorionic 

gonadotrophin stimulation testing in the 

evaluation of cryptorchidism 

JR Dixon, S Murthy, E McNeil, M Wallace, S O'Toole 

& SF Ahmed 

P712 Stage-specific mRNA expression of androgen 

receptor correlated with FSH receptor in 

individual pre-antral follicles isolated from 

human ovary 

S Rice, K Ojha, S Whitehead & H Mason 

P713 Hyperprolactinaemia due to big prolactin 

JA Ahlquist, AR Ellis & MN Fahie-Wilson 

P714 Efficacy of testogel in the treatment of 

hypogonadism in routine clinical practice 

TH Jones, LR Chilukuri & A Munir 

P715 Which clinical features of polycystic ovary 

syndrome are improved with metformin 

therapy? A retrospective study 

MA Elrishi, MJ Levy & TA Howlett 

www.ece2006.com

P716 Comparison of insulin resistance levels in preand 

post-menopausal women, women with 

polycystic ovarian syndrome and 

postmenopausal women with type 2 diabetes 

LW Cho, V Jayagopal, ES Kilpatrick, P Jennings & 

SL Atkin 

P717 11β-Hydroxysteroid dehydrogenase (11βHSD) 

activities in porcine granulosa cells from 

ovarian follicles and cysts 

N Sunak, V Sharp, LR Abeydeera, LM Thurston & 

AE Michael 

P718 Secretion of adiponectin by human placenta: 

differential modulation by cytokines 

M Vatish, J Chen, E Karteris, S Zervou, JE Digby, 

EW Hillhouse & HS Randeva 

P719 Functionality of largest follicles is affected in 

gonadotrophin-stimulated cycles 

A Veiga-Lopez, MJ Cocero, V Dominguez, 

CJH Souza, RM Garcia-Garcia, C Ariznavarreta, 

JAF Tresguerres, AS McNeilly & A Gonzalez-Bulnes 

P720 Screening for gene SRY by FISH in patients 

with Turner syndrome 

J Guimarães, T Almeida Santos, A Barbosa, 

M Bastos, A Almeida Santos & M Carvalheiro 

P721 Serum anti-Mullerian hormone (AMH) 

concentrations in infants and children 

G Wilson, R Fleming, P Galloway, AM Wallace & 

SF Ahmed 

P722 Prenatal diagnosis of P450 oxidoreductase 

deficiency 

HE Ivison, BA Hughes, EM Blair, A Haskins Olney, 

CHL Shackleton & W Arlt 

P723 Isolated progesterone secretion by an ovarian 

Leydig cell tumour: I, hormonal and 

immunohistochemical characterization; II, 

effects on the gonadotrope axis 

H Bry, G Meduri, F Abirached, E Constancis, 

S Brailly, P Chanson & J Young 

P724 Serum inhibin levels in patients with polycystic 


M Lankarani & N Valizadeh 

P725 Outcomes of pregnancy and glycaemic 

control in patients with type 1 diabetes 

N Asatiani, R Kurashvili, M Dundua, E Shelestova, 

K Pagava, M Hod, S Smirnov & V Vlasov 

P726 Characteristic changes of skin and its 

accessories in relation to diabetic peripheral 

neuropathy in patients with type 2 diabetes 

mellitus 

LR Nikoleishvili, RB Kurashvili & NG Khachapuridze 

Steroids 

P727 High risk of adrenal insufficiency after single 

intra- or peri-articular steroid administration in 

young healthy sportsmen 

M Duclos, M Guinot, M Colsy, F Merle, JB Corcuff & 

Y Le Bouc 


P728 Capillary blood, an alternative to saliva for the 

diagnosis of Cushing's syndrome? 

N Belaidi, S Mimouni, C Ourioux, B Gatta & 

JB Corcuff 

P729 Gonadal dysfunction in male hypercortisolic 

subjects 

F Chentli, H Boudina, K Gati, S Azzoug & 

N Meziani 

P730 A ras recruitment screen for glucocorticoid 

receptor-interacting proteins using the entire 

receptor as bait 

K Ecker, F Wolf, S Geley & A Helmberg 

P731 Hormones of cortex of adrenal glands in 

patients after cardiac arrest in early post 

resuscitation period 

A Samborska-Sablik, Z Sablik, W Gaszynski, 

JH Goch & K Kula 

P732 Clinical presentation of a patient with novel 

mutation in CYP17 gene 

LK Dzeranova, AN Tiulpakov, EA Pigarova, 

AV Voroncov & AM Artemova 

P733 Hypothalamic-pituitary-adrenal axis in 

diabetes: role of autonomic imbalance 

I Chiodini, V Morelli, S Di Lembo, P Epaminonda, 

F Coletti, B Masserini, A Scillitani, M Arosio & 

G Adda 

P734 Establishing circadian rhythm profiles for 

salivary testosterone in women: evidence of 

decline during ageing 

EAS Al-Dujaili & MA Sharp 

P735 Prevalence of classical forms of 21-hydroxylase 

deficiency in western Siberia according to the 

results of neonatal screening of congenital 

adrenal hyperplasia 

LA Suplotova, EB Hramova, OB Makarova, 

NU Yuzakova & TV Barcova 

P736 The New Zealand white albino rabbit is a 

suitable model for the evaluation of 11betahydroxysteroid 

dehydrogenase type 1 activity 

in ocular tissues 

CU Onyimba, P Khosla, SV Hughes, PI Murray, 

PM Stewart, EA Walker & S Rauz 

P737 Androgen status in women with 

hypogonadotropic hypogonadism 

IA Ilovayskaya, VU Zektser, NV Latkina, 

NP Goncharov, EI Marova & GA Melnichenko 

P738 Long-term glucocorticoid repression of proopiomelanocortin 

(POMC) expression 

A Eltobgi, L Abbott & J Newell-Price 

P739 A novel CYP11B2 gene mutation in an Asian 

family with aldosterone synthase deficiency 

K Lovas, I McFarlane, CA Dorrian, J Schwabe, 

AM Wallace & VKK Chatterjee 


POSTERS

POSTERS 

60 


P740 Long-term effect of flutamide, metformin and 

their combination in dieting obese women 

with polycystic ovary syndrome 

A Gambineri, L Patton, A Vaccina, U Pagotto & 

R Pasquali 

P741 Can the 250mcg Synacthen test be used to 

screen for primary hyperaldosteronism? 

K Mullan, H Leslie, B Sheridan & AB Atkinson 

P742 The functional consequences of local 

glucocorticoid metabolism in synovial 

fibroblasts 

RSH Hardy, CDB Buckley, MH Hewison, LR Rabbitt 

& MSC Cooper 

P743 Challanges in paediatric Cushing's disease 

RM Fikri & P Winocour 

P744 Endogenous corticosteroid synthesis in 

subjects after bilateral adrenalectomy 

M Freel, R Fraser, M Ingram, E Davies, M Wallace & 

J Connell 

P745 Tissue specific regulation of insulin signalling: 

a mechanism of glucocorticoid induced 

obesity? 

LL Gathercole, IJ Bujalska, PM Stewart & 

JW Tomlinson 

P746 BXL-628, a vitamin D analogue, decreases 

RhoA/ROK signalling in rat and human 

bladder 

A Morelli, S Filippi, R Mancina, L Vignozzi, 

GB Vannelli, S Ambrosini, C Crescioli, S Donati, 

L Adorini & M Maggi 

P747 Evaluation of aldosterone to renin ratio in 

patients with adrenal incidentalomas and/or 

hypertension 

G Efremidis, D Vassiliadi, A Sabo, A Evaggelopoulos, 

E Botoula, M Tzanela & NC Thalassinos 

P748 Prenatal diagnosis of the 'low-oestriol' 

disorders Smith-Lemli-Opitz syndrome (SLOS), 

oxidoreductase deficiency (ORD) and sulfatase 

deficiency (STSD) 

CHL Shackleton, W Craig, W Arlt & J Marcos 

P749 Corticosteroid replacement therapy - the 

controversy continues... 

M Freel, A Thomson, M Devers, K Campbell, 

D Grant, M Wallace & J Connell 

P750 Dietary polyunsaturated fatty acid 

supplementation in vivo modulates ovine 

adrenal steroidogenesis in vitro 

EC Chin, JM Naddafy, Z Cheng, JS Brickell, 

DC Wathes & DRE Abayasekara 

P751 Human endothelial cells (HUVECs) potentiate 

aldosterone secretion from human 

adrenocortical cells through a PKAindependent 

pathway 

I Ansurudeen, AW Krug, S Kopprasch, 

M Ehrhart-Bornstein & SR Bornstein 

P752 Alterations in scavenger receptor B1 and 

steroidogenic enzymes within the adrenal 

gland in response to dietary bile acids 

AD McNeilly, DEW Livingstone, SM MacKenzie, 

E Davies, CJ Kenyon, BR Walker & R Andrew 

P753 Salivary cortisol as an alternative to serum 

cortisol in 1µg ACTH test 

K Simunkova, K Vondra, R Hampl, J Skibova, 

H Kazihnitkova, K Dvorakova, J Doucha & L Starka 

P754 Novel mutations in the ACTH receptor gene as 

a cause of familial glucocorticoid deficiency 

LF Chan, LA Metherell, H Krude, JC Carel, 

PV DeLamater, A Huebner & AJL Clark 

P755 Opposite effects of DHEA and DHEAS on 

chromaffin cell proliferation 

F Sicard, AW Krug, CG Ziegler, S Sperber, 

M Ehrhart-Bornstein & SR Bornstein 

P756 The glucocorticoid receptor 1A promoter in 

CD4+CD8+ thymocytes is rapidly upregulated 

following dexamethasone treatment in vitro 

J Nixon, J Sheridan, C Blackburn & K Chapman 

P757 11beta-hydroxysteroid dehydrogenase is an 

early and essential marker of human 

adipogenesis 

IJ Bujalska, LL Gatherocole, JW Tomlinson, 

C Darimont & PM Stewart 

P758 Mechanisms of human prolactin regulation by 

oestrogen 

AD Adamson, S Friedrichsen, S Semprini, M Wilding, 

CV Harper, MRH White & JRE Davis 

P759 Dimerisation of the melanocortin-2 receptor 

accessory protein (MRAP) 

MI Almiro do Vale, M Egertová, MR Elphick & 

AJ Clark 

P760 Expression of oestrogen receptor related 

protein beta occurs in multiple cell types 

within human endometrium during the 

normal menstrual cycle 

V Bombail, T Henderson, HOD Critchley & 

PTK Saunders 

P761 Rapid glucocorticoid effects on insulin 

sensitivity 

BZ Beleslin, J Ciric, M Stojkovic, S Savic, Z Penezic, 

B Trbojevic & M Zarkovic 

P762 Differential regulation of Cyp4A isoforms in 

mouse kidney during the development of 

mineralocorticoid, salt-sensitive induced 

hypertension 

E Marshall, D Roy, J Mullins, C Kenyon & R Brown 

P763 Glucocorticoid receptors exert a profound 

anti-proliferative and anti-survival effect on 

human small cell lung cancer cells 

P Le Rouzic, H Gillingham, A Berry, M Kayahara, 

T Huynh, P Sommer, A White & DW Ray 

www.ece2006.com

P764 Quantitative analysis of mifepristone 

(RU38486) in plasma by HPLC triple 

quadrupole mass spectrometry 

NZM Homer, GR Small, LY Ooi, H Bollina, 

RM Reynolds, BR Walker & R Andrew 

P765 NaB affects the local regulation of vitamin D in 

colorectal cancer 

BW Ogunkolade, S Khalaf, BJ Boucher, D Davis, 

S Dorudi, PJ Jenkins & SA Bustin 

P766 Bone mineral density in patients with 

Cushing's disease. The impact of impaired 

glucose homeostasis 

M Toth, J Toke, L Futo, A Patocs, R Bertalan, 

P Gergics, I Varga, E Glaz & K Racz 

P767 Bone mineral density and its correlation with 

plasma cortisol concentrations in patients with 

inactive adrenal adenomas and in patients 

with subclinical and overt Cushing's syndrome 

L Futo, J Toke, A Patocs, P Gergics, R Bertalan, 

I Varga, M Sereg, E Glaz, K Racz & M Toth 

P768 Phenotypic variability in P450 oxidoreductase 

deficiency may be caused by differential 

effects of P450 oxidoreductase mutations on 

steroidogenesis 

V Dhir, HE Ivison, AJ Doherty, PM Stewart & W Arlt 

P769 Insulin-like factor 3: a new circulating marker 

for the polycystic ovary syndrome-type of 

ovarian dysfunction 

R Pasquali, L Patton, A Vaccina, R De Iasio, 

U Pagotto & A Gambineri 

P770 Transcriptional control of differential 

glucocorticoid receptor expression: 

determining tissue specific expression and 

protein isoforms 

JD Turner & CP Muller 

Thyroid 

P771 In healthy women increasing TSH 

concentrations within the normal range are 

associated with increasing cardiovascular risk 

DF Waterhouse, AM McLaughlin, F Sheehan & 

D O'Shea 

P772 A case of delayed diagnosis of pituitary 

resistance to thyroid hormone (PRTH) 

A Nyunt & SM Orme 

P773 Relationship between sodium iodine 

symporter and thyroid peroxidase expression 

and cytokines production by thyrocytes from 

patients with immune and non-immune 

thyroid disorders 

A Bossowski, B Czarnocka, A Stasiak-Barmuta, 

K Bardadin, M Urban, A Lyczkowska, J Czerwinska 

& J Dadan 


P774 The reference ranges of maternal thyroid 

hormones (thyrotropin and free thyroxine) at 

the second and third trimesters of pregnancy: 

impact of FT4 assays 

M d'Herbomez, G Forzy, R Sapin, D Houze de 

l'Aulnoit, S Lepers & P Caron 

P775 The effect of high calcium on activity of 

thyroid gland in rat 

F Ebrahimian & S Zahedi-Asl 

P776 Safety and efficacy of administering 0.2mg of 

recombinant human TSH for two consecutive 

days as an adjuvant to low-dose radioiodine 

therapy in out-patients with large non-toxic 

multinodular goitre 

M Giusti, C Cappi, B Santaniello, E Ceresola, 

C Augeri, C Lagasio & F Minuto 

P777 Clinical aspects and diagnostics of follicular 

thyroid tumours 

I Abesadze, I Martirosyan, EA Troshina & 

NV Mazurina 

P778 Prevalence of thyroid dysfunction in old 

residents in the province of Pavia, northern 

Italy 

F Magri, CA Galimberti, S Chytiris, L Chiovato & 

E Ferrari 

P779 Thyroid function in patients with atrial 

fibrillation 

TV Bystrova, EA Troshina, FM Abdulchabirova & 

LA Panchenkova 

P780 Hyperthyreosis treated with thyroid artery 

embolization 

GW Kaminski, A Jaroszuk, K Brzozowski, 

A Kowalczyk, P Zukowski, Z Podgajny, 

P Twarkowski & M Siekierzynski 

P781 Psychological wellbeing correlates with free T4 

but not free T3 levels in patients on 'adequate' 

thyroid hormone replacement 

P Saravanan, T Visser & CM Dayan 

P782 Correlation between endogenous thyroxine 

and A, G and M immunoglobulins in 

dysthyreosis 

A Laszlo, I Pascanu, C Gliga, A Schiopu & M Laszlo 

P783 Long-term results of decompression surgery in 

thyroid-associated ophthalmopathy 

M Jernfors, M Välimäki, A Pitkäranta, K Setälä & 

K Laitinen 

P784 Fixed dose radioactive iodine therapy for 

hyperthyroidism: the west of Ireland 

experience 

JH McDermott & J O'Donnell 

P785 Pathogenic mutations in gene RET in patients 

with medullary thyroid carcinoma found in 

Polish population 

Z Paszko, M Sromek, M Czetwertynska, 

D Czapczak, A Wisniewska, E Skasko, I Kozlowicz- 

Gudzinska, A Prokurat & M Chrupek 


POSTERS

POSTERS 

62 


P786 Epidemiology of endemic goiter in mountain 

region of Adjara Autonomy Republic (Georgia) 

N Sekhniashvili, R Kvanchakhadze, D Tsereteli, 

Z Sekhniashvili & L Baramidze 

P787 Epidemiologic analysis of thyroid fine needle 

aspiration biopsies over a period of 18 years 

(1987-2004) 

S Polyzos, M Kita, DG Goulis, A Benos, N Flaris, 

M Leontsini & A Avramides 

P788 Differentiated thyroid carcinoma - experiences 

from a centre in South India 

K Sudeep, N Thomas, M Seshadri, S Anjali, 

R Oommen & TV Paul 

P789 Ultrasound thyroid changes: Moscow 

population screening results 

EA Troshina, NV Mazurina, NV Galkina & 

IT Martirosyan 

P790 Quality of life, health status, symptoms and 

treatment satisfaction in subclinical 

hypothyroidism: a double-blind 12-week 

cross-over study of L-thyroxine versus placebo 

S Razvi, CV McMillan & JU Weaver 

P791 Loss of heterozygosity and genetic association 

analyses within 11q13.5-q14 chromosomal 

region in papillary thyroid carcinoma 

R Ramirez-Lorca, E Ferrero Herrero, ME Saez, 

M Labalde Martinez, LM Real, A Ruiz & M Hidalgo 

Pascual 

P792 Environmental and socio-economic risk factors 

of thyroid cancer in Olsztyn and the Warmia 

and Mazury region, Poland 

E Bandurska-Stankiewicz & E Aksamit-Bialoszewska 

P793 Reverse transcriptase (RT) inhibitors down 

regulate tumor growth, induce cell 

differentiation and re-establish iodine uptake 

in human thyroid anaplastic carcinoma in vitro 

and in vivo 

M Landriscina, A Fabiano, S Altamura, C Bagalà, 

A Piscazzi, N Maiorano, F Giorgino, C Barone & 

M Cignarelli 

P794 The effect of block and replacement regime 

following radioiodine therapy for 

thyrotoxicosis on thyroid function in the postradioiodine 

period 

B Vaidya & S Estcourt 

P795 Prevalence of amiodarone-induced thyroid 

disorders in iodine deficiency region 

SI Ismailov, NL Kayumova & N Abdusalamova 

P796 Correction of oxidative metabolism in 

myocardium by oligocrine during 

experimental thyrotoxicosis 

M Kvirikashvili, T Sanikidze & D Metreveli 

P797 The metabolic syndrome and the thyroid in 

euthyroidism 

A Roos, SJL Bakker, TP Links & BHR Wolffenbuttel 

P798 Thyroid disease prevalence and incidence in a 

Dutch population survey 

A Roos, TP Links, SJL Bakker & 

LTW de Jong-van den Berg 

P799 Increased lipid peroxidation in critically ill 

patients with low-T3 syndrome 

M Karbownik, A Kokoszko, M Jozefiak & A Lewinski 

P800 Asymmetric dimethyl arginine levels in thyroid 

dysfunctions 

E Arikan, CH Karadag & S Guldiken 

P801 Results of fine-needle aspiration biopsy of 

thyroid nodules in region of mild iodine 

deficiency 

D Metreveli & K Mikadze 

P802 Thyroid cancer: diagnostic role of ultrasound 

and ultrasound-guided fine needle aspiration 

biopsy (US-FNAB) evaluation 

V Triggiani, E Guastamacchia, F Resta, C Sabba & 

E Tafaro 

P803 Parathyroid hormone determination in fine 

needle aspirates (PTH-FNAB) allows the 

differentiation between thyroid and 

parathyroid lesions 

V Triggiani, E Guastamacchia, F Resta, C Sabba & 

E Tafaro 

P804 Heart rate variability in thyroidectomized 

patients using suppressive therapy with 

thyroxine 

AV Kovalchuk, ST Zubkova & VN Kovalchuk 

P805 Clinical value of the assessment of neopterin 

in Graves' ophthalmopathy 

A Baldys-Waligorska, B Kusnierz-Cabala, 

E Placzkiewicz-Jankowska & B Huszno 

P806 Maternal iodine deficiency alters learning 

ability and emotional state of the progeny 

A Sarishvili, N Lazrishvili & D Metreveli 

P807 Quantitative and qualitative evaluation of the 

impact of a ten-year iodine intervention 

programme in rural areas of Tehran 

N Salarkia, F Rabiee & F Azizi 

P808 Effect of oral administration of propylthiouracil 

during pregnancy and lactation period on 

isolated aorta response of their adult male 

offspring 

S Zahedi, M Khaksari, M Shafiee & A Gasemi 

P809 Study of the prevalence and mechanisms of 

action of TSH receptor and Gs protein alfasubunit 

mutations in toxic multinodular goiter 

and toxic adenoma in Galicia (Spain) 

F Palos, O Perez, V Alvarez-Iglesias, J Cameselle, 

F Barreiro, D Araujo, R Argueso, M Botana, 

JM Cabezas, L Dominguez, T Martinez, J Nuño, 

JC Rueda & J Lado-Abeal 

P810 The relationship between echocardiographic 

left atrial size and atrial fibrillation in patients 

with Graves' disease 

IA Vaychulis & II Shaposhnik 

www.ece2006.com

P811 ClC-5 does not affect megalin expression and 

function in the thyroid gland 

S Lisi, T Maritzen, R Botta, A Pinchera, C Marcocci, 

TJ Jentsch & M Marinò 

P812 RAP (LDL receptor-associated protein) 

expression in thyroid epithelial cells: evidence 

for TSH-dependence in vivo and in vitro 

R Botta, S Lisi, A Pinchera, C Segnani, L Cianferotti, 

MA Altea, F Menconi, L Mattii, GU Corsini, 

C Marcocci, A Dolfi, N Bernardini & M Marinò 

P813 Liver enzyme alterations during high dose 

intravenous glucocorticoid pulse therapy for 

Graves' ophthalmopathy: frequency and 

putative risk factors 

MA Altea, E Morabito, F Menconi, R Piccione, 

F Latrofa, B Mazzi, L Bartalena, A Pinchera, 

C Marcocci & M Marinò 

P814 High-intensity focused ultrasound (HIFU) 

treatment for thyroid nodules: first clinical 

study 

OE Esnault, BF Franc, FM Ménégaux, AR Rouxel, 

EDK Kerviller, PB Bourrier & LL Leenhardt 

P815 Digital infra-red orbital thermography in the 

assessment of thyroid eye disease 

SE Williams, AR Hill & BW Fleck 

P816 Prognostic factors for persistent or recurrent 

disease from a series of 81 patients with 

oncocytic thyroid carcinoma 

CD Cao, H Mirghani, JL Wemeau, E Leteurtre, 

M D'Herbomez, X Marchandise & C Proye 

P817 Association of CTLA-4 exon 1 polymorphism 

with Graves' disease in Spanish patients 

P Álvarez-Vázquez, D Valverde, L Constela, L Pérez 

Méndez & RV García-Mayor 

P818 Reference intervals of maternal free thyroxine 

(FT4) at the second and third trimesters of 

pregnancy using the Beckman Coulter's Access 

Free T4 assay 

V Jarrige, H Meurisse & M D'Herbomez 

P819 Bioavailability of iodine bound in humic 

substances in drinking water and the impact 

on thyroid function 

S Andersen, P Gustenhoff, F Iversen, S Terpling, 

KM Pedersen & P Laurberg 

P820 Application of positron emission tomography 

(PET) in the study of cerebral glucose uptake 

in hypothyroid rats: effect of T3 administration 

M De Servi, N Belcari, J Bernal, S Refetoff, 

P Salvadori, E Gianetti, G De Marco, M Tonacchera, 

P Vitti, A Del Guerra & A Pinchera 

P821 The development of a symptom-based clinical 

activity score for thyroid eye disease 

CE Elder, BW Fleck & S Rajack 

P822 A qualitative study of patients' experience of 

thyroid eye disease 

CE Elder & BW Fleck 


P823 Etiology of congenital hypothyroidism in 

children with a normal located thyroid gland 

C Di Cosmo, M Tonacchera, G De Marco, P Agretti, 

ME Banco, A Perri, H Ramos, C Ceccarelli, P Vitti & 

A Pinchera 

P824 Clinical characterisation and genetic analysis of 

a large euthyroid family with TSH-receptor 

germline mutation (N372T) and a 

hyperthyroid index patient with an additional 

somatic TSH-receptor mutation (S281N) on 

the second TSH-receptor allele 

HI Gozu, R Bircan, K Krohn, S Müller, D Yavuzer, 

G Ekinci, H Sargin, M Sargin, E Orbay, B Cirakoglu 

& R Paschke 

P825 Estimation of the optimal diagnostic complex 

of the treatment of the nodular euthyroid 

formations of thyroid 

V Chachibaia, B Gvadzabia, E Giorgadze & 

K Mirianashvili 

P826 The diagnostic value of Doppler 

ultrasonography in determining the 

malignancy potential of thyroid nodules 

F Sahin, M Varer, A Sarsilmaz, G Oruk, M Apaydin 

& E Uluc 

P827 Favourable outcome of Graves' 

ophthalmopathy (GO) after glucocorticoids 

(GC) in patients treated with total thyroid 

ablation (TTA): results of a randomized clinical 

trial 

FM Menconi, MM Marinò, LB Bartalena, RR Rocchi, 

MN Nardi, AP Pinchera & CM Marcocci 

P828 Lipids profile and carotid scan atherosclerotic 

parameters in newly diagnosed hypothyroid 

females 

VP Popovic-Radinovic, ZG Gluvic, MV Vujovic, 

JT Tica, ZR Rasic-Milutinovic, DM Milicevic, 

EI Isenovic & MP Pavicevic 

P829 Safety of pharmacological treatment of thyroid 

diseases during pregnancy 

E Gianetti, M Tonacchera, L Russo, A Perri, P Vitti & 

A Pinchera 

P830 Increase of L-thyroxine requirement during 

pregnancy 

L Russo, M Tonacchera, E Gianetti, A Perri, P Vitti & 

A Pinchera 

P831 Congenital thyroid hemiagenesis in associaton 

with multinodular goitre - a case report 

M Varer, A Sarsilmaz, G Oruk, H Akin, M Apaydin 

& E Uluc 

P832 Insulin-like growth factor-I counteracts 131I induced thyroid stunning by stimulating the 

transcription of the sodium/iodide symporter 

(NIS) 

M Nordén, C Johanson, S Tedelind, F Larsson, 

T Carlsson & M Nilsson 

P833 A case of Riedel's thyroiditis successfully 

treated with glucocorticoids 

G Viccica, T Rago, P Berti, A Pinchera & C Marcocci 


POSTERS

POSTERS 

64 


P834 An audit of radioiodine treatment for 

thyrotoxicosis in Cambridge 

H Andreou, S Kalavalapalli, M Gurnell, H Simpson, 

DF Wood, KK Balan & VKK Chatterjee 

P835 On-levothyroxine measurement of 

thyroglobulin is not a reliable screening test 

for patients at high risk of remnant/recurrent 

differentiated thyroid carcinoma 

A Gholamrezanezhad, M Saghari, S Mirpour & 

D Beiki 

P836 Prevalence of somatic TSHR and Gs alpha 

mutations in toxic thyroid nodules (TTNs) in 

endemic and non-endemic goiter areas of 

Turkey 

HI Gozu, R Bircan, K Krohn, S Müller, S Vural, 

C Gezen, H Sargin, M Sargin, B Çirakoglu & 

R Paschke 

P837 The role of autoimmunity and thyroid function 

on pregnancy outcomes in euthyroid women 

with autoimmune disease undergoing assisted 

reproduction 

R Negro, G Formoso, L Coppola, G Presicce, 

T Mangieri, A Pezzarossa & D Dazzi 

P838 Value of routine measurement of serum 

calcitonin concentrations in patients with 

nodular goiter: a multicenter study 

G Papi, SM Corsello, K Cioni, AM Pizzini, S Corrado, 

C Carapezzi, G Fadda, A Baldini, C Carani, 

A Pontecorvi & E Roti 

P839 Association between patient- and tumorrelated 

factors and the gene expression profile 

of papillary thyroid cancer 

S Szpak-Ulczok, M Wiench, 

M Oczko-Wojciechowska, J Wloch, K Fujarewicz, 

A Swierniak, D Lange & B Jarzab 

P840 Levothyroxine suppressive therapy in thyroid 

nodules 

S Azzoug, K Maachi & F Chentli 

P841 Levothyroxine suppressive therapy and body 

composition 

S Dubois-Ginouves, S Laboureau-Soares Barbosa, 

JF Dumas, P Abraham, A Sallé, F Illouz, P Rodien, 

P Ritz & V Rohmer 

P842 Differential regulation of soluble Fas in 

patients with autoimmune thyroid disease 

S Fountoulakis, N Kolaitis, G Philippou, 

G Vartholomatos & A Tsatsoulis 

P843 Application of new technology of anti-DNA 

antibodies detection in diagnostics of 

autoimmune thyroiditis 

G Vagapova, L Anchikova, O Konovalova, 

L Sattarova, E Podshivalina, V Vinter & M Salahov 

P844 Thyroxine replacement dose in patients with 

Hashimoto disease: a potential role for 

interleukin-6 

NP Papanas, DP Papazoglou, KP Papatheodorou, 

LP Papazoglou, TE Exiara, MB Bitsakaki, SK Kotsiou 

& EM Maltezos 

P845 The glutathione peroxidase 3 promoter is 

activated by Pax8 

B Mentrup, N Renault, C Schmutzler & J Köhrle 

P846 Similarities in the role of FoxE1 in thyrocytes 

and keratinocytes? 

M Bullock, M Jehani, P Bowden & M Ludgate 

P847 Inhibin B/inhibin binding protein complex is 

differentially expressed in normal and nodular 

human thyroid tissue 

M Della Guardia, A Franchi, S Nardo, 

MG Santaguida, R Sibilla & M Centanni 

P848 Towards the development of a valid quality of 

life questionnaire for patients with thyroid 

diseases: which questions shall we ask? 

T Watt, M Groenvold, AK Rasmussen, SJ Bonnema, 

L Hegedüs, JB Bjorner & U Feldt-Rasmussen 

P849 The efficacy of levothyroxine therapy in the 

nontoxic multinodular goiter 

AM Mihai, AE Ranetti, C Spiroiu, A Mazilu & 

C Ranetti 

P850 Association of the FCRL3 gene with Graves' 

disease in the UK Caucasian population 

MJ Simmonds, JM Heward, J Carr-Smith, JA 

Franklyn & SCL Gough 

P851 Treatment options in progressive medullary, 

follicular, and papillary thyroid carcinomas: 

evaluation of chemotherapy with doxorubicin 

A Matuszczyk, A Bockisch, P Veit, K Mann & 

S Petersenn 

P852 Staging of progressive papillary, follicular, or 

medullary thyroid carcinomas: comparison of 

various staging procedures to define the 

extent and progress of disease 

A Matuszczyk, S Petersenn, A Bockisch, S Sheu, 

P Veit & K Mann 

P853 The effect of obesity and weight loss on 

thyroid hormone status 

L Keskin, I Sahin, R Bentli, S Senel & C Taskapan 

P854 The research of IQ level in school children 

who live in the regions with iodine deficiency 

SL Slovjeva, A Troshina & AO Zhukov 

P855 Unmasking of central hypothyroidism 

following growth hormone replacement in 

adult hypopituitary patients 

A Agha, D Walker, WM Drake, SL Chew, 

AB Grossman, PJ Jenkins & JP Monson 

P856 Somatostatin receptor scintigraphy with 

99mTc-HYNIC-TATE in visualization of nonradioiodine-avid 

differentiated thyroid 

carcinoma 

Z Podgajny, G Kaminski, N Szalus, A Kowalczyk, 

J Pietrzykowski, A Jaroszuk & M Siekierzynski 

P857 A novel test with recombinant human TSH for 

the differential diagnosis of congenital 

hypothyroidism in pediatric age 

L Fugazzola, G Weber, D Mannavola, G Vannucchi, 

M Carletto, V Longari, L Persani & P Beck-Peccoz 

www.ece2006.com

P858 The use of recombinant human thyrotropin 

(rhTSH) in amiodarone-induced 

hyperthyroidism 

Z Adamczewski, J Makarewicz, M Knapska- 

Kucharska, L Oszukowska, A Karwowska & 

A Lewinski 

P859 Thyrotropin receptor (TSHR) activation has 

variable effects on the TNF alpha axis in 

preadipocytes and osteoblast-like cell lines 

M Mandrikoula, M Henry, BAJ Evans & M Ludgate 

P860 Follicular and Hürthle thyroid nodule at 

cytology: diagnostic value of nuclear atypia 

cell neoplasia 

T Rago, G Di Coscio, F Basolo, M Scutari, P Berti, 

R Romani, P Faviana, P Miccoli, A Pinchera & P Vitti 

P861 The use of Konjac glucomannan to lower 

serum thyroid hormones in hyperthyroidism 

T Bayraktaroglu, F Kutluturk, A Azezli, Y Orhan & 

S Tanyolac 

P862 Comparison of the effects of thyrotropin 

receptor (TSHR) activation on preadipocyte 

cell lines from white (WAT) and brown (BAT) 

adipose tissue 

L Zhang, C Paddon, GC Baker & M Ludgate 

P863 Effects of increment of endogenous TSH levels 

on the effective half-life time of 131I and iodine 

uptake by thyroid remnants in patients after 

thyroidectomy 

M Knapska-Kucharska, J Makarewicz, 

L Oszukowska, Z Adamczewski & A Lewinski 

P864 Surgery should be considered equally with 131I and thionamide treatment as first line therapy 

for thyrotoxicosis 

T Sathyapalan, SL Atkin & RJA England 

P865 Thyrotoxicosis - a risk factor for subsequent 

development of osteoporosis? 

T Zimmermann-Belsing, B Langdahl, P Charles & 


P866 Relationship between cardiac arrhythmias and 

subclinical hyperthyroidism 

P De Remigis, L Vianale, A De Remigis, P Sabatini & 

E Di Girolamo 

P867 Cardiovascular disease in patients with and 

without hypothyroidism 

C Neves, JL Medina & F Lopes 

P868 Clinical parameters and echographic patterns 

are poor predictors of malignancy in follicular 

and Hürthle cell nodules at cytology 

T Rago, G Di Coscio, F Basolo, M Scutari, P Berti, 

R Romani, P Faviana, P Miccoli, A Pinchera & P Vitti 

P869 Identification of housekeeping genes useful for 

the normalization of RNA in studies of gene 

expression in thyroid carcinomas 

P Piampiani, C Romei, B Cosci, A Vivaldi, R Ciampi, 

A Pinchera & R Elisei 


P870 Identification of a novel germ-line point 

mutation of the RET gene (Met848Thr) in a 

patient affected by medullary thyroid 

carcinoma and Castleman's syndrome 

B Cosci, M Altea, M Castagna, C Romei, 

P Piampiani, A Vivaldi, R Ciampi, P Faviana, 

F Basolo, A Pinchera & R Elisei 

P871 Usefulness of molecular analysis of BRAF 

mutation and RET/PTC rearrangements in fine 

needle aspiration (FNA) of thyroid nodules 

with non-diagnostic cytology 

C Romei, T Rago, M Scutari, V Bottici, G Di Coscio, 

F Basolo, P Berti, A Pinchera, P Vitti & R Elisei 

P872 Does selenium deficit trigger post partum 

thyroiditis? 

HG Bohnet 

P873 17-AAG and DIDS increase the iodide 

retention time in thyroid cancer cells 

transfected with NIS 

A Vivaldi, R Ciampi, F Santini, B Cosci, P Piampiani, 

C Romei, A Pinchera & R Elisei 

P874 Demethylating treatment with azacytidine 

induces retinoic acid receptor RAR beta 

expression in human thyroid cancer cells 

FY Miasaki, A Vivaldi, R Ciampi, L Agate, B Cosci, 

P Piampiani, C Romei, A Pinchera & R Elisei 

P875 Free thyroxine (FT4) is the analyte of choice in 

early gestation 

B Dando, R Taylor, R Henley, AB Parkes, R John & 

JH Lazarus 

P876 Comparison of TPOAb assays in early 

pregnancy 

R Henley, AB Parkes, L Taylor, R John & JH Lazarus 

P877 Age and gender differences and phenotypes 

of patients with autoimmune thyroid disease - 

the UK AITD consortium 

JD Carr-Smith, N Manji, K Boelaert, A Allahabadia, 

M Armitage, J Lazarus, S Pearce, B Viadja, 

SC Gough & JA Franklyn 

P878 Influence of family history on the age of 

presentation of AITD - the UK AITD 

consortium 

N Manji, JD Carr-Smith, K Boelaert, A Allahabadia, 

M Armitage, J Lazarus, S Pearce, B Viadja, 

SC Gough & JA Franklyn 

P879 Prevalence of thyroid dysfunction and other 

autoimmune disorders within the families of 

subjects with autoimmune thyroid disease - 

the UK AITD consortium 

N Manji, JD Carr-Smith, MJ Simmonds, 

A Allahabadia, M Armitage, J Lazarus, S Pearce, 

B Viadja, JA Franklyn & SC Gough 

P880 Do SNPs within the PTPN22 gene contribute 

to autoimmune disease via different 

mechanisms? 

J Heward, M Simmonds, JA Franklyn & SC Gough 


POSTERS

POSTERS 

66 


P881 Screening of autoimmune thyroid disorders in 

pregnancy in a highland district 

J Horacek, S Spitalnikova, J Cepkova, V Ceeova, 

J Dolezal, J Vizda & J Maly 

P882 Gene expression profile in functioning and 

non-functioning nodules of autonomous 

multinodular goiters from an area of iodine 

deficiency 

P Agretti, G de Marco, M de Servi, E Gianetti, 

F Basolo, A Pinchera, P Vitti & M Tonacchera 

P883 Comparison of efficiency of iodine-prophylaxis 

in healthy pregnant women and pregnant 

women with non-toxic goiter, living in a 

region with mild iodine-deficiency 

TPS Shestakova, AVD Dreval & OAN Nechaeva 

P884 Gene expression profile in orbital fibroblasts 

from a TAO patient before and after 

adipocytic differentiation 

P Agretti, G de Marco, E Ferrarini, A Dimida, 

D Sansone, M Banco, M de Servi, S Lisi, C Marcocci, 

M Marinò, P Vitti, A Pinchera & M Tonacchera 

P885 Is subclinical hyperthyroidism associated with 

blood pressure and hypertension? 

H Völzke, M Dörr & H Wallaschofski 

P886 Thyrotoxicosis in childhood. UK and Ireland 

Surveillance Study 2004-2005 

SM Williamson & SA Greene 

P887 PKA II mediates cAMP-dependent 

phosphorylation of CREB and activation of 

gene transcription in differentiated rat thyroid 

cells 

D Calebiro, T de Filippis, S Lucchi, P Porrazzi, 

P Beck-Peccoz & L Persani 

P888 Transcriptomic analysis of the oncocytic signal 

in vesicular thyroid tumours 

JF Fontaine, F Savagner, M Melo, B Ballester, 

R Houlgatte & Y Malthièry 

P889 Application of MRI in the differential diagnosis 

of different forms of Hashimoto's thyroiditis in 

patients from the iodine deficient region 

G Vagapova & I Mikhailov 

P890 Immunohistochemical staining for thyroid 

peroxidase (TPO) of TRU-CUT biopsies from 

scintigraphically cold thyroid nodules 

U Yousaf, L Christensen, AK Rasmussen, F Jensen, 

E Hilmer, C Mollerup, J Kirkegaard, I Lausen & 


P891 Regulation of fibroblast growth factor 

receptor-1 (FGFR1) by thyroid hormone (T3): 

identification of a thyroid hormone response 

element (TRE) in the murine Fgfr1 promoter 

PJ O'Shea, GR Williams & SY Cheng 

P892 Subclinical hypothyroidism - how soon to 

treat? 

S Ghita, M Musat, M Simescu, E Balmes, H Ursu, 

C Badiu & G Totoianu 

P893 Cytostatic effect of plitidepsin (aplidintm) in 

human undifferentiated (anaplastic) thyroid 

carcinoma 

S Bravo, M Garcia-Renduelles, R Seoane, V Dosil, 

J Cameselle, L Lopez-Lázaro, J Zalvide, F Barreiro, 

C Pombo & C Alvarez 

P894 A case of severe thyrotoxic hypercalcaemia 

VKB Prabhakar & PJ Hale 

P895 Efficacy of high dose radioiodine in the 

treatment of elevated serum thyroglobulin in 

patients with differentiated thyroid carcinoma 

and negative whole body iodine scan 

A Gholamrezanezhad, M Saghari, S Mirpour, 

D Beiki & B Fallahi 

P896 Isometric tension studies in a transgenic 

mouse model of thyroid hormone resistance 

PJD Owen, D Tomlinson, H Ying, D Lang, SY Cheng 

& JH Lazarus 

P897 The GH response to ghrelin in humans is 

reduced in conditions of hyper- and 


F Broglio, F Prodam, F Riganti, E Gramaglia, 

R Rossetto, M Maccario & E Ghigo 

P898 Multicenter evaluation of the Abbott Architect 

anti-Tg and anti-TPO assays 

R Anarat, C Bena, H Garth, M Klein, A Radicioni, 

S Schmitt, C Smith, S Szepanski, M Turanchik & 

J Waterston 

P899 Autoantibody profile in patients with Graves' 

disease and thyroid-associated 


NV Latkina, IA Ilovayskaya & IV Kryukova 

P900 Treatment of disseminated non-radioiodine- 

AVID papillary thyroid cancer with 90Y-DOTA- 

TATE preparation 

N Szalus, G Kaminski, K Obuchowski, 

J Pietrzykowski, Z Podgajny, M Zagrodzka & 

E Dziuk 

P901 Hashimoto's thyroiditis in the children. Clinical 

features at presentation 

VT Skarpa, ED Kostakioti, AK Tertipi, PA Petrou, 

E Posnaghidou, M Anastasakou, P Papahilleos, 

A Papathanasiou & C Hadjiathanasiou 

P902 Corticotherapy alone or corticotherapy 

combined with orbital radiotherapy in severe 

active Graves' ophthalmopathy: therapeutic 

outcome in 905 patients 

H Jastrzebska, M Gietka-Czernel, J Janik, 

S Zgliczynski, R Karczmarzyk & J Fijuth 

P903 The effects of treatment with L-thyroxine on 

level of prolactin, CRP and insulin in 

premenopausal women with subclinical 


Z Velija-Asimi & B Heljic 

www.ece2006.com

P904 Modifications in the frequency of presentation 

and the TNM stage at diagnosis of thyroid 

carcinoma in the last decade in Valencia 

(Spain) 

J Yanini, R Casañ, K García, A Jover, M Gómez, 

E Solá, C Morillas, H Peña, ML Muñoz & 

A Hernández 

P905 Pretreatment with rhTSH allows effective 131I therapy in patients with multinodular toxic 

goiter and low radioiodine uptake 

M Gietka-Czernel, H Jastrzebska, W Zgliczynski, 

G Wasniewska, M Wróblewska, K Wernic, 

B Cybulska & E Karpińska 

P906 Repression of the human NIS upstream 

enhancer (hNUE) by PTTG 

VE Smith, K Boelaert, AL Stratford, SR James, 

R Susarla, T Kogai, MC Eggo, JA Franklyn & 

CJ McCabe 

P907 Comparison of cytogenetic damage in 

patients with differentiated thyroid cancer 

receiving ablative 131I therapy in the 

hypothyroid status versus the euthyroid status 

(rhTSH assisted treatment) 

A Frigo, G Francia, MV Davi, G Boni, C Traino, 

L Scilanga, F Bernardi, G Mariani, A Vaiano, 

C Colato, V lo Cascio & M Ferdeghini 

P908 Correction of hypomagnesaemia improves the 

symptoms of hypocalcaemia after 

thyroidectomy 

MFA Abdelhamid, MS Barsoum, SA Shaheen & 

LA Mansour 

P909 The thyroid gland and its selenoenzymes are 

preferentially supplied in selenium-deficient 

transgenic mice 

L Schomburg, C Riese, M Michaelis, E Griebert, 

MO Klein, R Sapin, U Schweizer & J Koehrle 

P910 Changes in thyroxine requirement in the longterm 

follow-up of hypothyroid patients 

AK Viswanath, A Avenell, S Philip, S Acharya, 

G MacLennan, K Dalziel, SA Copland, JS Bevan & 

P Abraham 

P911 Problems of identifying independent non-class 

II susceptibility loci within the HLA region for 

Graves' disease 

MJ Simmonds, JM Heward, JA Franklyn & 

SCL Gough 

P912 Is 131I therapy for hyperthyroidism harmful for 

testis function? 

C Ceccarelli, D Canale, E Fiore, C Moschini, 

C Caglieresi, P Vitti & A Pinchera 

P913 What is the most effective screening interval in 

the long-term follow-up of stable hypothyroid 

patients on thyroxine? 

AK Viswanath, A Avenell, S Philip, S Acharya, 

G MacLennan, K Dalziel, O Pereira, SA Copland, 

JS Bevan & P Abraham 


P914 Expression and signal transduction of the 

cAMP-binding protein Epac in thyroid cells 

and thyroid tumors 

M Broecker-Preuss, S-Y Sheu, J Baten, M Bollepalli, 

M Schmidt, KW Schmid & K Mann 

P915 Orbital tissue expansion expressed as a 

number: usefulness in grading the severity of 

thyroid-associated ophthalmopathy (TAO) 

GM Vannucchi, I Campi, S Avignone, AM Minetti, 

C Guastella, F Sbrozzi, P Beck-Peccoz & M Salvi 

P916 Radioiodine treatment for hyperthyroidism - 

do Royal College guidelines suggest too high 

a radioiodine dose? 

R Zakir Ahmed & J P Hosker 

P917 Thyroid cancer management: are guidelines 

being met? 

HS Chahal, S Velmurugan, SA Mellish, R Lewis, 

KA Metcalfe & JA Ahlquist 

P918 Treatment of patients with Graves' disease and 

ophthalmopathy with the anti-CD20 

monoclonal antibody rituximab 

M Salvi, GM Vannucchi, I Campi, C Guastella, 

F Sbrozzi, S Simonetta, S Rossi, P Bonara, 

S Avignone & R Ratiglia 

P919 Withdrawal of alfacalcidol supplements 

following thyroidectomy: baseline plasma PTH 

predicts successful outcome 

M Morris & P Perros 

P920 Treatment of pretibial myxedema with 

dexamethasone injected subcutaneously by 

mesotherapy needles 

I Campi, GM Vannucchi, L Forzenigo, P Beck-Peccoz 

& M Salvi 

P921 Radioiodine uptake test reduces duration of 

restrictions following radioiodine therapy for 

management of hyperthyroidism 

VN Cherukuri, M Edavalath, N Iqbal, SL Ryan, 

BM Singh & HN Buch 

P922 The distance between histotypes of 

differentiated thyroid cancer: gene expression 

profiling study 

B Jarzab, J Wloch, D Lange, M Oczko- 

Wojciechowska, E Chmielik, A Czarniecka, 

M Kowalska, K Fujarewicz, K Simek, G Gala & 

A Swierniak 

P923 The risk of hypercholesterolemia in patients 

with subclinical hypothyroidism 

L Marina, Z Penezic, S Vujovic, M Stojanovic, 

M Ivovic & M Drezgic 

P924 Audit of management of hypothyroidism in a 

joint endocrine/antenatal clinic 

N Batra, E Ferriman & PE Belchetz 

P925 Thyrotoxicosis is coupled with quantitative 

and qualitative sleep disruptions 

F Riganti, F Prodam, E Gramaglia, E van Cauter, 

E Ghigo & F Broglio 


POSTERS

POSTERS 

68 


P926 The Gods placed the diagnosis before the 

therapy: case reports of the Slovak families 

with resistance to thyroid hormones 

P Vanuga, E Mendelova, G Fodor, K Vitesnik, 

F Savagner, Y Malthiery & M Pura 

P927 Epidemiology of thyroid cancer in Republic of 

Sakha during 1970-2001 

A Makarov, E Makarova, V Argunov & F Ivanova 

P928 Rate of decrease in anti-thyroid antibody levels 

after therapeutic intervention in patients with 

thyroid cancer 

D Thomas, I Kostoglou-Athanassiou, E Vassiliou, 

V Liakos, N Mytakidis, F Chatzimarkou, 

P Athanassiou & P Kaldrymidis 

P929 Futher results of treatment and outcomes in 

patients with subacute thyroiditis observed in 

the period from 1993 to 2005 

EV Petrova, NM Platonova, LA Kabelnitskaya & 

EA Troshina 

P930 Cowden syndrome - a clinical entity to be 

aware of 

O Schmiedel, K Becker & JK Platts 

P931 Fine-needle aspiration biopsy of thyroid 

nodules 

S Radenkovic, M Pes˘ic, R Kocic, D Dimic, 

D Mikic & M Velojic Golubovic 

P932 Palpation versus ultrasonography-guided fineneedle 

aspiration biopsy of thyroid nodules in 

endemic goiter area 

BK Koroglu, N Tamer, M Koroglu, NE Gulcelik & 

O Aksu 

P933 Thyroid storm induced cardiomyopathy is 

reversible 

NM Neary, AEC Fountain, ECI Hatfield, KF Fox & 

K Meeran 

P934 Medullary thyroid carcinoma - which test is 

the best? 

D Ciobanu, C Vulpoi, B Galusca, L Andriescu, 

A Grigorovici, C Cristea, V Mogos, MS Mihailovici & 

E Zbranca 

P935 Glutamic acid decarboxylase (GAD) and antityrosine 

phosphatase (IA2) antibody positivity 

in newly-diagnosed Graves' disease patients 

A Harmanci, M Bayraktar, G Hascelik & A Gurlek 

P936 Hyperthyroidism presenting as ventricular 

fibrillation 

LR Chilukuri, Z Merza & TH Jones 

P937 Heart rate dynamics in hyperthyroidism 

J-L Chen, Y-J Tseng & W-C Chu 

P938 Impact of TNM classification categories on 

thyroid gland carcinoma 

P Sykorova, P Vlcek, L Jirsa & K Personova 

P939 Antiproliferative effects of SOM230 on orbital 

fibroblasts from active Graves' 


D Pasquali, V Rossi, G Bellastella, D Esposito, 

MC Quinto, A Bellastella & AA Sinisi 

P940 Further results of treatment and outcomes in 

patients with subacute thyroiditis observed in 

the period from 1993 to 2005 

LA Kabelnitskaya, EB Petrova, N Platonova & 

EA Troshina 

P941 Age related changes of soluble Fas, Fas ligand 

and Bcl-2 in autoimmune thyroid diseases 

JK Mysliwiec, M Oklota, A Nikolajuk & M Gorska 

P942 Comparison of radioiodine with radioiodine 

plus lithium in the treatment of 

hyperthyroidism 

K Ahmed, GMK Nijher, A Banerjee, 

J Frank & K Meeran 

P943 Monitoring of goiter and urinary iodine 

excretion in 6- to10-year-old school children 

in Ahvaz (2003-2004) 

H Shahbazian & S Saiedinia 

P944 Prevalence of subclinical dysfunctions of 

thyroid gland in women older than 40 years 

S Glonti, L Jashi, G Tsetskhladze & T Rukhadze 

www.ece2006.com

Floor Plan – Hall 3 

Emergency 

Exit 

Vehicle Access 

Door 3.2 

F.P. 

Emergency 

Exit 


Door 3.1 

Exhibitors 

FH 

FH 

1 Pfizer Endocrine Care 

2 International Journal of 

Endocrinology and Metabolism 

3 European Society of 

Endocrinology 

4 S Karger Publishers 

5 LINCO Research 

6 Internet café 

KINDLY SUPPORTED BY ORGANON 

7 GlaxoSmithKline 

8 Novartis 

9-11 Novo Nordisk 

12-15 Ipsen Ltd 

F.P. 

F.P. 

29 

28 

27 

25 

36 

Seating Area 

42 39 

34 

41 

38 

35 

30 

40 

26 

24 

22 

23 

33 

32 

31 

21 19 

20 

REG DESK 

F.P. 

FH 

Exit / Entrance 

Catering 

18 

16 

17 

9 10 

15 12 1 

14 13 

16-17 Eli Lilly 

18 BioSource 

19 Ardana 

20 Society for Endocrinology/ 

BioScientifica Ltd 

21 Schering Healthcare 

22 Roche 

23 Ferring Pharmaceuticals 

24 British Thyroid Foundation 

25 AACE 

26 Thyroid Eye Disease 

27 The Endocrine Society 

11 

STORAGE STORAGE 

REG DESK 

8 

REG DESK REG DESK 

Registration Area 

Emergency 



28 ECE 2007 

29 EASO 

30 Pituitary Foundation 

31-32 Genzyme 

33 IDS 

34 Shire Pharmaceuticals 

35 Addisons Disease Self-Help Group 

36 Wisepress 

38 AMEND 

39 HRA Pharma 

40 Turner Syndrome Support Society 

41 Glasgow Convention Bureau 


FH 

6 

Emergency 

Exit 


Door 3.3 

2 3 

5 

4 

7 

F.P. 

F.P. 


FH 

FH 

FH 

KIOSK 

KEEP 

CLEAR 

F.P. 

KIOSK 

F.P. 

F.P. 

ROLLER SHUTTER ROLLER SHUTTERS ROLLER SHUTTERS 

F.P. 

PRIVATE 

Emergency 

Exit Doors 

EXHIBITORS AND SPONSORS

EXHIBITORS AND SPONSORS 

74 


Exhibitors and Sponsors 

Gold sponsors 

Bronze sponsors 

Ipsen Ltd Novartis Pharmaceuticals Pfizer 

Exhibitors and sponsors 

Eli Lilly Novo Nordisk Roche 

Addison’s Disease Self-Help 

Group 

AMEND 

American Association of 

Clinical Endocrinologists 

Ardana 

BioSource 

British Thyroid Foundation 

ECE 2007 

The Endocrine Society 

European Society 

of Endocrinology 

European Association 

for the Study of Obesity 

Ferring Pharmaceuticals 

Genzyme 

Glasgow Convention Bureau 

GlaxoSmithKline 

HRA Pharma 

IDS 

International Journal of 

Endocrinology and Metabolism 

LINCO Research 

Organon Laboratories 

Pituitary Foundation 

S Karger Publishing 

Schering Healthcare 



and BioScientifica Ltd 

Thyroid Eye Disease 

Turner Syndrome 

Support Society 

Wisepress 

www.ece2006.com

Exhibitor and Sponsor Profiles (in alphabetical order) 

American Association of Clinical 

Endocrinologists (AACE) 

STAND 25 

AACE is a professional community 

of clinical endocrinologists that is 

committed to transforming the lives of patients by 

enabling each other to practise leading-edge, proactive, 

ethical and cost-effective medicine. 

In 2010, AACE will score its success against its stated aim 

to be the physician organisation that is most valued by 

clinical endocrine and metabolic specialists, trusted by 

patients, and respected by health care decision makers 

worldwide for maintaining the highest standards for 

patient-focused preventive endocrine and metabolic 

medical care. 

Members of AACE are physicians with special education, 

training and interest in the practice of clinical 

endocrinology. These physicians devote a significant part 

of their career to the evaluation and management of 

patients with endocrine disease. All members of AACE 

are physicians (MD, DO or foreign equivalent) and most 

are certified by boards that are recognised by the 

American Board of Medical Specialties. Members are 

recognised clinicians, educators and scientists, many of 

whom are affiliated to medical schools and universities. 

Members of AACE contribute on a regular and 

continuing basis to the scientific literature on endocrine 

diseases and conduct medical education programmes on 

this subject. 

Ardana 

STAND 19 

Ardana is a pharmaceutical 

company focused on improving 

human reproductive health. The company was listed on 

the London Stock Exchange in March 2005. It was 

founded in 2000 to commercialise the pioneering 

research undertaken by the Medical Research Council's 

Human Reproductive Science Unit (HRSU) in Edinburgh, 

UK. 

Since its foundation, Edinburgh-based Ardana has built a 

broad portfolio of products and actively pursues product 

and technology in-licensing and out-licensing to 

maintain a robust pipeline. 

Products include a testosterone replacement therapy that 

has already been launched by Ardana as a treatment for 

men with hypogonadism. Products in clinical 

development cover a range of conditions, including a 

further compound for male hypogonadism, and others 

for growth hormone deficiency, prostate cancer, benign 

prostatic hyperplasia, erectile dysfunction and 

endometriosis. In addition, Ardana has a strong portfolio 

of follow-on products in development. 

BioScientifica Ltd 

STAND 20 


BioScientifica offers a range of 

services of interest to scientific 

societies and the pharmaceutical industry: conference 

management, secretariat and membership services, 

public relations and book and journal publishing. So, if 

you are looking for someone to run your conference, 

your society membership or publish your journals or the 

proceedings for your conference, come talk to us! Our 

stand at Glasgow showcases: 

• European Journal of Endocrinology, published in print 

and online with HighWire Press for the European 

Society of Endocrinology 

• Reproduction, published in print and online with 

HighWire Press for the Society for Reproduction and 

Fertility 

• A range of books including, Zuckerman: Scientist 

extraordinary, Handbook of Acromegaly, also available as 

a CD-ROM, Molecular Pathology and Therapy of Pituitary 

Disease, Pituitary and Periphery: Communication In and 

Out, Central and Peripheral Mechanisms in Pituitary 

Disease, The Expanding Role of Octreotide I: Advances in 

Oncology, The Expanding Role of Octreotide II: Advances 

in Endocrinology, Targets for Growth Hormone and IGF-I, 

Action and Hormone Action: Basic and Clinical Aspects. 

Discounts to the books are available for conference 

delegates. Reduced rate subscriptions to journals are also 

available to some groups. Please come along to the 

stand to find out more and see our online 

demonstrations of the journals. BioScientifica is owned 

by the Society for Endocrinology. 

BioSource 

STAND 18 

BioSource, now part of Invitrogen 

Corporation, provides life science 

researchers with the basic reagents for signal 

transduction, cytokine and immunology research, 

including Luminex Multiplex solutions. Our high 

standard diagnostic products allow physicians and 

clinical laboratories to measure confidently hormones 

and proteins that are important in investigating growth, 

fertility and reproduction, diabetes, cancer, immunology, 

the cardiovascular system, bone metabolism, biogenic 

amines, cytokines, thyroid diseases, Down's syndrome or 

prenatal screening. 

BioSource, Rue de l'Industrie 8, B-1400 Nivelles, 

Belgium (Tel: +32 67 889933/37; 

Email: tech.support@biosource.be; 

Web: www.biosource-diagnostics.com). 


EXHIBITOR AND SPONSOR PROFILES

EXHIBITOR AND SPONSOR PROFILES 

76 


Exhibitor and Sponsor Profiles - continued 

The Endocrine Society 

STAND 27 

Founded in 1916, The Endocrine 

Society is the world's oldest, largest 

and most active organization devoted to research on 

hormones and the clinical practice of endocrinology. 

The Endocrine Society represents the entire endocrine 

community with a membership of 13,000 scientists, 

physicians, educators, nurses and students in more than 

80 countries. Together, these members represent all 

basic, applied and clinical interests in endocrinology. 

The Endocrine Society offers exceptional educational and 

scientific programs throughout the year, including 

ENDO®, the Society's annual meeting. ENDO attracts 

more than 6,000 attendees from over 70 countries and 

highlights the latest advances in endocrine research and 

clinical care as presented by the thought leaders in the 

field. ENDO 2006 will be held June 24-27 in Boston, 

Massachusetts. For more information, visit www.endosociety.org/endo06. 

The Endocrine Society is based in Chevy Chase, 

Maryland. To learn more about the Society, visit 

www.endo-society.org. 

European Association for the 

Study of Obesity (EASO) 

STAND 29 

Obesity poses one of the greatest public health 

challenges for the 21st century, with particularly 

alarming trends in several parts of the world, including 

Europe. The prevalence of adult obesity has risen threefold 

in many European countries since the 1980s and the 

epidemic is spreading at particularly high rates in 

children. The management of obesity and its related 

disorders is now at the forefront of Government and 

Public Health initiatives across Europe. There is 

increasing concern within the European Union and the 

WHO Regional Office for Europe about obesity and its 

co-morbidities such as type 2 diabetes, hypertension, 

cardiovascular disease and cardiometabolic risk and 

prevention. 

The European Association for the Study of Obesity 

(EASO) aims to promote research into obesity, facilitate 

contact between individuals and organisations, and 

promote action that tackles the epidemic of obesity. It 

can be anticipated that obesity will be a major political 

issue in Europe in 2007 and the 15th European Congress 

on Obesity will provide an essential platform for 

discussion on the latest scientific developments in the 

field. To find out more about this congress and other 

EASO initiatives, please visit us at stand number 29. 

The European Society of Endocrinology 

STAND 3 

The European Society of 

Endocrinology (ESE) was launched 

in January 2006 and has been created to promote for the 

public benefit research, education and clinical practice in 

endocrinology by the organisation of conferences, 

training courses and publications, by raising public 

awareness, liaison with national and international 

legislators, and by any other appropriate means. 

Major activities include the organization of the European 

Congress of Endocrinology. This has become so 

successful that it is now held annually. In addition, the 

ESE organizes a number of postgraduate courses. ESE 

also publishes the scientific journal European Journal of 

Endocrinology through the Society of the European 

Journal of Endocrinology and has three other official 

journals, Journal of Endocrinology, Journal of Molecular 

Endocrinology and Endocrine-Related Cancer. 

Further information about the ESE can be found at 

www.euro-endo.org or by contacting the ESE Secretariat 

at: European Society of Endocrinology, Euro House, 22 

Apex Court, Woodlands, Bradley Stoke, Bristol BS32 4JT, 

UK (Tel: +44 1454 642247, Fax: +44 1454 642222). 

GlaxoSmithKline 

STAND 7 

Our mission is to improve the 

quality of human life by enabling 

people to do more, feel better and live longer. We are 

the only pharmaceutical company to tackle the World 

Health Organization's three 'priority' diseases - HIV/AIDS, 

tuberculosis and malaria. 

Headquartered in the UK , we are one of the industry 

leaders. Our business employs 110,000 employees in 80 

countries. We employ 1150 employees across Scotland 

involved in sales, marketing and manufacturing. We 

operate global manufacturing from our Irvine and 

Montrose sites. 

As a company with a firm foundation in science, we have a 

flair for research and a track record of turning that research 

into powerful, marketable drugs. Every hour we spend 

more than £300,000 (US$562,000) to find new medicines. 

GSK at a glance 

• We are a research-based pharmaceutical company 

• Our business employs 110,000 employees in 80 

countries 

• We make almost four billion packs of medicines and 

healthcare products every year 

• Over 15,000 people work in our research teams to 

discover new medicines 

www.ece2006.com


• We screen about 65 million compounds every year in 

our search for new medicines 

• We supply one quarter of the world's vaccines 

• We have protected more than 85 million people from 

lymphatic filariasis (elephantiasis) with GSK-donated 

albendazole 

• In 2004 we shipped more than 33 million tablets of 

preferentially-priced Combivir (our HIV treatment) to 

Africa 

• More than 100 countries have benefited from our 

humanitarian product donations 

• We produce over 600 million tubes of toothpaste every 

year 

Genzyme 

STANDS 31-32 

Thyrogen (thyrotropin alfa) is the 

recombinant human thyroid 

stimulating hormone (rhTSH), developed by Genzyme (a 

highly diversified global health care biotech company) 

for use in patients with well-differentiated thyroid cancer 

who have had their thyroid gland removed. These 

patients must take thyroid hormone suppression therapy 

(THST) and undergo periodic testing for recurrent or 

metastatic cancer. Thyrogen allows patients to remain 

on their THST and avoid the debilitating symptoms of 

clinical hypothyroidism. 

4620 Kingsgate, Cascade Way, Oxford Business Park 

South, Oxford, OX4 2SU, UK (Tel: +44 -1865 -405-217, 

Fax: +44 -1865 -402-964, Website: www.genzyme.com) 

HRA Pharma 

STAND 39 

Laboratoire HRA Pharma commercialises pharmaceutical 

products that fulfil unmet medical needs. The company 

identifies and develops its products using its own internal 

resources and through collaborative endeavours with 

public research institutions. It focuses primarily on women's 

and reproductive health and oncology, but is open to other 

opportunities that fit within its overall mission. 

HRA Pharma was founded in 1996 by two experienced 

professionals from the pharmaceutical industry. Between 

1995 and 1999 the company's founders, in collaboration 

with a small but experienced team, worked to develop 

several products. This work was entirely financed by the 

founders' own personal resources and contributions from 

private investors. 

The company's first product, NorLevo emergency 

contraception, was launched in France in May 1999. 

NorLevo generated such strong interest among key 

players in public health that French health authorities 

took measures to make it more readily available. As a 


result, NorLevo became the first hormonal contraceptive 

available without a medical prescription in France, and 

the only contraceptive available free of charge for 

adolescents (under age 18) in pharmacies. 

From 1999 to 2002, Laboratoire HRA Pharma focused its 

energy on the international development of NorLevo via 

product licensing agreements. As a result, NorLevo is 

now available in over 50 countries. 

In parallel, the company has developed new products, 

and today Laboratoire HRA Pharma has four products: 

NorLevo, Lysodren, Gymiso and Cicatridine. The 

company has a worldwide exclusive licence agreement 

for the KPH Hip Protector, which is commercialised 

through licensing agreements. HRA Pharma also 

currently promotes some products from the portfolio of 

Orion Pharma (Finland) in France. 

In 2005, HRA Pharma completed an alliance with 

Celogos, an emerging biotechnology company in the 

field of cell therapy. 

IDS 

STAND 33 

Immunodiagnostic Systems (IDS) 

offers a range of esoteric 

immunoassay kits for clinical and research use. The 

company focuses on bone and mineral metabolism and 

growth factor research, and engages in collaborative 

projects with researchers worldwide. 

IDS is a leader in the field of vitamin D analysis, offering 

both manual and automated 25-hydroxyvitamin D 

methods, an award-winning 1,25-dihydroxyvitamin D 

RIA system, and now announcing a 1,25dihydroxyvitamin 

D EIA that employs the proven 

immunocapsule sample preparation. The IDS VDBP 

reagent pack has recently been launched to provide a 

measure of the specific capacity of vitamin D binding 

protein for vitamin D compounds in serum samples. 

IDS offers a full range of bone and skeletal products, 

covering intact PTH, bone-specific alkaline phosphatase 

(Ostase ® BAP), BoneTRAP ® , RatTRAPTM , MouseTRAPTM , 

urinary DPD, RANKL and OPG (osteoprotegerin) for both 

clinical and research (animal) use. The IDS growth and 

research product range includes IGF-I (animal and 

human use), IGFBP-1 and -3 (animal), corticosterone 

(animal) and POMC. 

In the UK, IDS also distributes products of other 

reputable suppliers such as DRG, Brahms, IBL, Cayman, 

BBI, Diaclone etc. 

Visit www.idsltd.com for more information. 

Immunodiagnostic Systems (IDS) Ltd, 10 Didcot Way, 

Boldon Business Park, Boldon NE35 9PD, UK (Tel: +44 

(0)191 5190660; Fax: +44 (0)191 5190760; Email: 

marketing@idsltd.com; Web: www.idsltd.com). 



EXHIBITOR AND SPONSOR PROFILES 

78 



Ipsen Ltd 

STANDS 12-15 

Ipsen is a European pharmaceutical 

group with over 20 products on 

the market and a total worldwide staff of nearly 4000. 

The company's development strategy is based on a 

combination of products in targeted therapeutic areas 

(oncology, endocrinology and neuromuscular disorders), 

which are growth drivers, and primary care products 

which contribute significantly to its research financing. 

This strategy is also supported by an active policy of 

partnerships. The locations of its four research and 

development centres (Paris, Boston, Barcelona and 

London) give the group a competitive edge in gaining 

access to leading university research teams and highly 

qualified personnel. In 2004, research and development 

expenditure reached €143.2 million, or 18.7% of 

consolidated sales. These amounted to €767.8 million in 

the group's pro-forma accounts set up according to the 

IFRS. More than 650 people in research and 

development are dedicated to the discovery and 

development of innovative drugs for patient care. 

Ipsen Ltd, 42 rue du Dr Blanche, France 

(Tel: +33 -1 -44304315; Fax: +33 -1 -44304200; 

Web: www.ipsen.com). 

LINCO Research 

STAND 5 

LINCO Research develops, manufactures and markets 

"gold standard" RIA and ELISA immunodiagnostic test kits 

used worldwide for diabetes and obesity research, and 

LINCOplex ® multi-analyte panels using Luminex xMAP 

technology. LINCOplex panels are available for 

cytokines/chemokines, as well as biomarkers for the study 

of metabolic disease (diabetes, obesity, cardiac disease). 

LINCO Research, 6 Research Park Drive, St Charles, MO 

63304, USA (Tel: +1 636-441-8400; Fax: +1 636-441- 

8050; Email: info@lincoresearch.com; Web: 

www.lincoresearch.com) 

The Pituitary Foundation 

STAND 30 

The Pituitary Foundation is a 

national UK charity which is 

working to provide information and support to those 

living with pituitary disorders, including patients, their 

relatives, friends and carers. We also work to increase 

public awareness and act as a 'Patient Voice' in order to 

improve services and policies to meet the needs of the 

pituitary population. 

We provide support to patients, carers and relatives 

including: 

• An Information and Support Helpline (0845 450 0375) 

Open 9:00 to 5:00 Mondays through Fridays 

• An Endocrine Nurse Helpline (0845 450 0377) 

Open Tuesday Mornings 9:30 to 12:30 and Thursday 

Evenings 6:30 to 9:30 

• A Network of Local Support Groups around the United 

Kingdom and Ireland 

• A Telephone Buddy Support Network 

• An Ongoing Schedule of National and Regional 

Conferences 

• Informational Newsletters 

The Pituitary Foundation also acts as a source of 

validated information for patients, carers, primary care 

and other clinicians, and raises public awareness of 

pituitary disorders. This includes leaflets on conditions 

and publications for patients and GPs. We also provide 

information on particular conditions and lifestyle issues. 

Pituitary Foundation, PO Box 1944, Bristol BS99 2UB, UK 

(Tel: +44 (0)845 450 0376; Web: www.pituitary.org.uk). 

Pfizer Endocrine Care 

STAND 1 

Thank you for inviting us to work 

closely with you to best serve your 

patients' needs. We take pleasure in inviting you to visit 

our Pfizer Endocrine Care exhibition booth during the 

8th European Congress of Endocrinology: 

• Study the data supporting the medical rationale for 

treating adult growth hormone deficiency (GHD) 

across different age and patient groups, including 

transition and older adult GHD patients 

• Celebrate the 10th anniversary of the first use of 

Somavert in humans 

• Learn how Somavert benefits the acromegaly patient 

with diabetes 

• Find out more about KIMS and Acrostudy 

Pfizer Endocrine Care are sponsoring two satellite 

symposia during the congress which we hope you are 

able to attend: 

Young, middle-aged, and elderly patients with GH 

deficiency: insights into age-related responses to GH 

replacement on Monday 3 April, 12.20-13.50 in the 

Clyde Auditorium 

Clinical management of acromegaly: applying 10 

years of human experience with pegvisomant on 

Monday 3 April, 18.30-20.00 in the Clyde Auditorium 

We look forward to welcoming you to the booth, and 

hope you have an enlightening and productive ECE 2006! 

www.ece2006.com


Organon 

Organon have kindly supported 

the Internet Café at ECE 2006. 

Organon are not exhibiting at ECE 2006. 

Organon - with shared head offices in Roseland, NJ, USA 

and Oss, The Netherlands - creates, manufactures and 

markets prescription medicines that improve the health 

and quality of human life. Through a combination of 

independent growth and business partnerships, Organon 

strives to remain or become one of the leading 

pharmaceutical companies in each of its core therapeutic 

fields: gynecology, fertility, neuroscience and anesthesia. 

Organon products are sold in over 100 countries, of which 

more than 60 have an Organon subsidiary. Organon is the 

human health care business unit of Akzo Nobel. 

S. Karger Publishers 

STAND 4 

Karger's range of publications in 

the field of endocrinology includes 

the scientific journals Hormone Research (Editor-in-Chief: 

P. Czernichow, Paris) and Neuroendocrinology (Editor-in- 

Chief: R. Millar, Edinburgh), as well as the book series 

Endocrine Development edited by M.O. Savage and 

Frontiers of Hormone Research edited by A.B. Grossmann. 

New releases presented during the 8th European 

Congress of Endocrinology Growth Hormone Deficiency in 

Adults, edited by J.O.L. Jørgensen and J.S. Christiansen, 

Pituitary Surgery - A Modern Approach, edited by E.R. 

Laws, Jr. and J.P. Sheehan, Yearbook of Pediatric 

Endocrinology 2005, edited by J-C. Carel and Z. 

Hochberg, and many more. Publications are accessible 

online at www.karger.com/endocrinology, with full-text 

search of articles and many other services. 

S. Karger Medical and Scientific Publishers is an 

international privately-owned publishing house, which 

combines highly sophisticated production technology 

with customized services for its authors, editors and 

readers. 

Schering Healthcare 

STAND 21 

Schering is the UK subsidiary of 

Schering AG, a research-based 

pharmaceutical company based in Berlin, Germany. We 

focus on four strategic business areas: gynaecology & 

andrology, oncology, diagnostic imaging and specialized 

therapeutics. 

Our andrology portfolio consists of Nebido ® (testosterone 

undecanoate) and Testogel ® (testosterone) licensed for 

the treatment of hypogonadism in men. 

As a successful pharmaceutical company, we are investing 

in the future of medicine, developing drugs of high 

medical value so as to continuously improve quality of life. 

Making the most of knowledge, we use interdisciplinary 

networks to build bridges to academic researchers around 

the world, as well as to highly specialised biotechnology 

pioneers and partners in the pharmaceutical industry. We 

combine our own long-standing medical and 

pharmaceutical expertise with the latest discoveries from 

genomic research. Throughout, our research focuses on a 

meaningful combination of early diagnosis, prevention, 

treatment and therapy control. 


STAND 34 

Shire Pharmaceuticals Group plc is 

a global specialty pharmaceutical 

company with a strategic focus on meeting the needs of 

the specialist physician. Shire currently focuses on 

developing projects and marketing products in the fields 

of the CNS, gastrointestinal tract and renal diseases. Shire 

has operations in the world's key pharmaceutical markets 

(USA, Canada, UK, France, Italy, Spain and Germany) as 

well as a specialist drug delivery unit in the USA. 

For further information, visit www.shire.com. 

Wisepress 

STAND 36-37 


Wisepress Online 

Bookshop is 

pleased to present a display of titles selected from the 

world's leading publishing houses especially for ECE 

2006, incorporating the British Endocrine Societies. All 

titles can be bought or ordered either at the congress or 

via our web site: www.wisepress.co.uk. We can also order 

free sample copies of the journals on display for you, and 

take subscription orders. Whatever your book 

requirements, Wisepress will be happy to help. Whether 

you are an author seeking a publisher or are having 

difficulty obtaining a title, our professional staff will be 

happy to assist you. 

Wisepress Online Bookshop, The Old Lamp Works, 25 

High Path, Merton Abbey, London SW19 2JL, UK (Email: 

bookshop@wisepress.co.uk; Web: www.wisepress.co.uk). 



GENERAL UK INFORMATION 

80 


General UK Information 

Banking 

Most banks are open from Monday to Friday between 

0900 and 1700. Some city centre offices are also open 

on Saturday mornings. Automatic teller machines (ATMs) 

are widely available throughout the area and most are 

linked to Cirrus, Maestro or Plus International money 

systems. Visitors are advised to check with their local 

bank prior to travelling. 

Bureaux de change 

Bureaux de change can be found at the airports, railway 

stations, most city centre banks, Tourist Information 

Centres and travel outlets. 

Credit cards 

Most hotels, restaurants and shops in the UK accept 

major credit cards such as Visa, Mastercard, American 

Express, Diners Club and JCB. 

Currency 

UK currency is the pound sterling (£) and is made up of 

100 pence (p). Several Scottish banks issue their own 

notes in denominations of £5, £10, £20, £50 and £100. 

These are also legal tender elsewhere in the UK. Likewise, 

English and Northern Irish banknotes are legal tender in 

Scotland. Coins come in denominations of 1p, 2p, 5p, 

10p, 20p, 50p, £1 and £2. 

Customs 

For information regarding customs and duty free 

allowances, please see the HM Revenue and Customs 

web site (www.hmrc.gov.uk/home.htm). 

Electricity 

The standard voltage in the UK is 240V AC, 50Hz. Any 

non-UK appliance will require an adapter; North 

American appliances will need a transformer and an 

adapter. Plugs have three square pins and adapters are 

widely available. 

Embassies and consulates 

Foreign embassies can assist travellers with lost or stolen 

passports and provide assistance in emergencies. For 

information on European Union embassies in the UK see 

www.cec.org.uk. 

Emergency services 

For police, fire brigade, ambulance and, in some areas, 

mountain rescue or coastguard, dial 999. 

Health care 

EU citizens are entitled to free or reduced cost medical 

treatment at National Health Service hospitals. With the 

exception of accident and emergency treatment, all non- 

EU members will be charged for medical treatment and 

must have adequate health insurance when travelling. 

Smoking 

Smoking in Scotland is prohibited in enclosed public 

places from 26 March 2006. 

Telephone 

Most public telephones accept coins (10p, 20p, 50p, 

£1), with a minimum connection charge of 20p. An 

increasing number of kiosks also accept credit cards and 

offer email and internet access. 

Time 

Between late March and late October, British Summer 

Time applies in the whole UK. This is 1 hour ahead of 

Greenwich Mean Time. Most public transport timetables 

use the 24-hour clock. 

Tipping 

There are no exact rules for tipping in the UK. If you are 

happy with the service, a 10-15% tip is customary, 

particularly in a restaurant or café with table service. 

Tipping is not expected in bars. For taxi fares, it is usual 

to round up to the nearest pound (£). 

Travel insurance 

It is strongly recommended that visitors to the UK 

arrange travel insurance to cover the loss of possessions 

and money as well as health and dental treatment. 

Vaccinations 

No vaccinations are required prior to visiting the UK. 

Value-added tax (VAT) 

All purchases in Britain, with the exception of 

unprepared food and books, are subject to VAT, which 

increases the cost of an item by 17.5%. This is generally 

already included in the requested price. Visitors from 

non-EU countries can claim a refund of VAT from 

selected shops on goods that are to be taken out of the 

country, under the Retail Export Scheme. 

Visas 

EU members may travel and work in the UK without a 

visa. Citizens from the USA, Canada, South Africa, 

Australia or New Zealand do not require a visa to visit 

the UK but are prohibited from working. Citizens from 

other countries require a visa, which can be obtained 

from their nearest British Consular office. For additional 

information on UK immigration and visa requirements 

visit the Foreign and Commonwealth Office web site 

(www.fco.gov.uk). 

www.ece2006.com

TIMETABLE 8th European Congress of Endocrinology 

07.00 

07.30 

08.00 

08.30 

09.00 

09.30 

10.00 

10.30 

11.00 

11.30 

12.00 

12.30 

13.00 

13.30 

14.00 

14.30 

15.00 

15.30 

16.00 

16.30 

17.00 

17.30 

18.00 

18.30 

19.00 

19.30 

20.00 

Key to Meet the Expert Sessions 

1: Macroprolactinaemia 

2: Gestational diabetes 

3: Chips, arrays and biosensors: bioinformatics 

in endocrine research 

4: Cell immortalisation in endocrine research 

5: Papillary thyroid cancer management 

6: Adrenal carcinoma 

7: Transgenic techniques 

8: Pitfalls in signal transduction research 

9: Medical management of Cushing's disease 

10: Graves' ophthalmopathy 

11: Metabolic, functional and oncological 

consequences of altered GH/IGF expression 

12: Growth hormone deficiency in adults 

13: Pregnancy-related pituitary disorders 

14: Hypoglycaemia and insulinoma 

15: Interference in hormone assays 

16: Mouse genetics in the identification of 

quantitative traits 

SATURDAY 1 APRIL 

Registration 

(from 12.00 onwards) 

Opening Ceremony 

European Journal of Endocrinology 

Prize Lecture 

S Costagliola 

Geoffrey Harris Prize Lecture 

F Casanueva 

Welcome Reception 

HALL 3 

CA 

CA 

CA 

07.00 

07.30 

08.00 

08.30 

09.00 

09.30 

10.00 

10.30 

11.00 

11.30 

12.00 

12.30 

13.00 

13.30 

14.00 

14.30 

15.00 

15.30 

16.00 

16.30 

17.00 

17.30 

18.00 

18.30 

19.00 

19.30 

Meet the Expert 1 (CA) 

Meet the Expert 2 (LA) 



SUNDAY 2 APRIL 

Meet the Expert 3 (H1) 

Meet the Expert 4 (FR) 

Symposium 1: Thyroid and the heart (CA) 

Symposium 2: 

The endocrinology of psychiatric disease (LA) 

Clinical Management Workshop 1: 

Green over-the-counter endocrinology (H1) 

Oral Communications 1: Signal transduction (AR) 

Young Endocrinologists Session: Presenting 

your research - getting your work known (FR) 

COFFEE 


D Mangelsdorf 



Novartis Pharmaceuticals 

Satellite Symposium: 



POSTERS 

& LUNCH 

HALL 3 

Symposium 3: 

Cancer and the skeleton (CA) 

Symposium 4: 

Cannabinoid signalling (LA) 


Management of complex genital anomalies and 

the transition from childhood to adulthood (FR) 

Oral Communications 2: 

Steroids and reproductive endocrinology (H1) 

Ipsen Satellite 

Symposium: 

Tailoring therapies 

for patients with 

endocrine disorders 

TEA 

Plenary 1: 

Vitamin D action 


20.00 

CA 

20.00 

CA 

TIGER TIGER 

Free Evening 

HALL 3 

CA 

HALL 3 

The Sunday Social 

07.00 

07.30 

08.00 

08.30 

09.00 

09.30 

10.00 

10.30 

11.00 

11.30 

12.00 

12.30 

13.00 

13.30 

14.30 

15.00 

15.30 

16.00 

16.30 

17.00 

17.30 

18.00 

18.30 

19.00 

19.30 

Symposium 5: 

Novel peptides in reproduction (CA) 


Clinical endocrinology (H1) 

Symposium 6: 

Hot topics (LA) 

Symposium 7: 

Flies, worms and fish: 

use in endocrine research (FR) 

Clinical Endocrinology Trust 

Visiting Professor Lecture 

W Crowley 


Satellite Symposium: 

PCOS - The cruel face 

of a complex disease 

MONDAY 3 APRIL 

COFFEE 

Pfizer Satellite 

Symposium 1: 

Young, middle-aged 

and elderly patients 

with GHD: insights into 

age-related responses to 

GH replacement 

FR FR 

CA 

14.00 

BM1 

CA 





BM2 

POSTERS 

& LUNCH 

Symposium 8: 

Clinical lessons from novel aspects of 

G protein-coupled receptors signalling (CA) 


Management of Graves' ophthalmopathy (LA) 

Basic Workshop: 

In vivo imaging of signalling (H1) 


Diabetes and metabolism (FR) 

TEA 

Plenary 2: 



Statins and rhabdomyolysis 

Pfizer Satellite Symposium 2: 

Clinical management of acromegaly: 

applying 10 years of human experience 

with pegvisomant 

HALL 3 

CA 



07.00 

07.30 

08.00 

08.30 

09.00 

09.30 

10.00 

10.30 

11.00 

11.30 

12.00 

12.30 

13.00 

13.30 

14.00 

14.30 

15.00 

15.30 

16.00 

16.30 

17.00 

HALL 3 

17.30 

HALL 3 

18.00 


J Findlay 

CA 

CA 

18.30 

19.00 

19.30 

20.00 



TUESDAY 4 APRIL 

Symposium 9: 

Stromal cell-matrix interactions (LA) 

Symposium 10: 

Controversies in male health (CA) 


Neuroendocrinology and neoplasia (FR) 

Nurses Session: 

Metabolic syndrome (AR) 

COFFEE 

British Thyroid Association 

Pitt-Rivers Lecture 

B Vennström 



European Society of Endocrinology AGM 

POSTERS 

& LUNCH 

HALL 3 HALL 3 

Symposium 11: 

How hormones get into cells (CA) 

Symposium 12: 

Endocrinology in the fetus (H1) 


Contrasting practices in European 

endocrinology (LA) 


Endocrine genetics (FR) 

TEA 





Congress Banquet and Ceilidh 

HILTON HOTEL 

07.00 

07.30 

08.00 

08.30 

09.00 

09.30 

10.00 

COFFEE 

HALL 3 10.30 

HALL 3 

11.00 

Clinical Endocrinology 

Trust Lecture 

CA 

A Weetman 

CA 

11.30 

CA 

12.00 

12.30 

13.00 

13.30 

14.00 

14.30 

15.00 

15.30 

16.00 

16.30 

17.00 

17.30 

18.00 

18.30 

19.00 

19.30 

20.00 

WEDNESDAY 5 APRIL 

Meet the Expert 13 (CA) Meet the Expert 15 (H1) 


Symposium 13: Monogenic disorders 

illuminate metabolic disease (CA) 

Symposium 14: 

Steroid hormone receptors (H1) 

Symposium 15: 

Anabolic hormones in sport (LA) 


Calcium and bone (FR) 

Plenary 3: 

Stem cells: regeneration in type 1 diabetes (LA) 

Debate (CA) 

LUNCH 

HALL 3 

Symposium 16: 

Disorders of melanocortin receptor functions (LA) 

Symposium 17: 

Endocrine oncogenesis and management of 

hereditary endocrine tumours (CA) 


Research management workshop (H1) 


Thyroid (FR) 

Novartis Oncology Young Investigator 


Meeting Close 

CA 

Key to locations 

CA Clyde Auditorium 

LA Lomond Auditorium 

H1 Hall 1 

FR Forth Room 

AR Alsh Room 

Key to Business Meetings 

BM1 Society for Endocrinology EGM 


BM2 British Thyroid Association AGM 

ALSH ROOM 

www.ece2006.com 


Meet the Expert 13 (CA) Meet the Expert 15 (H1) 


Meet the Expert 16 (FR)

SPONSORS 

The ECE 2006 Organising Committee would like to thank all the sponsors 

and supporters of this meeting, in particular: 

THE GOLD SPONSORS 

THE BRONZE SPONSORS 

ECE 2006 Secretariat 


22 Apex Court, Woodlands 

Bradley Stoke, Bristol BS32 4JT, UK 

Contact: Liz Brookes 

Tel: +44 (0)1454 642210 

Fax: +44 (0)1454 642222 

Email:conferences@endocrinology.org 

Website: www.ece2006.com 

The Society for Endocrinology 

Company Limited by Guarantee 

Registered in England No 349408 

Registered office as shown above 

Registered Charity No 26618

ECE2006 - Society for Endocrinology

Create successful ePaper yourself

Delete template?

Save as template?